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Summary 
The integrity of DNA in living organisms is permanently threatened by many endogenous and 
exogenous factors. Damages can lead to cell death and serious diseases and have to be re-
paired by the organism. The focus of this thesis is the investigation of the ability of high (Bst 
Pol I, Klenow fragment exo- (KFexo-)) and low fidelity polymerases (Pol , Pol ) to insert and 
bypass several oxidatively-derived purine-lesions. 8-Oxopurines (8-oxodA, 8-oxodG) and 
formamidopyrimidines (FaPydA, FaPydG) are the major oxidative DNA lesions, but also gua-
nine-derived imidazolone (dIz) and its further degradation products oxazolone and guanidi-
noformimine are produced to a large extent. In order to examine the mutagenic potential of 
these lesions we first analyzed the ability of the polymerases to insert nucleotide triphos-
phates opposite the lesions by single nucleotide insertion studies. To further analyze and 
quantify the lesion bypass abilities of the polymerases we subsequently performed primer 
extension coupled pyrosequencing with fully elongated primers. 
Whereas the adenine-derived lesions are mainly base-paired with the correct dTTP, the gua-
nine-derived lesions exhibit substantial mutagenic properties. Next to correct base pairing 
with dCTP, misincorporation of dATP opposite carbocyclic FaPydG (cFaPydG) and 8-oxodG 
occurs to a significant extent. In addition, the Iz-derived lesions are base-paired with dATP, 
dCTP, and dGTP in a disperse manner and misincorporations range from 40-75% with the in-
vestigated polymerases. In contrast to the FaPy- and 8-oxo-lesions, which are replicated with 
good efficiencies, the Iz-derived lesions stall the polymerases to a large extent. 
In order to support the biochemical data and to reveal the replication mechanism of a high 
fidelity polymerase with FaPy-lesions we performed co-crystallization studies with Bst Pol I. 
Due to the thermostability and remaining activity of Bst Pol I inside the crystal we could ob-
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serve sequential primer extension of cFaPydA and cFaPydG. We obtained structures showing 
the error-free replication with dTTP and dCTP, respectively. No structure showing erroneous 
replication of cFaPydA was obtained underscoring the weak mutagenic potential of this le-
sion. In contrast, we obtained structures showing a cFaPydG:dA base pair after one and two 
rounds of replication. The crystal structures revealed that the mutagenic potential of 8-
oxodG requires base pairing in the syn conformation with dATP. We expected a similar be-
havior for cFaPydG. Nevertheless, our structures of cFaPydG:dA clearly show base pairing in 
the anti conformation. 
In comparison to undamaged base pairs all structures with FaPy-lesions in the post-insertion 
site of the polymerase revealed that the active center is distorted and that the template 
strands are shifted against each other. Despite this, several catalytic residues and the primer 
strand are retained in the correct position for further primer extension. Hence, despite the 
perturbations in the template strands, previously formed base pairs can be elongated.  
After the discovery that oxidative modifications of the base methylcytosine (mC) occur natu-
rally within the genome and play a key role during cellular development we sought to ad-
dress the question of their mutagenic potential. Our studies reveal that none of the mC-
derivatives is mutagenic, which supports their key role in epigenetics. 
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1 Introduction 
1.1 DNA - The Molecule of Life 
DNA is probably the most important macromolecule of living organisms. All the genetic in-
formation is saved in this molecule as chemical information; this is called the genetic code. 
DNA is the substance, which controls life and which is responsible for the correct translation 
of the code into proteins and thus for the correct “work cycle” in living organisms. 
DNA is a polymer of four nucleobases (adenine, cytosine, guanine, and thymine), which are 
connected via desoxyribose and a phosphate backbone. Pyrimidines and purines are the two 
main building blocks for the nucleobases. Whereas adenine and guanine are purines, cyto-
sine and thymine are pyrimidine bases. 
In 1869, Friedrich Miescher isolated crude DNA for the first time, but it was only 84 years 
later, in 1953, that the structural composition of DNA was uncovered by James D. Watson 
and Francis H. C. Crick.[1] They revealed that DNA is constructed as a double helix, formed of 
two complementary strands. In general, the base pairs are formed between adenine and 
thymine, and between guanine and cytosine (Fig. 1). The stability of the duplex is assured by 
two main interactions; H-bonds between the opposing and extensive base stacking between 
the adjacent nucleobases.[2]  
 
Figure 1: Base pairing of the nucleosides. The dashed lines represent the H-bonds between the nucleobases. 
  
2 
 
While in bacteria and viruses the genomic information is mostly stored in circular molecules, 
the eukaryotic system is more complex, which is also in relation to the different size of the 
DNA. Eukaryotic organisms, in comparison to prokaryotic organisms, have to store much 
more information. To circumvent the size problem, the DNA is compactly stored in chromo-
somes; specific constructions of proteins and DNA. Therein, the DNA is wrapped around a 
spool-like complex of 8 histones, the nucleosome, and these histone octamers built a long 
fiber with a diameter of 30 nm. Interactions between the nucleosomes result in folding of 
the chromatin fiber and thus further condensation (e.g. during mitosis) to the so-called 
chromosome.[3]  
The number of chromosomes depends on the organism. In addition, organisms can either 
have one, two, or even more sets of chromosomes, consequently being called haploid, dip-
loid, or polyploid. Humans, the  example for a diploid organism, have two sets of 23 chromo-
somes each (22 pairs of autosomes and one pair of sex chromosomes), resulting in 46 chro-
mosomes in each somatic cell nucleus.[4] 
 
1.2 Epigenetics 
All cells within an organism, in spite of their various functions, possess the same genotype. 
Within the DNA, specific base sequences stand for a huge variety of genes, but not all genes 
are incessantly transcribed into proteins. Depending on the cell types, the proteomes can 
differ enormously. Not all proteins are required at all times, therefore tight and specific con-
trol is needed to guarantee proper gene transcription.  
Typical mechanisms to regulate gene expression are chemical modifications of bases and his-
tones (e.g. methylation, phosphorylation, and acetylation),[3, 5] intervention of non-coding 
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RNAs,[6] and DNA-binding proteins (e.g. transcription factors).[7] These modifications can 
change the DNA-histone interaction strength, and therefore en- or disable transcription. This 
control is an extremely important process for versatile cellular differentiation and morpho-
genesis. In general, these modifications are reversible and belong to the huge field of the ep-
igenetic marking system (Greek: επί-, epi-; over/above). 
 
1.2.1 The Role of DNA-Methylation 
DNA-methylation is a biological process, which affects transcription and whose main func-
tion is to maintain the genomic integrity. However, the key function of methylation is to si-
lence certain genes, which is achieved by transfer of a methyl-group to the C(5) position of 
cytosines. Localization of the C(5) methyl group in the major groove of the DNA influences 
specific interactions with various proteins.[8] All in all, methylation is a crucial process in-
volved in gene expression,[9] embryonic development,[10] differentiation,[11] imprinting,[12] X-
chromosome inactivation,[8, 13] neuroplasticity,[14] and carcinogenesis.[15]  
Given its importance, 5-methylcytosine (mC) is often referred to as the 5th base of the ge-
nome. In mammals, methylation occurs mostly at CpG dinucleotides, which are unevenly dis-
tributed within the genome, but to a lesser degree it has also been found at non-CpG 
sites.[16-17] In human DNA, albeit having a GC-content of 42%, only 1% of the cytosines are 
followed by a guanine.[18] Approximately 70-80% CpG dinucleotides throughout the whole 
mammalian genome are methylated.[19] The remaining unmethylated CpG dyads are often 
found in dense clusters (referred to as CpG islands) with close proximity to promoter regions 
and are involved in the control of gene expression.[12, 20] 
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In human peripheral blood mononuclear cells, almost 70% of annotated gene-promoters are 
linked with CpG islands, but less than 0.2% of non-CpG sites were methylated.[21] In contrast, 
studies with embryonic stem cells (ESC) show a completely different methylation pattern, 
where approximately 25% of non-CpG sites are methylated.[16]  
Generally, methylation of CpG dyades undergoes widespread changes during cellular differ-
entiation and the regulation of these patterns is of immense importance to ensure correct 
mammalian development. Whereas the CpG dinucleotides of the gametes are highly meth-
ylated,[22] the paternal and maternal methylation patterns are rapidly changed after fertiliza-
tion.[23] During embryonic development a new wave of methylation takes place.[13] The pro-
moters of several transcription factors (e. g. NANOG and OCT4), which are associated with 
pluripotency, are unmethylated in the early embryo to enable their gene expression, where-
as most tissue-specific genes are methylated.[24] On the contrary, in the later phases of dif-
ferentiation and in somatic cells, their promoters are mainly methylated and the tissue-
specific genes expressed.[10] This is in accordance with the fact that mC-deficient ESC retain 
pluripotency but lose their differentiation ability.[25]  
 
1.2.2 Methylation by DNMTs 
In mammals, methylation is accomplished by three active DNA methyl-transferases (DNMT); 
DNMT1, DNMT3A, and DNMT3B. The formerly identified DNMT2 does not methylate DNA 
but RNA and has been renamed to tRNA aspartic acid methyltransferase 1 (TRDMT1), in ac-
cordance with its biological function.[26] While new methylation patterns are established by 
DNMT3A/B/L (de novo methyltransferases), DNMT1 preferentially works on hemimethylated 
strands and is associated with maintenance of existing DNA methylation patterns during rep-
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lication. All DNMTs methylate the cytosine at carbon-5 and require S-adenosylmethionine as 
their cofactor, whose S-methyl group is transferred to the DNA base.[27] DNMT1 harbors a 
zinc-finger CXXC domain (C = cysteine, X = any amino acid) and a conserved region, which 
play a role in DNA recognition.[28-29] This region has also been found in other proteins, e.g. 
MBD1 (methyl binding domain protein),[30] TET1 (ten-eleven-translocation protein),[31] and 
TET3.[32] During S-phase, DNMT1 is localized to replication foci and functions to convert hem-
imethylated DNA strands into the fully methylated state.[33] In general, it methylates CpGs 
through an interaction with UHRF1 (ubiquitin-like with PHD and ring finger domains).[34-35]  
In 2011 and 2012, Song et al. published two crystal structures of truncated mouse DNMT1 in 
complex with un- and hemimethylated DNA duplexes, thus allowing further insight into the 
binding mechanism.[36-37] DNMT1 recognizes and binds to un- and hemimethylated DNA with 
two distinct but supportive domains - the CXXC and the target recognition domain (TRD) - 
which together ensure accurate replication of methylation patterns. Binding to unmethylat-
ed CpGs is proposed to play an autoinhibitory role by preventing de novo methylation.[36] 
When bound to an unmethylated CpG, the entry of the unmethylated cytosine into the ac-
tive site is prevented by an autoinhibitory loop.[36] In the crystal structure with hemimethyl-
ated DNA this loop is shifted and enables therefore the cytosine to enter the active site (Fig. 
2).[37]  
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Figure 2: Overlay of the active with the autoinhibitive mDNMT1-DNA complex (PDB codes 4DA4 and 3PT6). The 
close-up shows the shifted catalytic loop.
[36-37]
  
In order to enhance its accessibility for methylation, DNMT1 flips the to be methylated cyto-
sine out of the helix,[37] thereby following a similar mechanism as has been shown previously 
for M.Hha1 from Haemophilus haemolyticus.[38-39] 
DNMT3 (DNMT3A, 3B, and 3L) proteins are generally responsible for de novo methylation, 
particularly during gametogenesis and development, all exhibit distinct functions. DNMT3B 
seems to be essential during early development, whereas DNMT3A plays an important role 
during late development or post-natal stages.[40] DNMT3L (DNMT3-Like protein), despite its 
sequence similarities to DNMT3A and B, is catalytically inactive and is required during de no-
vo methylation of DNA as a cofactor for DNMT3A and B.[41-44] 
 
1.2.3 TET-Enzymes and Their Role in the Oxidation of mC  
hmC, nowadays proposed to be the 6th base of the genome,[45] arises from the radical-based 
oxidation of the methylgroup of S-methylcytosines. The oxidation is carried out by the ten-
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eleven-translocation proteins (TET1, TET2, and TET3), a family of 2-oxoglutarate- and Fe(II)-
dependent dioxygenases. Their characteristic feature is the successive conversion of mC to 
hmC, formylcytosine (fC) and carboxylcytosine (caC) in vivo and in vitro (Scheme 1).[46-48]  
 
Scheme 1: Successive conversion of mC to hmC, fC, and caC by the TET enzymes and potential active demethyl-
ation pathways (see chapter 1.2.4). While mechanism 1 involves direct elimination of the functional groups, 
mechanism 2 involves base excision repair-based replacement of fC and caC by dC, or of hmC by dC after prior 
deamination of hmC to hmU. 
The cofactor 2-oxoglutarate is produced by isocitrate dehydrogenases (IDH), which catalyze 
the oxidative decarboxylation of isocitrate.[31] In 1972, 5-hydroxymethylcytosine (hmC) had 
already been detected in DNA of various animals,[49] but it was only in 2009, that Rao and 
coworkers identified TET1 to carry out the conversion of mC to hmC in mouse embryonic 
stem cells (mESC).[50] At the same time Kriaucionis and Heintz discovered hmC in neurons.[51] 
Despite the short time since 2009, a huge amount of publications appeared describing the 
function of these bases. Genome wide mapping studies and even base resolution sequencing 
are reported.[31, 52-55] In a very simplified view, the hydroxylase activities of the TET enzymes 
catalyze the reversal of the silencing effect achieved by cytosine methylation. 
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All TET proteins have a conserved iron-binding subunit, and in the case of TET1 and TET3 an 
additional CXXC region.[31-32, 50] Nevertheless, in vivo studies of the CXXC domain of TET1 re-
vealed no DNA binding activity and no function could be found.[56] 
 
 
Figure 3: Schematic overview of the family of TET proteins.  
The amount of mC and its oxidized products as well as the expression of the TET enzymes 
depends largely on the kind of tissue that is analyzed and the differentiation state of stem 
cells.[46, 57-58] While TET1 is mostly expressed in ESC and decreases during differentiation,[57, 
59] TET2 and TET3 have been found more ubiquitously.[50, 57] TET1 and TET2 are associated 
with maintaining pluripotency and lineage specification,[60-61] TET3 seems to be important for 
differentiation processes and is also highly expressed in brain tissues.[23, 57, 62] The level of 
hmC decreases within the first days of differentiation but increases in further differentia-
tion.[57] 
It is known, that TET1 binds preferentially to CpG-rich promoters, in accordance with the el-
evated hmC-levels in these regulatory regions.[31, 63-64] This is further supported by TET1 
knock-out studies in mESC, which showed a reduction of the hmC-levels by 35%.[62] TET1-
depleted mice are viable and fertile but some have a slightly reduced body size.  No further 
defect in maintaining pluripotency is detected.[59] In this scenario, the expected enhanced 
expression of TET2 or TET3 is not observed, thereby supporting the independent expressi-
on.[62]  
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TET2-deficient mice are also viable and exhibit a normal phenotype, but they seem to be 
more susceptible to hematopoietic malignancies.[65-67] In combination with in vitro data, this 
points towards a role of TET2 in self-renewal, proliferation, and differentiation of hemato-
poietic stem cells.[65]  
Double knock-down of TET1 and TET2 further reduces the hmC level in comparison to single 
knock-down,[62] and leads to an elevated level of perinatal lethality.[68] However, these stud-
ies all support the hypothesis that TET1 and TET2  might be able to compensate for each 
other during early developmental stages.[68] 
In contrast to TET1 and TET2, the levels of TET3 in ESC have been found to be very low.[57] 
This protein seems to play an important role in early eye and neural development in 
Xenopus.[32] It is the only TET enzyme, which has been found in oocytes and zygotes and is 
assumed to play a role in demethylation of the paternal pronucleus.[23, 62] During zygote de-
velopment, the level of TET3 diminishes at the two-cell stage.[62]  
 
1.2.4 Demethylation Mechanisms of DNA 
(De)methylation is an important process, which influences transcriptional activity, therefore 
regulating gene expression, embryonic development and many more biological functions.[69] 
Genomic methylation patterns can be erased in a passive and in an active way. During cell 
division, the methylation patterns are maintained by methyltransferases (e.g. DNMT1), but 
their inhibition or absence leads to a gradual loss of methylated patterns.[70] This occurs for 
example in the paternal pronucleus in preimplantation embryos.[71] In addition, it was shown 
in vitro that DNMT1 is acting 50 times more efficiently on mC- than on hmC-hemimethylated 
DNA strands, supporting the role of hmC during passive demethylation.[72] In contrast, in vivo 
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studies revealed UHRF1-mediated DNMT1-binding to hmC-containing DNA strands and sug-
gested that they play a role in dictating methylation sites on the daughter strand.[34] Further 
studies will be needed to clarify this issue.  
In addition to passive loss of methylation, two pathways of active demethylation have been 
proposed. One involves BER, the other requires the direct removal of the functional groups 
(Scheme 1). In both cases the result is an unmethylated cytosine, reversing the silencing ef-
fects caused by previous methylation.  
All active demethylation pathways start with the oxidation of mC to hmC (Scheme 1, mech-
anism 2). Subsequently, the TET enzymes can further oxidize hmC to fC and caC.  Chemically, 
the oxidation of hmC to fC is about ten times faster than from fC to caC.[46-47, 73] During BER, 
fC and caC can be recognized by the thymine-DNA glycosylase (TDG). The resulting abasic 
site is replaced by an unmethylated cytosine.[48, 74-75] The study of He et al. supports this role 
of TDG by showing that TDG-deficient mESC accumulated caC.[48] Since hmC is not a good 
substrate for TDG,[48, 75-76] a similar pathway involving hmC-deamination was proposed with 
the actions of the deaminases AID (activation-induced deaminase) and APOBEC (apolipopro-
tein B mRNA editing enzyme catalytic polypeptide-like). SMUG1 (single-strand-selective 
monofunctional uracil-DNA glycosylase 1) is also needed in this pathway. The AID/APOBEC 
enzymes are thought to deaminate hmC to 5hmU. This is excised by the 5hmU glycosylases, 
SMUG1, followed by repair via the BER.[77-78] In contrast to TDG, hmC is a good substrate for 
AID.[78]  
Another possible active demethylation pathway of the oxidative mC-derivatives would in-
clude the direct removal of the functional group (dehydroxymethylation, deformylation, and 
decarboxylation), resulting in an unmethylated cytosine (Scheme 1, mechanism 1). Chemi-
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cally in comparison to dehydroxymethylation, deformylation and decarboxylation are the 
easier processes.[73] Based on in vitro data, a recent study suggests that decarboxylation of 
caC to C can take place in vivo, but so far, no enzyme carrying out these removals has been 
discovered.[79]  
 
1.2.5 Base-Pairing Properties of mC and its Oxidized Forms 
The mutagenic base pairing properties of the mC-derivatives are very low.[80-81] Kamiya et al. 
showed that fC can lead to various mutations in simian kidney cells (COS-7), nevertheless he 
also found that the mutation frequency is extremely low (0.03%-0.28%).[80] When the oxi-
dized nucleobases fC and caC were discovered,[46-48] fC was believed to have a not negligible 
mutagenic potential. This was explained by a potential shift from its amino- to the imino-
form, due to a putative strong intramolecular H-bond between the exocyclic NH2(4) group 
and the carbonyl oxygen at C(5). Thus, base pairing with dATP would be enabled (Fig. 4).[80-
82] Its potential role as major epigenetic control intermediates could in this case be problem-
atic. A similar behavior could be possible for caC (Fig. 4). We assumed that the previously de-
tected mutagenic behavior in vivo is not caused by the replicative polymerase but by other 
cellular processes. Therefore, the mutagenic potential would not lie within the base pairing 
properties but in a spontaneous deamination reactions caused e.g. by AID or APOBEC. De-
amination of cytosine and its derivatives leads to the formation of U, 5mU, 5hmU, 5fU, and 
5caU. Without repair, these deamination products could lead to spontaneous base pairing 
with dA and thus to C→T transversion mutations.[83-84] 
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Figure 4: An intramolecular hydrogen bond (red) between the exocyclic NH2(4) group and the carbonyl oxygen 
at C(5) of fC and caC was proposed to shift the amino/imino-equilibrium towards the imino tautomeric form. 
This could in consequence lead to base pairing with dA. 
 
1.2.6 Cancer and Other Diseases 
An aberrant methylation pattern in cells often leads to malignant tumors, which are known 
to show global hypomethylation, genomic instability, promoter hypermethylation, and fur-
ther aberrant features associated with healthy tissue.[65] In this context, studies with 
DNMT3-deficient mice revealed various defects and the mice die at different developmental 
stages.[40] In humans, mutations in DNMT3B lead to hypomethylation of centromeric satel-
lites and to heterochromatin instability, and thus to the ICF (Immunodeficiency, Centromere 
instability) syndrome. These findings suggest a major function of DNMT3B in maintaining 
chromosome stability.[40] Mutations within the DNMT3A gene are closely related to myeloid 
leukemia (AML) and myelodysplastic syndromes.[85] Decreased levels of hmC as an oxidative 
product of mC are often correlated with various types of cancer.[86] In the case of hepatocel-
lular carcinoma (HCC), one of the most common type of cancer in humans, Chen et al. even 
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suggested hmC as a potential biomarker since its reduced appearance correlates largely with 
tumor stages.[87] Other studies reveal reduced hmC levels in squamous cell lung cancers, 
prostate, breast, colon, and brain tumors.[86] In healthy tissues, the highest level of hmC has 
been found in brain tissues, which are associated with higher cognitive functions.[45] In con-
trast, the hmC level in brain tumors is strongly reduced.[86, 88] Mutations within the TET en-
zymes, which are known to catalyze the oxidation of mC to hmC, also correlate with several 
types of cancers.[89] TET2 mutations are associated with hematopoietic malignancies, e.g. 
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative 
neoplasms (MPN).[65] Expression of TET1 is significantly decreased in breast and prostate 
cancer tissues,[90] and TET1/2/3 are downregulated in melanomas.[91] Also mutations of the 
isocitrate dehydrogenases and subsequent inhibition of TET-mediated conversion of 5-mC to 
5-hmC lead to several types of cancer.[91] In addition, upregulation of AID and APOBEC, 
which are expressed tissue-specifically, is also implicated in cancer development of the re-
spective tissues, e.g. hepatocytes and B-cells.[92-94] In conclusion, the maintenance of meth-
ylation patterns is crucial for correct development in mammals and aberrant methylation 
due to mutations can lead to cancer. 
 
1.3 DNA Damage 
DNA is not inert, it can be damaged by many exogenous (e.g. UV light, X- and γ-rays, chemi-
cals) and endogenous factors (e.g. products of cellular metabolism such as reactive oxygen 
or nitrogen species (ROS resp. RNS), oxidation, replication errors). These damages could slow 
down or block transcription, cause mutations, and they could also lead to cell death. If those 
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damages are not repaired they can cause serious diseases due to their cancerogenic or cyto-
toxic properties. In addition, they are implicated in aging.[95] 
1.3.1 Biological Implications of Reactive Oxygen Species 
In living organisms reactive oxygen species (ROS) are typical side products of cellular metab-
olism (respiration) in the mitochondria. In the case of overproduction or misregulation, this 
leads to oxidative stress. In general, cells rely on ROS for cellular signaling (growth, prolifera-
tion of stem cells, migration of cells, neurogenesis), however, the specific role of individual 
ROS is largely unknown. It is a complicated system with many stations of control, so if one 
layer of control is not working properly, unwanted damages to biomolecules can occur.[96] 
The main biologically relevant ROS are superoxide [O2]
•−, hydrogen peroxide H2O2, hypo-
chlorous acid HOCl, singlet oxygen 1O2, lipid peroxides ROOH, ozone O3 and hydroxyl radicals 
[OH]•.[96] They are generated in various organelles of the cell, particularly in mitochondria, 
endoplasmatic reticulum, cell membranes, phagosomes, and peroxisomes. They can mediate 
miscellaneous redox modifications on molecules, e.g. DNA, RNA, lipids and proteins, and 
regulate diverse physiological processes, e.g. cell migration, circadian rhythm, stem cell pro-
liferation, and subsequent neurogenesis.[96] Many highly reactive oxidants have short half-
lives within the cellular milieu. [OH]• for example has a half-life of 10−9 s. For this reason they 
do not diffuse far from their production site. One exception is H2O2, which in the cellular mi-
lieu has a half-life of up to 1 ms and is therefore able to migrate further to reach its target.  
The level of oxidized bases with approx. one per 108 normal nucleosides is rather low. While 
the hydroxyl radical [OH]• reacts with all four nucleobases as well as with the desoxyribose, 
1O2 can only react with guanine.
[97] O2
•- is not reacting with the bases or sugars at all; its dis-
mutation product H2O2 is mainly reacting with them in the presence of metal ions (Fenton 
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reaction).[97] Often, mainly as a results of [OH]• or of one-electron oxidation, tandem-base 
lesion are produced. The chapter of oxidatively formed lesions is very complex and many 
studies have been performed in order to understand the various mechanisms.[96-102] 
 
1.3.2 Oxidation of Purine Bases 
Out of the four canonical DNA bases, guanine has the lowest oxidation potential (guanine 
1.29 V < adenine 1.42 V < cytosine 1.6 V < thymine 1.7 V vs. NHE) and can therefore be very 
easily oxidized.[100] This explains why most oxidized bases arise from guanine or adenine 
(Scheme 2 and 3).[103-104]  
When DNA is irradiated in aqueous solution, ten times more FaPydG/8-oxodG is produced 
compared to the respective A-lesions.[105] Radiolysis experiments under O2-deficient condi-
tions in chromatin exhibit a higher formation of FaPy-lesions (dA and dG) than 8-oxo-lesions. 
When the experiment is performed in the presence of oxygen, the yield of the 8-oxo-lesions 
increases enormously, whereas the yield of the formamidopyrimidines stays roughly the 
same.[103, 106] In general, irradiation of DNA at 254 nm yields higher levels of FaPy- and 8-oxo-
lesions in comparison to typical pyrimidine lesions.[107] 
 
1.3.2.1 Oxidation of Guanine 
Next to one- or two-electron oxidations, guanine can also be attacked by hydroxyl radicals or 
singlet oxygen (Scheme 2). Oxidation through one-electron abstraction or oxidation through 
hydroxyl radicals leads to the same products. Single electron transfer can be achieved by ion-
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izing radiation, type I photosensitizers, or by multiple oxidants, such as nitrosoperoxycar-
bonate.[108] 
 
Scheme 2: Schematic overview of the oxidation of guanine. 
One-electron abstraction from guanine (1) generates a radical cation (2), which, under protic 
conditions, is in equilibrium with the guanine radical (3). Under basic conditions the latter 
can be deprotonated to the radical anion (4).[98, 109] The addition of a hydroxyl ion to the 
guanine radical cation (2) results in a “redox ambivalent” C8-hydroxy radical (5). The for-
mation of the C8-adduct is also possible by a direct attack of a hydroxyl radical to the C8 of 
the undamaged guanine base (1).[109] Depending on the conditions, this adduct can be fur-
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ther oxidized or reduced, leading either to 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG, 
6) or 2,6-diamino-4-oxo-5-formamidopyrimidine (FaPydG, 7). In the latter case, subsequent 
hydrolysis including the cleavage of the C8-N9 imidazole bond after the reduction is re-
quired. A reaction of oxygen with the guanine radical (3) results in the formation of a peroxyl 
radical (8). This can further react to the relatively unstable 2,5-diamino-4H-imidazol-4-one 
(imidazolon; dIz, 9) and in aqueous solution will be hydrolyzed to 2,2,4-triamino-5-(2H)-
oxazolone (oxazolone; dZ, 10), which are both the predominant products of this 
pathway.[110-111] Also in this case, the guanine radical (2) can be generated by the attack of 
hydroxyl radicals to the C4 of the undamaged guanine (1).[109] The reaction of a hydroxyl rad-
ical with guanine leads to ≈17% to C8- (5) and ≈60-70% to C4-addition (11).[109]  
With 0.74 V vs. NHE, 8-oxodG harbors an even lower oxidation potential than the undam-
aged guanine, explaining its high reactivity and fast further degradation to other more stable 
products.[112] These reactions generally include ring opening and subsequent rearrange-
ments, leading to e.g. imidazolone (9), oxazolone (10), guanidinohydantoin, spiroiminodihy-
dantoin, or even urea.[113-114]  
 
1.3.2.2 Oxidation of Adenine 
As has been shown previously for guanine, one-electron oxidation of adenine (12) leads to a 
radical cation (13), which exhibits very strong acidic properties (pKa ≤ 1, Scheme 3).[98, 115]  
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Scheme 3: Schematic overview of the oxidation of adenine. 
Thus, the radical cation (13) can be directly protonated leading to the adenine radical (14). 
This can be further deaminated, leading to another major degradation product hypoxanthine 
(15). Nevertheless, the radical cation (13) can also be hydroxylated resulting in the formation 
of the C8-adduct (16). In the case of one-electron oxidation of this reducing radical 8-Oxo-
7,8-dihydro-2’-deoxyadenosine (8-oxodA, 17) is formed, and in the case of reduction and 
subsequent hydrolysis 4,6-diamino-5-formamidopyrimidine (FaPydA, 18) is generated.[116] 
Again, both A-lesions arise from the same C8 intermediate. The reaction can also be initiated 
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by the attack of a hydroxyl radical, leading to the generation of the C4- (19) and C8-adduct 
(16). Whereas the first is quite unstable and remains at equilibrium with the educt, the for-
mation of the C8-adduct is irreversible.[117] The reaction of a hydroxyl radical with adenine 
results in ≈37% to C8- and ≈50% to C4-addition.[98, 101] Analogous to 8-oxodG, 8-oxodA exhib-
its a low oxidation potential (0.92 V vs. NHE).[118] In contrast to 8-oxodG no further oxidation 
has been observed so far. 
 
1.3.2.3 Epimerization and Deglycosylation of Formamidopyrimidines 
A typical feature of formamidopyrimidines is their ability to readily epimerize and rearrange 
from the furanose (,-7) to the more stable pyranose form (21, Scheme 4).[119] This is ex-
plained by the fact that the glycosidic bond does involve a nitrogen atom, which is not part 
of an aromatic, stabilized heterocycle. Furthermore, deglycosylation could occur, but this oc-
curs at much slower rate (22, 23).  
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Scheme 4: Epimerisation, anomerisation, and deglycosylation of FaPydG. 
In deglycosylation studies with nucleosides FaPydG exhibits a half-life of more than 500 
hours at 55°C, FaPydA in comparison has a half-life of 20.5 h. Even at 90°C FaPydG is still 16 
times more stable than FaPydA with a half-life of around 91 h. Deglycosylation studies of 
FaPydA show at 37°C a half-life time of 103 h, while for FaPydG those studies were, due to 
time limitations, not done. Overall, these results reveal a higher stability of FaPydG in com-
parison to FaPydA.[120] The ratio of the - and -anomers changes within 6 hours at 37°C 
from : 1:1 to 1:1.33.[120] The -anomer of FaPydG is known to block replication, whereas 
the -anomer is bypassed during replication and can induce mutations.[121-122] The mutagenic 
-anomer is known to be present in double-stranded DNA[123-124] whereas the -anomer is 
the dominant species in single-stranded DNA (: → 2-3:1).[124] In the DNA-duplex, the le-
sion exists almost exclusively as the -anomer. In general, it seems that in duplex DNA -
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anomers are more stable than -anomers.[124-126] Based on their results of the work with the 
formamidopyrimidine-type DNA adduct of Aflatoxin B1, Brown et al. conclude, that it is very 
unlikely that much -anomer is present in genomic DNA.[124] Under their experimental con-
ditions, the half-life of the -anomer in double-stranded DNA is 16 h at pH 7.0. Therefore, 
anomerization during replication is quite unlikely.  
The process of epimerization from the furanose to the more stable pyranose form makes 
synthesis of FaPy-containing oligonucleotides quite difficult. The epimerization cannot occur 
within the strand, where the 5’-substituent is a phosphate. Synthesis of FaPy-containing DNA 
oligos always results therefore in a mixture of - and -anomers, making it difficult to per-
form viable biological experiments and to obtain accurate results. Therefore the need for a 
synthesis that avoids rearrangement emerged, and in addition, stereodefined FaPy-analogs, 
so either - or -analogs, were synthesized. Insertion of the lesion-containing phosphor-
amidite as a dinucleotide circumvents epimerization during oligonucleotide synthesis.[127] To 
this end bioisosteric compounds were developed. Two well-known approaches for bioiso-
steric FaPy-analogs are the C-nucleosides from the Greenberg-group[128-129] and the carbocy-
clic FaPys from the Carell-group[130] (see next chapter). 
 
1.3.2.4 Bioisosteric Analogs of the Formamidopyrimidines 
In order to investigate the properties of formamidopyrimidines the need evolved for bioiso-
steric analogs. In comparison to the natural lesions these compounds should have similar 
structures and the same hydrogen bonding properties but should be anomerically stable 
during DNA synthesis and manipulation. This allows the preparation of FaPy-analog-
containing oligonucleotides in sufficient quantity and purity. Given that DNA polymerases 
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choose nucleotides based on their sugar moiety,[131-134] it is important to use analogs with 
similar structural conformations compared to the desoxyribose. The compounds used in this 
thesis were found to be good mimics of the formamidopyrimidines and they enabled us to 
do co-crystallization studies with polymerases or repair proteins. Additionally, they were 
used as inhibitors of repair enzymes.[119] 
 
1.3.2.4.1 C-nucleoside Analogs 
One approach to investigate the biology of formamidopyrimidines in DNA was conducted by 
the Greenberg-group using the stereodefined C-nucleosides, in which the N(9) is replaced by 
a C (Fig. 5).[128-129] The geometry at the connection between the base and the sugar is there-
fore changed from trigonal planar (Csp3-Nsp3-bond) to a tetraedric form (Csp3- Csp3-bond). 
 
Figure 5: C-nucleoside FaPy-analogs of the Greenberg group. 
When comparing thermodynamic properties of DNA duplexes containing either the canoni-
cal nucleoside, the natural formamidopyrimidines or the C-nucleoside analogs paired with 
the right base, the melting temperature of the duplex strand with the native base pair is the 
highest whereas the one with the C-nucleoside analog is the lowest.[129, 135] No difference be-
tween the - and -anomer is observed when measuring the melting temperature of DNA 
duplexes containing C-FaPydA.[135] 
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1.3.2.4.2 Carbocyclic Analogs 
Another possibility to prevent anomerization of the FaPy-lesions that is applied by the Carell 
group is the use of bioisosteric lesion-analogs where the sugar oxygen is replaced by a meth-
ylene group (Fig. 6).[130]  
 
Figure 6: Carbocyclic FaPy-analogs developed by the Carell group. 
The so-called carbocycle prevents anomerization and has no influence on the base pairing it-
self. To prove that the carbocycle does not change the thermodynamic properties, carbocy-
clic dG (cdG) and natural dG were compared. They were found to exhibit similar melting 
points when base paired with dA, dC, dG, or dT. In general, the base pairs with the carbocy-
clic nucleoside are slightly more stable.[136] Compared to the native bases dA or dG, a DNA 
duplex containing the carbocyclic FaPy-lesion is less stable.[136]  
 
Previous investigations of how the carbocycle influences the syn/anti-conformation indicat-
ed only marginal differences between the 2’-deoxyribose and the carbocycle.[130] In agree-
ment with NOESY experiments, the anti conformation is favored.127,134 For standard nucleo-
tides it was reported that the duplex stability and structure is only marginally affected by the 
mutation from the oxygen to the methylene group.[137-139]  
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To investigate of how the carbocycle influences the syn/anti-conformation during base pair-
ing, theoretical studies were performed.[136] The torsion potentials of the C’-N bonds of natu-
ral and carbocyclic FaPydG were calculated using B3LYP/6-31G* density functional calcula-
tion. In both cases the anti conformation is about 6 kcal mol-1 more stable.[136] Additionally, 
the results are supported by 2D-torsional screens around the C1'-NH and around the NH-C4 
bond of both monomers using the force field SYBYL mmff94s.[140]  
 
1.4 Replication of Oxidative Lesions 
In general, oxidative lesions reduce the replication efficiency of high-fidelity polymerases 
(for further details see chapter 1.5) and often serve as templating bases with mutagenic po-
tential.[141-142] It should be noted that the lesions derived from adenine inhibit a much small-
er mutagenic potential then the ones derived from guanine.[143] However, the level of muta-
genicity depends much on the DNA sequence context,[144] the structure of the lesion itself, 
and on the structural deviations caused within the DNA strand by the lesion.[145] When a pol-
ymerase encounters a damaged DNA base, this lesion can either be blocking, coding or mis-
coding.  The first two possibilities are rather harmless, but a miscoding lesion can lead to 
mutations and, in the worst case, to diseases.[146] 8-oxodG is one famous example of a mis-
coding lesion, since a stable base pair with dATP can even be elongated.[147] When a repli-
cative polymerase cannot bypass a certain lesion or is too slow, a process called translesion 
synthesis (TLS) takes place, helping to bypass the lesion. In general, depending on the type of 
lesion, TLS requires two main polymerases.[148] One, which inserts one or two bases opposite 
the lesion, and a second one which elongates the strand past this lesion.[146, 149] When the le-
sion is bypassed, the original replicative polymerase can restart. Typical inserter polymerases 
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are Pol , , , or , and typical extenders are Pol  or . PCNA (Proliferating Cell Nuclear An-
tigen) is the central scaffold promoting the access of TLS polymerases to the replication en-
semble stalled at a lesion site. It is also called the replication sliding clamp and is largely 
regulated by ubiquitylation and sumoylation.[150] This mechanism is extremely important for 
lesions, which could otherwise not be handled by high-fidelity polymerases. Even though the 
active site of TLS polymerases is not as tightly structured as the one of high-fidelity polymer-
ases, their relative “correct insertion fidelity” is sufficient to decrease the proportion of mis-
insertions.[146, 151] 
 
1.5 Polymerases 
In all living organisms there is the need to amplify the genetic information with high accura-
cy. To comply with this aim, nature has developed complex processes, relying on a variety of 
in concert working proteins including several classes of polymerases.[146] In general, all poly-
merases have a similar overall structure,36,37 but their specific size and composition can vary 
enormously. Whereas Pol  (repair function) has a size of 39 kDa and works as a single subu-
nit,[152] DNA Pol III from E. coli (replicative function) functions only as a complex, multichain 
enzyme (holoenzyme), which contains 10 different subunits.[153] Their main functions are 
replication, recombination, and repair events.[154-155] Based on sequence homologies, poly-
merases are grouped into seven different families (Table 1). The overall structure of a poly-
merase resembles a human right hand with fingers, thumb and palm. The palm is highly con-
served in most polymerases and contains the catalytic center including residues responsible 
for metal-ion binding. They ensure the cleavage of the incoming dNTP when it is added to 
the 3’-OH group of the primer strand. This two-metal mechanism is found in every polymer-
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ase and in most cases Mg2+ is used.[155] In contrast, the finger and thumb regions can differ in 
the various families.[155] In addition, some polymerases contain a conserved 3’-5’ proofread-
ing exonuclease domain.[156]  
Table 1:  Classification of the prokaryotic and eukaryotic polymerases. Table adapted from 
[146, 157]
 
Family Prokaryotic Function Eukaryotic Function 
A DNA Pol I replication, repair 
DNA Pol γ 
DNA Pol θ 
 
DNA Pol ν 
replication in mitochondria and of plastid DNA 
replication of cross links, BER, hypermutation of im-
munglobulin genes 
repair 
B DNA Pol II 
repair, replication, 
translesion synthesis 
DNA Pol α 
DNA Pol δ 
DNA Pol ε 
DNA Pol ζ 
replication (priming) 
replication (lagging strand), repair 
replication (leading strand), repair 
translesion synthesis (extension) 
C 
DNA Pol III 
DNA Pol E 
Replication   
X DNA Pol X Repair 
DNA Pol β 
DNA Pol λ 
 
DNA Pol μ 
DNA Pol σ 
TdT 
BER 
BER, double strand break repair, immunglobulin re-
combinational repair (IRR), translesion synthesis 
immunglobulin recombinational repair  
sister chromatid cohesion 
antigen receptor diversity 
Y 
DNA Pol IV 
DNA Pol V 
translesion synthesis 
DNA Pol η 
DNA Pol ι 
DNA Pol κ 
Rev1L 
translesion synthesis (incorporation) 
RT   Telomerase replication of chromosome ends 
 
1.5.1 The Prokaryotic Polymerases of the A-Family  
The A-family of polymerases is represented by high-fidelity polymerases and famous mem-
bers are the DNA polymerases I from E. coli,[158] B. subtilis,[159] G. stearothermophilus[160] and 
T. aquaticus.[161] In general, they have the common architecture of a right hand with thumb, 
fingers, and palm domain, and in addition, they feature a 3’-5’-exonuclease domain respon-
sible for proofreading. Therefore, they have two active sites, where one is responsible for 
polymerization and one for exonucleolytic proofreading.[156] However, some do only contain 
a vestigial, non-functional 3’-5’-exonuclease domain (e.g. B. subtilis,[159] G. stearothermo-
philus[160]). High fidelity polymerases play an important role in repair and replication and 
copy DNA templates in a very fast and accurate manner. Considerable sequence and struc-
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tural deviations between the various members are observed within the finger and the thumb 
domains.[162] One characteristic aspect of a binary complex of Pol I and a dsDNA is that the 
acceptor template base for the incoming dNTP is not positioned in the insertion site next to 
the previously formed base pair; it has to enter a pre-insertion site first.[162] This mechanism 
might explain their ability to discriminate strongly against frameshifts, e.g. KF exhibits an er-
ror rate of ≤10−5.[162-163] 
 
1.5.1.1 E. coli DNA Pol I and its Large Fragment Klenow   
Escherichia coli is a gram-negative bacterium, which is naturally found in the intestine of 
birds and endothermic mammals. In 1956, Kornberg and coworkers discovered the first 
known polymerase, which was the DNA Pol I of E. coli.[158] Playing an important role in repair 
(e.g. BER[164] and NER[165]) and in replication, it binds efficiently to nicked and gapped DNA. It 
also removes the RNA primer of the Okazaki fragments and replaces the gaps of the lagging 
strand during DNA replication.[146] The optimal growth temperature of E. coli is 37°C. Its Pol I 
belongs to the A-family, and its polypeptide chain consists of 928 amino acids (103 kDa). As 
all A-family polymerases, it contains an 5’-3’-polymerase activity, 5’-3’-exonuclease activity 
as well as the 3’-5’-proofreading exonuclease activity. The large fragment of Pol I is called 
Klenow fragment (KF); it lacks the 5‘-3‘-exonuclease, but retains the polymerase and proof-
reading activity. KF is extensively used in molecular studies as a model system for determin-
ing polymerase structure and functions. The missing exonuclease makes it suitable for many 
applications. In 1985, Ollis et al. published the crystal structure of KF in complex with dT, 
which was the first high resolution structure of a high fidelity polymerase.[166] For certain ap-
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plications where the proofreading exonuclease is unsuitable, another mutant, called KFexo-, is 
used instead.  
Opposite 8-oxodG, KFexo- inserts efficiently 4-fold more dCTP than dATP.[167] Insertion studies 
with KF and the FaPy-lesions reveal a persistently lower mutagenic potential compared to 
the 8-oxo lesions.[141] Opposite FaPydA and FaPydG, the correct nucleotides dTTP and dCTP 
are inserted more slowly than opposite the native bases.[141-142] The misinsertion of dATP 
opposite FaPydG by KFexo- is 1-5%, depending largely on the sequence context.[141] Addition-
ally, KFexo- is able to insert one nucleotide opposite imidazolone and oxazolone. After inser-
tion, however, it generally stalls.  
 
1.5.1.2 G. stearothermophilus DNA Pol I and its Large Fragment Bst Pol I 
Geobacillus stearothermophilus is a thermophilic bacterium, which was isolated in a calcium 
carbonate mount of a hot spring in Yellowstone National Park in Idaho. The strain has an op-
timal growth temperature of 71°C and its DNA polymerase I is thus a thermostable member 
of the A-family, which is composed of 876 amino acids (97 kDa). It displays polymerase activ-
ity, strand displacement and 5'-3'-exonuclease activity, but it lacks the proofreading 3'-5'- 
exonuclease activity. We refer here to Bst Pol I as the large fragment of the polymerase I, 
which contains the 592 carboxy-terminal amino acids (67.7 kDa). In size and domain struc-
ture it is similar to the Klenow fragment from E. coli DNA polymerase I, but it lacks the 3'-5'- 
exonuclease activity. Nevertheless, it has a higher processivity than KF (Bst Pol I: 111 nucleo-
tides/s; KF: 7.7 nucleotides/s).[160]  
Sequence alignments of Bst Pol I with KF[160, 168] and Klentaq1[160, 169] (analogous large frag-
ment of DNA polymerase I of the thermophilic bacterium Thermus aquaticus) revealed little 
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overall sequence similarities (37.7% within the polymerase domain and 9.8% within the N-
terminal exonuclease domain), but the overall topology shows high structural resemblance 
between these three polymerases. In 1997, Kiefer et al. published the first high resolution 
structure of Bst Pol I,[160] therefore making it possible to analyze and compare the structures 
e.g. during DNA lesion bypass. Studies with various 8-oxodG-analogs with KFexo- and Bst Pol I 
pointed out that KFexo- is less sensitive to alterations in the imidazole ring of dG during incor-
poration of dCTP.[170] 
The polymerase Bst Pol I consists of 4 main domains (Fig. 7): the vestigial 3’-5’-exonuclease 
domain, the palm domain, the thumb domain, and the finger domain. The N-terminal do-
main corresponds to the vestigial 3’-5’-exonuclease domain, which, in the case of Bst Pol I, is 
inactive due to lacking metal binding ability and structural and topological changes in the ac-
tive-site cleft.[160, 171-172] The sequence identity between Bst Pol I and KF in the palm respec-
tively polymerase domain is 71.0%.[160] In general, DNA polymerases have three highly con-
served carboxylate residues within the active site, which are responsible for catalysis.[173-174] 
In Bst Pol I, the corresponding amino acids are Asp653, Asp830, and Glu831 (in KF: Asp705, 
Asp882, and Glu883). When the active site is formed, the thumb domain plays an important 
role in stabilizing the DNA. In contrast to KF[171] and Klentaq1,[175] the joint between two heli-
ces (I and I1) is shorter in Bst Pol I. Conceivably this region is less flexible, therefore contrib-
uting to a more stable DNA-protein association, which could explain the higher processivity. 
The comparison of the finger domain reveals only marginal differences between the two 
polymerase fragments. In this region, the O-helices are located, which are essential for dNTP 
and template binding.[160, 174] Herein, two further highly conserved residues are located, 
Phe710 and Tyr714 (in KF: Phe762 and Tyr766).[160]  
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Figure 7: Crystal structure showing the topology of the large fragment of Bst Pol I in complex with DNA. 
The close resemblance of Bst Pol I to KF and Klentaq1 makes it a good model system for oth-
er polymerases of the A-family. One advantage of Bst Pol I is its remaining activity in the 
crystal. Therefore, soaking crystals with additional nucleotides can result in further elonga-
tion of the DNA template strand.[162, 176] This makes it possible to crystallographically capture 
many stages of the replication cycle.[147, 162, 176-183] In general, the accuracy of the polymerase 
depends largely on the metal ions used in the reaction buffer, e.g. Mg2+ ensures a higher re-
liability then Mn2+.[178] Co-crystallization studies with undamaged DNA duplex strands were 
reported before this study.[162, 176, 178] Additionally, lesion- (e.g. cFaPydG,[147] O6-methyl-
guanine,[180] or bulky adducts[177, 179]) or mismatch-containing DNA duplexes were also co-
crystallized with Bst Pol I.[178] 
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1.5.1.2.1 Replication of a DNA Lesion within Bst Pol I 
When binding to a lesion containing DNA duplex strand, the polymerase is in an open con-
formation and the unpaired lesion is positioned between the helices O and O1, which corre-
sponds to the pre-insertion site (pre-IS). In this state, the highly conserved amino acid 
Tyr714 (located in helix O) is stacking with the template base of the base pair at the post-
insertion site (post-IS) n-1 and it is therefore blocking the insertion site (IS).[160, 176] Asp830 
forms a hydrogen bond with the 3’-OH group of the primer strand (Scheme 5a).[160]  
 
Scheme 5: Replication of a DNA-lesion (n; red) by Bst Pol I. 
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When a dNTP is bound, the polymerase is closing by moving its thumb towards the fingers, 
thereby defining the active center. During this movement the template base is shifted to-
wards the newly formed insertion site and the triphosphate group of the nucleotide is coor-
dinated by two magnesium ions (Scheme 5b).[162] Therefore, a nucleophilic attack is enabled 
and the base pair can be formed.[162] In this state, the Tyr714, formerly blocking the insertion 
site, is displaced, but now the pre-insertion site is blocked by the loop connecting the helices 
O and O1.[162] Subsequent release of pyrophosphate during covalent binding of the dNTP to 
(the 3’-OH terminus) of the primer strand destabilizes the closed conformation of the poly-
merase leading to translocation of the newly formed base pair to the post-insertion site 
(post-IS, n-1) (Scheme 5c).[131, 184] This translocation mechanism, whose driving force is the 
cleavage of the triphosphate, is an important step for frameshift prevention.[162] At the post-
insertion site, Tyr714 stabilizes the templating base by π-stacking. Additionally, the highly 
conserved amino acids Arg615 and Gln797 form hydrogen bonds to the correct base pair and 
stabilize its position.[176]  
After another elongation step the newly formed base pair is shifted to the n-2 position in the 
DNA duplex binding region (DBR) (Scheme 5d). This region binds 4 base pairs with the regis-
ter positions n-2 to n-5.[162] An interesting observation made by Kiefer et al. was that the 
DNA, when being shifted to the duplex binding region, is underwinding significantly, result-
ing in a structural change from B- to A-conformation.[176] The DNA, which is not located in-
side the polymerase remains in the B-form conformation. The part of the DNA, which is 
bound in the polymerase changes back to the B-form when being shifted away from position 
n-5.[176] 
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Mispairs or lesions can lead to distortions within the DNA strand and subsequently in the 
polymerase active site,[185] possibly resulting in reduced processivity or dissociation of the 
polymerase.[178, 180, 183] There are many stages of proof within the replication cycle to ensure 
that the right nucleotide is paired to the templating base. One checkpoint is the correct for-
mation of the insertion site. Only in the case of a suitable dNTP the insertion site can be fully 
constructed, which ensures proper base pairing of the nucleotide with the templating nucle-
obase, because only in this case the interactions between polymerase, nucleotide and tem-
plate base are strong enough. To establish Watson-Crick base pairing, the conformation of 
the base pair in the insertion site is strictly defined.[186-187] Another checkpoint is the amino 
acid Asp830. When the polymerase is in the open conformation, Asp830 is essential for the 
activity of the enzyme and coordinates the 3’-OH group of the primer end. In most cases the 
geometry of a mismatch differs in comparison to a correctly formed base pair. If the primer 
end is not positioned correctly within the active site, no hydrogen bonds with Asp830 can be 
formed and no further nucleotide can be incorporated.[176, 178] A further amino acid to guar-
antee proper base pairing is Tyr714. Site-directed mutagenesis studies of this residue in the 
Klenow fragment revealed tremendous effects on the fidelity of replication.[188] One feature 
of oxidative lesions is their ability to enhance their replication via altered H-bond-
formation.[147] 
 
1.5.2 The Eukaryotic Y- Family Polymerases 
The Y-family is represented by a group of repair polymerases, which play an important role 
in translesion synthesis (TLS) of DNA lesions. The members of this family (in eukaryotes: , , 
, Rev1, Table 1) are known to be error prone or of low fidelity. This is mainly due to struc-
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tural differences within the active site, which is more spacious than the one of high fidelity 
polymerases. Therefore, less contact between the polymerase, the template DNA and the 
nucleotide is established, allowing lesion bypass of e.g. more bulky lesions, which are gener-
ally excluded from the tighter active sites of other polymerases. Their thumb and fingers are 
smaller than in other polymerases and they lack the -O helix, which in high fidelity poly-
merases is responsible for selectivity of nucleotides.[146, 149] They do not contain a proofread-
ing 3’-5’-exonuclease domain, but compared to other polymerase families, they have a C-
terminal polymerase-associated domain (PAD) or little finger domain (LF), which interacts 
with the DNA duplex.[149] In comparison to the replication efficiency of high fidelity polymer-
ases (10-5-10-6), their error-rate is much higher (10-1-10-4) and their processivity much lo-
wer.[146, 148, 189] Each of the Y-family polymerases has a unique DNA damage bypass ability 
und fidelity. 
 
1.5.2.1 Polymerase η 
Polymerase  is the best analyzed polymerase of the Y-family and is well-known for its ability 
to replicate quite accurately past UV lesions. In humans, mutations or deletions in the gene 
for Pol  lead to Xeroderma pigmentosum (XP-V) resulting in extreme light sensitivity and a 
highly enhanced predisposition for skin cancer due to UV-induced lesions.[190] Opposite the 
major UV lesion cyclobutane pyrimidine/thymine dimers (CPD), which induce severe distor-
tions within the DNA, Pol  correctly inserts two adenines.[191-192] It is also able to replicate 
past other types of lesions, albeit with less efficiency than with CPDs.[148] Crystal structures 
with cisplatin adducts (normally formed during chemotherapy with cisplatin) and yeast Pol  
revealed correct bypass of these intra-strand crosslinks.[193-195] The enzyme is also able to 
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replicate past some bulky adducts, e.g. acetylated aromatic amine lesions of guanine (AAF-
dG) or N2-AAF-dG, where it mainly incorporates the correct dCTP, although with reduced ef-
ficiency.[196-198] Yeast Pol  can also bypass 8-oxodG lesions, correctly inserting dCTP and ex-
tending the newly formed base pair.[199-200] Crystal structures were obtained of a ternary 
complex with yeast Pol , template-primer DNA with 8-oxodG and dCTP. They reveal an ac-
tive site that can accommodate this lesion with marginal structural changes.[200] Next to the 
correct insertion of dC, human Pol  incorporates a low amount of dA as well.[199] 
 
1.5.2.2 Polymerase κ 
In contrast to the other Y-family polymerases, Pol  is the only one having homologues in 
prokaryotes and archaea, including DinB (Pol IV) in Escherichia coli and Dbh and Dpo4 in Sul-
folobus solfataricus.[201] In addition, Pol  (as well as Rev1) contains an N-terminal subdo-
main (N-clasp), which is indispensable for catalytic activity and which allows the polymerase 
to completely encircle the DNA.[202-203] In contrast to Pol , its active site is more constrained 
and smaller, and smaller is also the finger domain.[203] This might explain its inability to insert 
nucleotides opposite many types of lesions (e.g. CDP, (6-4)TT photoproduct),[204-205] but it 
may also explain its enhanced fidelity and higher processivity on undamaged DNA in compar-
ison to the other Y-family polymerases.[206] Albeit it cannot insert nucleotides opposite cer-
tain lesions, Pol  can extend lesion base pairs previously formed by another polymerase.[148, 
201, 207] It is unable to insert nucleotides opposite the 3’-T of a cis-syn CPD, but it can extend 
very efficiently from a dG:CPD base pair.[204] It is not capable of extending a (6-4)TT photo-
product.[204-205] Opposite 8-oxodG, Pol  inserts more efficiently dA than dC.[207] Carpio et al. 
showed, that Pol  forms mostly a Hoogsteen base pair of 8-oxodG(syn):dA(anti). In the 
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structure it can be seen that the active site is well-adapted to accommodate 8-oxodG in the 
syn conformation and that the template strand is not affected.[208-209] 
 
1.6 Base Excision Repair 
Base excision repair (BER) is an essential repair process, which plays an important role in the 
removal of damaged DNA. In summary, repair initiation starts with recognition of (mainly) 
non-helix-distorting lesions by specialized excision proteins called glycosylases. They are re-
sponsible for cleavage of the glycosidic bond between the sugar and the lesion base, leaving 
an abasic site (also referred to as AP site (apurinic/apyrimidinic site)). Subsequently, this AP 
site is cleaved by an endonuclease and a polymerase refills the gap (Fig. 8).   
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Figure 8: Mechanism of the human base excision repair. 
Glycosylases are ubiquitous in all organisms. Each of them is specialized for the repair of cer-
tain DNA damages. Their main function is to recognize and subsequently excise the lesions. 
Some glycosylases possess only glycosylase activity (e.g. TDG, SMUG1, UNG), others addi-
tionally own a lyase function (e.g. FPG, OGG1, NTH1, NEI1-3), which is to cleave the prelimi-
nary formed AP site.[119] Hence, depending on their functions, they are either classified as 
mono- or bifunctional glycosylases.[210]  
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The lesion removal is initiated by flipping the base out of the DNA helix, consequently cleav-
ing the glycosidic bond between the sugar and the base.[211] In the case of monofunctional 
glycosylases, subsequent incision by the apurinic endonuclease (APE1) generates a repair in-
termediate that contains a single-strand break with 3’-hydroxyl and 5’-deoxyribose-5’-
phosphate (5’dRp) termini. The bifunctional glycosylases, after base removal, incise the DNA 
backbone 3’ to the abasic site by -elimination (e.g. OGG1, NTH1) or by /-elimination (e.g. 
FPG, NEIL1/2),[212] thereby creating non-conventional 5’- or 3’-termini (e.g. 5’dRP, 5’-OH, 3’-
PO4, 3’-PG, or 3’-PUA). These blocking termini have to be modified before further polymer-
ase actions are possible, which is achieved by APE1 or PNKP (polynucleotide kinase/ 
phosphatase). 
Once a lesion is recognized and excised, two possible pathways of repair can follow. Depend-
ing on the size of the repair patch, either short patch (in the case of 1 nucleotide)[213] or long 
patch (2-12 nucleotides)[214-215] BER is initiated. In short-patch BER, Pol , which possesses 
polymerase and 5’dRP lyase activity, inserts one nucleotide and excises the 5’dRP by creating 
the 5’-phosphate group, necessary for the final nick ligation by a complex of LIGIII (DNA lig-
ase III) and XRCC1 (X-ray repair cross complementing 1). In long-patch BER, PCNA (proliferat-
ing cell nuclear antigen; sliding clamp for pols), RF-C (replication factor C, which loads PCNA 
on DNA) and DNA Pols ,  and/or Pol  are required for strand displacement synthesis, to 
excise a long DNA patch 5’ of the lesion, which is finally removed by FEN1 (flap endonuclease 
1). The last step of ligation is fulfilled by DNA ligase I (LIGI). In 2009, van Loon et al. analyzed 
the repair of 8-oxodG via immunofluorescence experiments in ROS-exposed cells and pro-
posed a possible repair pathway of 8-oxodG.[216] Two major differences in the repair of this 
lesion have been observed, depending on the base opposite 8-oxodG and on the tissue. In 
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non-replicating tissues, an 8-oxodG:dC base pair is mainly recognized by OGG1 and removed 
by the short-patch BER. In replicating tissues, where 8-oxodG is often base paired with dA, 
MUTY firstly removes the opposing adenine via long-patch BER and subsequently short-
patch BER will remove the 8-oxodG.[151] 
The first glycosylase being found to recognize and efficiently excise formamidopyrimidine le-
sions was a glycosylase of E. coli, named after its function formamidopyrimidine glycosylase 
(FPG).[217-218] Being a bifunctional glycosylase it harbors an additional AP endonuclease activi-
ty, hence it can also act as a lyase.[219] In contrast to FaPydG and 8-oxodG, recognition and 
excision of FaPydA by FPG is independent from the nucleotide base paired with the 
lesions.[220] In general, FaPydG is excised more efficiently than 8-oxodG when base paired to 
dC, but both are less efficiently excised when opposite dA.[217, 221-222] A crystal structure of a 
binary complex of cFaPydG:dC-containing DNA duplex strand in complex with Lactococcus 
lactis FPG reveals a different recognition mechanism compared to 8-oxodG:dC. While FPG 
binds 8-oxodG in the syn conformation, FaPydG is bound in the anti conformation.[211, 223] 
Oxazolone is also excised by FPG, yet again with discriminating efficiency when base-paired 
with dA.[224] A similar behavior with respect to lesion recognition is shown by hOGG1 (human 
8-oxodG-glycosylase 1), the functional human homolog of FPG. In contrast, when investigat-
ed with the A-lesions, hOGG1 discriminates strongly against 8-oxodA and FaPydA.[212, 225] 8-
oxodA is only recognized and excised by OGG1 when base paired with dCTP.[226] While FPG 
and OGG1 excise the lesions from the DNA strand, another glycosylase, MUTY, is able to ex-
trude the incorrect base opposite the lesion from the DNA duplex and to hydrolyze its glyco-
sidic bond. While FPG is less efficient in excising e.g. FaPydG, 8-oxodG, or oxazolone when 
base paired with dA, MUTY is capable of excising dA, base-paired to the lesion.[221, 227] In hu-
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mans, mainly six bifunctional glycosylases are associated with the repair of oxidative lesions: 
OGG1, MYH (MUTY homolog), NTH1 (endonuclease III homolog), and NEIL1-3 (NEI-like en-
donuclease VIII).[210] NTH1 and NEIL1-3 are known to excise pyrimidines and pyrimidine-
derived lesions (FaPydG,[228-229] FaPydA,[225, 228-229] and oxazolone[224]) therefore preferentially 
acting on lesions base paired with purines.[228] Their ability to excise formamidopyrimidine 
but not 8-oxopurine lesions is assumed to depend on the recognition of the lesion structure, 
FaPys being recognized as modified pyrimidines.[228] Nevertheless, NEIL glycosylases excise 
FaPydA more efficiently than does NTH1.[228-229] All in all, a huge machinery of different en-
zymes acts in concert to remove DNA damage in order to sustain the genetic stability of or-
ganisms. Many biochemical and structural investigations reveal insights into the mechanisms 
of how the organism deals with oxidative lesion. However, further investigations have to be 
done. 
 
1.7 Biological Implications of the FaPy- and 8-oxo-Lesions 
In general, the oxidative lesions reduce the replication efficiency and can act as templing ba-
ses with mutagenic potential.[141-142] The lesions derived from adenine exhibit a much smaller 
mutagenic potential then those derived from guanine.[143] The mutagenicity depends also 
largely on the sequence context.[144] 
The Klenow Fragment from E. coli (KF) lacking the 3’-5’-exconuclease is known to induce 
A→T transversion mutations by misinserting dATP opposite FaPydA,[142] but in general, this 
lesion has only a small effect on the Klenow fidelity.[125] In vivo studies in simian kidney cells 
(COS-7) reveal in less than 1% A→C transversions by 8-oxodA.[144, 230] In general, the muta-
genic potential of 8-oxodA and its contribution to cellular damage is, in contrast to 8-oxodG 
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(6%-29%), assumed to be very low.[143, 231] Thereby, the vector survival rate of 8-oxodA (88-
90%) is considerably higher compared to 8-oxodG (64-78%).[143]  
The G-lesions mainly induce G→T transversion mutations and G→A transition mutations.[144, 
232] Primer extension studies with stabilized analogs,[136, 233] natural or methylated versions of 
FaPydG[141, 234-236] show either correct base pairing with dC or misincorporation of dA.[141] 
G→T transversions are observed when FaPydG (<1.9%) or 8-oxodG (3.1% - 9.8%) are by-
passed in wild-type E. coli[144] and those results are consistent with kinetic studies using KF 
and KFexo-.[141, 167, 232, 237] Bypass of FaPydG in COS-7 cells exhibits slightly more G→T trans-
versions than in 8-oxodG (8.2% vs. 6.1% in TXA sequence, and 29.6% vs. 23.5% in a TXT se-
quence).[144] In general, bypass of FaPydG is slower than bypass of 8-oxodG.[232] The bypass 
efficiency of FaPydG is comparable to those of oxazolone and imidazolone,[238-239] but in con-
trast, FaPydG and 8-oxodG have a lower mutation frequency.[232] It was further observed, 
that the 3’-5’-exonuclease activity has only little effect on FaPydG replication.[232] Kinetic 
primer extension studies with S. cerevisiae Pol  revealed that carbocyclic FaPydG is repli-
cated in an error-free fashion.[136] 
 
1.8 Biological Implications of Imidazolone and Oxazolone 
Imidazolone can arise from oxidation of guanine and further from facile oxidation of 8-
oxodG (Scheme 2).[114, 240-241] Subsequently, the more stable oxazolone arises from hydroly-
zation of imidazolone, which in aqueous solution at 20°C has a half life time of 18-24 h.[111] 
Both belong, next to 8-oxodG and FaPydG, to the major oxidation products of guanine.[110-
111] In primer extension studies with imidazolone-containing DNA, KF, and KFexo- only dGTP 
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was incorporated but bypass was inefficient.[240] Also in vivo studies showed mainly incorpo-
ration of dGTP opposite imidazolone, leading to G→C transversions mutations.[239]  
Oxazolone is bypassed quite efficiently and exhibits a similar in vivo mutation frequency as 
imidazolone (oxazolone 86%,[238] imidazolone 91%[239]). However, dATP is the mainly insert-
ed nucleotide opposite this lesion in vivo and in vitro, causing G→T transversion mutations. 
A small amount (≈5-10%) of dGTP is inserted as well.[224, 238] In primer extension studies with 
Pol  oxazolone represents a blocking lesion.[224] Altogether, the authors estimate its muta-
genic potential to be higher than that of 8-oxodG (mutation frequency of 8-oxodG 7% and of 
oxazolone 95%), even though the replication efficiency of oxazolone is lower compared to 8-
oxodG.[238]  
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1.9 Main Objectives of the Thesis 
The main aim of the project was the investigation of how low and high fidelity polymerases 
deal with certain purine-derived DNA lesions, such as formamidopyrimidines, imidazolone, 
and its derivatives. The ability of polymerases to insert nucleotide triphosphates opposite 
the lesions at defined sites in the DNA strand and subsequent bypass of the lesion-
containing base pair was thereby of major interest. In addition, quantitative analysis of the 
(mis)insertions should be performed. In order to support the biochemical data of the incor-
poration opposite the FaPy-lesions and to gain further insight into the insertion respectively 
bypass mechanisms co-crystallization experiments should be carried out with lesion-
containing DNA and with the large fragment of the thermostable and high fidelity model 
polymerase I of Geobacillus stearothermophilus (Bst Pol I). A special feature of Bst Pol I is its 
remaining activity in the crystal, making it possible to directly monitor sequential elongation 
steps inside the crystal. In this context, investigation of the position of the formamide-group 
and its role during base pairing was of special interest. 
Furthermore, given that an oxygen-containing group at the C(5) position of cytosine could in 
principle influence the base pairing properties, mC and its oxidative products, which are 
nowadays extensively found in genomes, should be investigated regarding their mutagenic 
potential. For this purpose, primer extension studies and subsequent pyrosequencing should 
be performed. 
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2 Abstracts of the Publications  
2.1 Gehrke, T.H.,1 Lischke, U.,1 Gasteiger, K. L.,1 Schneider, S.,1 Arnold, S., Müller, H. 
C., Stephenson, D. S., Zipse, H., Carell, T. “Unexpected non-Hoogsteen-based muta-
genicity mechanism of FaPy-DNA lesions.” Nat. Chem. Bio., 2013, 9, 455-461. 
 
ABSTRACT: 8-Oxopurines (8-oxodG/8-oxodA) and formamidopyrimidines (FaPydG/FaPydA) 
are major oxidative DNA lesions involved in cancer development and aging. Their mutageni-
city is believed to result from a conformational shift of the N9–C1’-glycosidic bonds from anti 
to syn, which allows the lesions to form noncanonical Hoogsteen-type base pairs with incom-
ing triphosphates during DNA replication. Here we present biochemical data and the first 
crystal structures of carbocyclic FaPydA and FaPydG containing DNA in complex with a high-
fidelity polymerase. Crystallographic snapshots show that the cFaPy lesions keep the anti-
geometry of the glycosidic bond during error-free and error-prone replication. The observed 
dG•dC  dT•dA transversion mutations are the result of base shifting and tautomerization. 
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2.2 Stathis, D.,1 Lischke, U., Koch, S.C. Deiml, C. A., Carell, T. “Discovery and muta-
genicity of a guanidinoformimine lesion as a new intermediate of the oxidative 
deoxyguanosine degradation pathway.” J. Am. Chem. Soc. 2012, 134, 4925-4930. 
 
ABSTRACT: Oxidative degradation of DNA is a major mutagenic process. Reactive oxygen 
species (ROS) produced in the course of oxidative phosphorylation or by exogenous factors 
are known to attack preferentially deoxyguanosine. The latter decomposes to give mutagen-
ic lesions, which under physiological conditions are efficiently repaired by specialized 
maintenance systems in the cell. Although many intermediates of the degradation pathway 
are today well-known, we report in this study the discovery of a new intermediate with an 
interesting guanidinoformimine structure. The structure elucidation of the new lesion was 
possible by using HPLC − MS techniques and organic synthesis. Finally we report the muta-
genic potential of the new lesion in comparison to the known lesions imidazolone and oxazo-
lone using primer extension and pyrosequencing experiments. 
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2.3 Münzel, M.,1 Lischke, U., Stathis, D. Pfaffeneder, T., Gnerlich, F. A., Deiml, C. A., 
Koch, S. C., Karaghiosoff, K., Carell, T. “Improved synthesis and mutagenicity of oli-
gonucleotides containing 5-hydroxymethylcytosine, 5-formylcytosine and 5-
carboxylcytosine.” Chemistry 2011, 17, 13782-13788. 
 
ABSTRACT: 5-Formylcytosine (fC or 5-CHOdC) and 5-carboxylcytosine (caC or 5-COOHdC) have re-
cently been identified as constituents of mammalian DNA. The nucleosides are formed from 
5-methylcytosine (mC or 5-MedC) via 5-hydroxymethylcytosine (hmC or 5-HOMedC) and are pos-
sible intermediates of an active DNA demethylation process. Here we show efficient synthe-
ses of phosphoramidites, which enable the synthesis of DNA strands containing these cyto-
sine modifications based on Pd0-catalyzed functionalization of 5-iododeoxycytidine. The first 
crystal structure of fC reveals the existence of an intramolecular H-bond between the exocy-
clic amine and the formyl group, which controls the conformation of the formyl substituent. 
Using a newly designed in vitro mutagenicity assay we show that fC and caC are only mar-
ginally mutagenic, which is a prerequisite for the bases to function as epigenetic control 
units. 
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Abbreviations 
8-oxodA   8-Oxo-7,8-dihydro-2′-deoxyadenosine 
8-oxodG   8-oxo-7,8-dihydro-2’-deoxyguanosine 
Å    Angstrom 
aa    amino acid 
AID    activation induced cytidine deaminase 
AP site    apurinic/apyrimidinic site= abasic site 
APE    apurinic endonuclease 
ATP    adenosine triphosphate 
BER    base excision repair 
c    carbocyclic 
CPD    cyclobutane pyrimidine/thymine dimers 
d    2'desoxy 
dA    2'-desoxyadenosine 
dATP    2'-desoxyadeninetriphosphat 
dC    2'-desoxycytidine 
dCTP    2'-desoxycytidinetriphosphat 
dG    2'-desoxyguanosine 
dGTP    2'-desoxyguaninetriphosphat 
dIz  2,5-diamino-4H-imidazol-4-one, imidazolone 
DNA  desoxyribonucleic acid 
DNMT  DNA methyltransferase 
dNTP  2'-desoxynucleotidetriphosphat 
dZ 2,2,4-triamino-5-(2H)-oxazolone, oxazolone 
DNA    deoxyribonucleic acid 
dR    2'-desoxyribose 
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dRP    5'-deoxyribose-5'-phosphate 
dT    2'-desoxythymidine 
dTTP    2'-desoxythymidine triphosphat 
et al.    lat. et alii, and others 
FaPydA   4,6-diamino-5-formamidopyrimidine 
FaPydG   2,6-diamino-4-oxo-5-formamidopyrimidine 
FEN    Flap endonuclease 
G    guanine 
h    hour 
His    histidine 
HPLC    high performance liquid chromatography 
Is    insertion site 
Iz    2,5-diamino-4H-imidazol-4-one, imidazolone 
KFexo-    Klenow Fragment (without 5’-3’ exonuclease) 
L    liter 
LIG    DNA ligase 
LF    little finger domain 
M    molecular weight (mol/L) 
MALDI-TOF   Matrix Assisted Laser Desorption Ionisation – time of flight 
min    minute 
ms    milli seconds 
NER    nucleotide excision repair 
NHE    normal hydrogen electrode 
nm    nanometer 
NMR    nuclear magnetic resonance  
O2    oxygen 
ODN    oligodesoxynucleotide 
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PAD    polymerase-associated domain 
PCNA    proliferating cell nuclear antigen 
PG    phosphoglycolate 
PNKP    Polynucleotide kinase / phosphatase 
Pol    polymerase 
post-IS    post-insertion site (n-1) 
pre-IS    pre-insertion site 
PUA    phosphor-,-unsaturated aldehyde 
Py    pyridine 
R    rest 
RFC    replication factor C 
RNA    ribonucleic acid 
ROS    reactive oxygen species 
RT    room temperature 
s    seconds 
T    temperature 
TDG    thymidine-DNA glycosylase 
TET    ten-eleven translocation protein 
TLS    translesion synthesis 
Tyr    tyrosine 
UV    ultraviolett 
V    Volt 
vs.    Versus 
XRCC    X-ray repair cross complementing 
Z    2,2,4-triamino-5-(2H)-oxazolone, oxazolone  
λ    wave length 
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Oxidative DNA damage is a very frequent mutagenic event inside a cell responsible for spontaneous cancer development, inflammation and aging1. The bases for lesion formation are 
processes associated with aerobic respiration. These give rise to the 
formation of reactive oxygen species such as O2·−, H2O2 and OH·, 
which attack the genetic material2. The purine nucleosides dG and 
dA are particularly vulnerable toward oxidative degradation owing 
to their comparably low oxidation potential3–5. Two major lesion 
types are formed (Supplementary Results, Supplementary Fig. 1). 
The two 8-oxo–type lesions 8-oxo-7,8-dihydro-2′-deoxyadenosine 
(8-oxodA) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) 
feature an oxidized C8 atom. In addition, the N7 atom carries a 
hydrogen atom, which changes this position from being hydrogen 
bond accepting to hydrogen bond donating. The second class of 
oxidative lesions are the ring-opened 4,6-diamino-5-formamidopy-
rimidine lesions FaPydA and FaPydG, which have a formamide 
group that has the potential to form a variety of different hydrogen 
bonds (Fig. 1 and Supplementary Fig. 1).
Whereas the mechanisms behind the mutagenicity of the 8-oxo– 
type lesions are today quite well investigated biochemically6,7 and 
structurally, with a variety of high-fidelity6,8,9 and low-fidelity10–14 
polymerases, little is known about the mutation mechanisms 
associated with FaPy-type lesions15. Particularly, crystal structures 
that could provide insights into the mutation mechanisms are not 
available. Whereas the α-FaPy lesions are known to block high- 
and low-fidelity polymerases16, the β-anomers do not stall repli-
cative polymerases but reduce the replication efficiency and serve 
as templating bases with considerable mutagenic potential17–19. 
This seems to be responsible for their moderate toxicity9,20. 
Opposite FaPydA, the Klenow exo− fragment from Escherichia 
coli DNA polymerase I is known to misincorporate dA, leading to 
dA·dT→dT·dA transversion mutations18. In addition, the incor-
poration of dC opposite FaPydA was observed17,21. The oxidative 
dG-derived lesions are known to induce a plethora of muta-
tions in vivo, of which dG·dC→dT·dA transversion mutations 
and dG·dC→dA·dT transition mutations are most frequently 
observed22,23. Primer extension studies with stabilized analogs of 
FaPydG16,20 or methylated versions of FaPydG21,24,25 showed either 
correct incorporation of dC or misincorporation of dA19.
Previous crystal structures and biochemical data of the oxidized 
lesion 8-oxodG in complex with various polymerases clarified that 
this lesion can adopt either a syn or an anti conformation of the 
N9-C1′ (glycosidic) bond (Fig. 1)6,8. Whereas the anti conformation 
enables error-free bypass of the lesion by replicative polymerases, 
the syn conformation is responsible for the mutagenic effect6,13. This 
conformer is able to form a stable noncanonical Hoogsteen base 
pair with dA that induces only little distortion in the active site of 
the polymerase6–8,10–14. Although a similar mutation mechanism was 
proposed for the corresponding FaPy lesions18,22, this has not been 
proven so far.
To enable biochemical and structural investigations of FaPy 
lesion–containing DNA, we used stabilized, bioisosteric FaPy 
lesion analogs in which the oxygen atom in the ribose is syn-
thetically replaced by a methylene group (Fig. 1 (X = CH2) and 
Supplementary Fig. 2; details on synthesis of cFaPydA are 
in Supplementary Note 1)16,20,26,27. These carbocyclic analogs 
(cFaPydA and cFaPydG) feature the same hydrogen-bonding 
properties as the natural lesions but are anomerically stable dur-
ing DNA synthesis and manipulation. This allows the prepara-
tion of carbocyclic β-FaPy lesion–containing oligonucleotides 
in sufficient quantity and excellent purity (>99%) as needed for 
crystallization studies. It is assumed that the naturally occurring 
FaPy lesions form initially as β-anomers but anomerize slowly to 
give a mixture of α- and β-anomers28. Although the equilibrium 
between α- and β-anomers may be affected upon binding of the 
lesion by the polymerases, which could increase the amount of 
the α-anomer, we report here crystallographic data of only the 
β-configured FaPy lesion in complex with the large fragment of 
the high-fidelity polymerase I from Geobacillus stearothermophilus 
(Bst Pol I). The crystal structures provide snapshot-type insights 
into the error-free and error-prone bypass reactions.
RESULTS
Chemical and biochemical studies
We first established that the carbocyclic analogs are suitable mimics 
of the natural lesions. To this end, we synthesized the carbocyclic 
version of the dG base (cdG; Supplementary Note 1) and compared 
it with dG with respect to the conformation of the glycosidic bond 
1Center for Integrated Protein Science at the Department of Chemistry, ludwig Maximilians university, Munich, Germany. 2Present address: Department of 
Chemistry, Technical university, Munich, Germany. 3These authors contributed equally to the work. *e-mail: thomas.carell@cup.uni-muenchen.de
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using quantitative two-dimensional NOESY NMR experiments 
(Fig. 1d and Supplementary Figs. 3 and 4).
For both cdG and dG, we observed, in total, the same through-
space interactions between C8H and the hydrogen atoms at C1′, 
C2′ and C3′. The C8H-C1H′ interaction is caused by the syn con-
former, whereas the other interactions stem from the anti con-
former. We quantified these interactions using the NOESY signal 
between C2′Ha and C2′Hb as internal standards and derived the 
same syn/anti ratio for dG and cdG, showing that the confor-
mational equilibrium is unaffected by the exchange of O to CH2 
(Supplementary Table 1). This result was further secured by a the-
oretical study of cdG versus dG and also of cFaPydG versus FaPydG 
at the B3LYP/6-31+G(d) and MP2(FC)/G3MP2large//B3LYP/6-
31+G(d) levels of theory. The obtained rotational profiles 
(Supplementary Note 2) around the N9-C1′ bonds were found 
to be similar, in agreement with the NMR data. We calculated that 
the positions of the conformational minima are the same and that 
the energetic positions of the barriers are influenced by the O to 
CH2 replacement by only a small extent (≤8 kJ mol−1).
With these results, we started biochemical studies. First, 
primer extension experiments were performed. The data shown in 
Figure 2a show that Bst Pol I29, which we used in this study as a 
model for high-fidelity polymerases, is able to misincorporate 
nucleoside triphosphates into a primer strand opposite both 
cFaPydG and cFaPydA and that full extension of some primers 
finally occurs despite the conformational flexibility in DNA30,31. 
In single-nucleotide insertion studies, Bst Pol I was found to incor-
porate predominantly the correct dTTP opposite cFaPydA and 
8-oxodA, enabling error-free bypass (Fig. 2a and Supplementary 
Fig. 5). Misincorporation is inefficient opposite both dA-derived 
lesions, showing that the misinstruction potential of cFaPydA and 
8-oxodA is rather low (described below), which is in agreement with 
other reports and with kinetic data18. In contrast, for cFaPydG and 
8-oxodG in addition to error-free bypass (insertion of dC), efficient 
misincorporation of dA is detected (Fig. 2a). With our primer 
sequence, this misincorporation results immediately in the +2 primer 
product, showing that extension of the cFaPydG·dA mispair is also 
possible. In addition, misincorporation of dG (the +1 product) is 
observed for cFaPydG. These data establish the cFaPydG lesion as a 
strongly misinstructing base, in agreement with a previous study19.
To gain quantitative insight into the misincorporation events 
and, in particular, into the extension process that is often the limit-
ing factor24,25, we coupled a pyrosequencing step to the primer exten-
sion studies (Fig. 2b,c)32. In this assay, the fully extended primers 
are sequenced, giving quantitative data about the different bypass 
events. For the study, the cFaPy or 8-oxo lesions were inserted into 
a slightly longer DNA template strand (Fig. 2b and Supplementary 
Table 2). After hybridization to a biotinylated primer, primer exten-
sion was performed with the large fragment of Bst Pol I in the pre-
sence of all four canonical triphosphates. The elongated primers 
were extracted from the assay using streptavidin beads, annealed 
to a reverse primer and subsequently pyrosequenced32,33. The data 
shown in Figure 2c confirm that cFaPydA is indeed a relatively 
weak mutagenic lesion, as the lesion is correctly paired with dT 
with a frequency of 99%. In the case of 8-oxodA, replication across 
the lesion with Bst Pol I is more error-prone: in addition to correct 
dTTP insertion, 9% dATP and 4% dGTP are misincorporated as 
well. For both dG-derived lesions, we again detected dATP misin-
corporations to a large extent. For cFaPydG, dATP misincorporation 
was observed in 11% of all cases, whereas for 8-oxodG, misin-
corporation of dATP was the dominant process (66%). In the 
pyrosequencing data, no misincorporation of dG opposite cFaPydG 
was observed, showing that the cFaPydG·dG mispair cannot be 
extended by the polymerase.
To confirm the above results, we next measured steady-state 
kinetic data with Bst Pol I under standing start conditions. The data, 
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Figure 1 | Representation of the two main oxidation products of 2′-
deoxyguanosine (8-oxodG, FaPydG) and FaPydA. (a) For 8-oxodG, the 
crystallographically observed 8-oxodG·dC and 8-oxodG·dA base pairs are 
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stabilized carbocyclic analogs of FaPydG (b) and FaPydA (c), X = CH2.  
(d) Depiction of the through-space interactions between C8H and the 
sugar protons in the anti conformer (red) and the syn conformer (blue).  
The reference NoESy signal between interactions was quantified, giving 
the same syn/anti distribution for both dG and cdG.
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Figure 2 | Nucleotide insertion and bypass of oxidative lesions.  
(a) Single-nucleotide insertion reactions opposite cFaPydA and cFaPydG 
in comparison to those opposite of 8-oxodA and 8-oxodG. The primer was 
hybridized to a lesion-free control DNA or lesion (X)-containing template 
strand. F, fluorescein; M, marker. (b) Schematic presentation of the analysis 
of the misinsertion frequency and mutagenic signature. The biotinylated 
primer strands from the primer extension reaction with Bst Pol I and all  
four dNTPs were isolated and subjected to pyrosequencing analysis. 
(c) Relative frequency of correct and incorrect lesion bypass from the 
pyrosequencing experiment. The given percentage values are averages of 
three independent experiments.
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shown in Table 1 (Supplementary Fig. 6), support that Bst Pol I 
inserts a dTTP three to four orders of magnitude faster opposite 
cFaPydA than it inserts dATP, dCTP or dGTP. For cFaPydG, in con-
trast, dCTP was most efficiently incorporated, followed by incor-
poration of dATP (fins = 0.71). Incorporation of dGTP and dTTP 
was found to be two to three orders of magnitude less efficient. It 
was previously shown that the incorporation efficiency of dTTP 
opposite FaPydA is just 70%18. The incorporation of dCTP oppo-
site FaPydG is approximately 50 times slower than formation of a 
dC:dG base pair25. These results show that the incorporation effi-
ciencies of dTTP and dCTP opposite cFaPydA and cFaPydG are 
substantially reduced9.
Error-free cFaPy bypass
In a previous crystal structure of the 8-oxodG lesion in complex 
with the large fragment of Bst Pol I (Protein Data Bank (PDB) code 
1U49), Hoogsteen base pairing of the lesion with an incoming 
dATP in the post-insertion site (post-IS) was observed, explain-
ing the mutagenic bypass reaction6. To investigate the mechanism 
behind error-free and error-prone replication through cFaPy 
lesions, we determined crystal structures of the large fragment 
of Bst Pol I in complex with DNA templates containing cFaPydA 
or cFaPydG. For the study, we either used prehybridized primer- 
template constructs or soaked the crystals in mother liquor con-
taining different dNTPs. Because the polymerase is active in the 
crystal, as reported previously34, this approach allows a direct, 
snapshot-like observation of the mutagenic and nonmutagenic 
primer extension reaction. Crystallographic data with 1.7- to 2.7-Å 
resolution for the error-free and error-prone translesion synthe-
sis process through cFaPydA and cFaPydG were obtained. Data 
processing and structure refinement statistics are summarized in 
Supplementary Tables 3 and 4. Examples for the quality of the 
electron density for the structures are shown in Supplementary 
Figures 7 and 8. Overall, we found, on average, about 15% larger 
B-factors for the lesions in the complex structures, indicating 
higher flexibility of the formamidopyrimidines.
In the case of cFaPydA, we determined the structure of the lesion 
first in the (n+1) position inside the preinsertion site (pre-IS) of the 
polymerase (Fig. 3a,b). The lesion occupies the same position as an 
undamaged dA (PDB code 1L3S34). The polymerase is as expected 
in the open conformation. The O and O1 helices as well as Tyr714 
occupy the same position as they do in a structure obtained with a 
lesion-free template strand. The lesion features the glycosidic bond 
in anti conformation. The residues Arg615, Gln797 and Tyr714 sta-
bilize the last formed base pair in the template-primer duplex in the 
post-IS at position n−1, as reported previously29.
Soaking the crystal in mother liquor containing dTTP allows 
the polymerase to perform the first primer extension reaction using 
the cFaPydA lesions as the templating base directly in the crystal. 
This structure is identical to a structure resulting from crystalli-
zation studies with a template-primer construct in which we syn-
thetically preformed the cFaPydA·dT base pair (data not shown). 
The obtained structures show the cFaPydA lesion during error-free 
bypass in a Watson-Crick–type base-pairing situation with dT in 
the post-IS position (n−1; PDB code 4B9M) (Fig. 3c,d). A com-
parison with a structure featuring an intact dA·dT base pair (PDB 
code 1L3T34) at this position (Supplementary Fig. 9a) shows that 
cFaPydA·dT is less buckled (12°) but has a stronger propeller twist 
(−15°) than the cognate dA·dT base pair (buckle = 22°; propeller = 
−7.4°) in the polymerase n−1 position. The cFaPydA lesion is dis-
placed by about 4.3 Å (C1′–C1′ distance; Supplementary Fig. 9a), 
which triggers repositioning of Tyr714 to optimize the π-stacking 
situation. The polymerase adopts an open-distorted conformation, 
which is accompanied by hinge movement of the O and O1 helices. 
This results in blocking of the pre-IS by the loop region between 
the O and O1 helix. The lesion-containing structure shows Tyr714 
stacking with cFaPydA and dT. In contrast, in the reference crystal 
structure, which has no lesions, Tyr714 stabilizes only the template 
base dA. The O and O1 helices are shifted, preventing entry of a new 
templating base into the pre-IS. In the structure, cFaPydA forms a 
Watson-Crick–type base pair with dT with the formamide group 
oriented almost orthogonally to the heterocycle (Supplementary 
Fig. 9a). Despite the presence of the cFaPydA lesion, the primer 
strand and, in particular, the 3′ OH group of the primer end are in 
the correct position for primer extension. Asp830 forms the essen-
tial hydrogen bond with the 3′ OH primer end to position it for 
the coming reaction with the incoming triphosphate. This is most 
likely why the enzyme accomplishes error-free lesion bypass (inser-
tion and extension) despite the structural distortion caused by the 
cFaPydA lesion.
To our surprise, we noted that the cFaPydA lesion also adopts 
a different conformation in the active site resulting from rotation 
around the C4-N9 bond. This is evident from the Fo-DFc difference 
density obtained during structure refinement (Supplementary 
Fig. 9b). The occupancy adjustment of the conformations in the 
refinement process allowed us to estimate the abundance of the 
rotated state to about 5% of the molecules. This rotation estab-
lishes a relatively close distance between the N(6)H2 of cFaPydA 
and N(3) of the T base (2.4 Å). The distance suggests the presence 
of an attractive hydrogen bond, which, however, requires one of 
the partners to switch into a different tautomeric state. Owing to 
the strong preference of dT for the keto form, despite the recent 
Table 1 | Kinetic parameters of dNTP insertion by G. stearothermophilus polymerase i opposite cFaPydA and cFaPydG
5′-aCtcFapyGaGaGaCatGCGaGaCtGC-3′
3′                    -CtCtCtGtaCGCtCtGaCG-5′
Incorporation vmax (mM min−1) KM (mM) kcat (min−1) kcat/KM (min−1 mM−1) finsa
dATP→cFaPydA 1.23 × 10−1 359.63 2.76 7.66 × 10−3 1.85 × 10−3
dCTP→cFaPydA 6.49 × 10−2 249.74 1.45 5.80 × 10−3 1.40 × 10−3
dGTP→cFaPydA 1.01 × 10−1 815.96 2.25 2.76 × 10−3 6.68 × 10−4
dTTP→cFaPydA 9.80 × 10−2 0.53 2.19 4.13 1.00
dATP→cFaPydG 5.43 × 10−2 0.46 1.21 2.63 7.06 × 10−1
dCTP→cFaPydG 6.25 × 10−2 0.38 1.40 3.72 1.00
dGTP→cFaPydG 6.62 × 10−2 39.87 1.48 3.71 × 10−2 9.97 × 10−3
dTTP→cFaPydG 4.07 × 10−2 194.15 0.91 4.67 × 10−3 1.26 × 10−3
afins = (vmax/KM)i / (vmax/KM)r, where r represents a correct base pair, and i represents an incorrect base pair. The kinetic studies were performed under standing start conditions, using 1 u Bst Pol I, 0.25 μM 
dsDNA and 0.1 nM−1 mM dNTPs. All of the reactions were carried out at 55 °C for 6 min.
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proof of rare tautomers in polymerases35,36, we believe that it is the 
lesion that is tautomerically more flexible.
Most importantly, the primer strand and the catalytic residues 
in the crystal structures remain in the correct position for the poly-
merase to extend the primer, despite the presence of cFaPydA. 
Indeed, when we used a template strand with a different sequence 
in which the cFaPydA lesion was followed by two further dA bases 
(oligodeoxynucleotide ODN4; Supplementary Table 2), soak-
ing the crystals with dTTP caused elongation of the primer strand 
in the crystal by three dTTPs showing the cFaPydA·dT base pair 
(Fig. 3e,f) in the DNA duplex binding position n−3 with little 
residual distortion detectable in the DNA backbone (Fig. 3e,f). The 
formamide group is, most likely because of its flexibility, not defined 
in this structure.
We next analyzed the error-free bypass of the cFaPydG lesion. 
The crystal structure of Bst Pol I in complex with DNA containing 
the cFaPydG in the pre-IS is unexpected because it shows that the 
lesion resides outside the protein. Here, again, the pre-IS is blocked 
by the hinge movement of the O-helices (Fig. 4a,b), and Tyr714 is 
shifted to stack with the primer end without changing the position of 
the primer 3′ OH in the active site. The heterocycle of the cFaPydG 
lesion is only partially defined by the electron density, showing its 
flexible arrangement outside the pre-IS (Supplementary Fig. 8). 
To prove the presence of the lesion in the template strand in the 
absence of defining electron density, we reisolated the DNA from 
the crystal and confirmed the presence of the lesion by HPLC-MS 
(Supplementary Table 2) after total DNA digestion. In contrast, 
8-oxodG does enter the pre-IS of the polymerase (Fig. 4a,b)6.
Soaking the crystal with dCTP results in the formation of the 
cFaPydG·dC pair in the n−1 position with the glycosidic bond of 
the lesion, still in anti conformation, engaged in Watson-Crick 
base pairing with dC (Fig. 4c,d and Supplementary Fig. 8b). This 
shows that the whole structure with the lesion outside the pre-IS is 
 sufficiently dynamic to enable loading of the cFaPydG lesion into 
the active site. In comparison, with the polymerase in complex with 
an intact dG·dC base pair (PDB code 1L5U34) at the same position, 
the lesion base pair shows a stronger propeller twist (−6.8°) than 
the dG·dC base pair (−2°) and no buckling (17.6° and 16°, respec-
tively) of the base pair plane. Structural deviations associated with 
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the  presence of the lesion are again limited to the template strand, 
which is shifted by about 3 Å. Again, Tyr714 is repositioned to opti-
mize the stacking interactions with the newly formed cFaPydG·dC 
base pair. This in turn causes a shift of Gln797 (Supplementary 
Fig. 10). Only small differences are observed in the primer position, 
once again structurally explaining the biochemically observed effi-
cient elongation of the primer after formation of the cFaPydG·dC 
base pair.
Error-prone bypass of cFaPydG
When we soaked crystals containing the cFaPydG lesion in the 
outer protein position in mother liquor containing dATP, we 
observed elongation of the primer and formation of the mutagenic 
cFaPydG·dA base pair in the crystal (Fig. 5). The cFaPydG lesion 
can obviously move into the active site from its outside position even 
when it involves formation of a ‘purine’-purine mismatch. However, 
whereas the 8-oxodG lesion flips under these circumstances into 
the syn conformation to enable Hoogsteen base pairing with dA 
(PDB code 1U496), the cFaPydG lesion forms the same base pair 
with the glycosidic bond remaining in anti conformation. The result 
is an interaction between cFaPydG and the dA counterbase that is 
stabilized by two hydrogen bonds (Fig. 5a,b). To form this anti 
cFaPydG·dA base pair, a 4.0-Å dislocation of the cFaPydG lesion is 
required (Fig. 5e), in contrast to a canonical dG·dC base pair at the 
same position. Again, this causes repositioning of Tyr714 and Gln797 
to adjust the required stabilizing stacking interactions. The template 
strand is more strongly distorted in comparison to the cFaPydG·dC 
structure. The structural changes detected for the primer strand are 
surprisingly small in contrast, which again explains why the poly-
merase is able to extend a mutagenic cFaPydG·dA base pair. The 
strain transferred to the primer strand by the ‘purine’-purine mis-
pair cFaPydG·dA is relieved by turning the dA base by about 10° 
toward the major groove (Fig. 5e and Supplementary Fig. 9e). The 
whole base pair is substantially forced out of planarity and more 
strongly buckled (26°) than the respective undamaged dG·dC base 
pair (PDB code 1L5U34) inside the polymerase (16°). In addition, 
the propeller twist is more than twice as large for the damaged base 
(−5°) than for the dG·dC base pair (−2°). In comparison, a dG·dA 
mismatch, which cannot be extended by the polymerase, shows a 
much stronger distortion of the DNA strand, with a buckle of 38° 
and a propeller twist of −16° (ref. 37).
Soaking a crystal with dATP where the cFaPydG is followed by 
two dT in the template sequence results in a structure that shows 
extension of the cFaPydG·dA mispair to the position n−2 (Fig. 5c,d). 
All of the observed structural perturbations are now strongly 
reduced. The C1′-C1′ distance between the cFaPydG and a dG in 
the reference crystal structure is 2.1 Å (Fig. 5f and Supplementary 
Fig. 9f), demonstrating that once the lesion-containing base pair is 
formed and shifted away from the active site, further primer exten-
sions are hard to avoid. In comparison with an analogous structure 
of a dG·dC base pair, the cFaPydG·dA (n−2) structure shows only 
small residual deviations.
DiSCUSSiON
The ability of cFaPydG to form an extendable base pair with an 
incoming dATP was expected from the biochemical data. However, 
it is unexpected and contradicts previous proposals that no 
Hoogsteen hydrogen bonding, enabled by rotation of the glycosidic 
bond from the canonical anti conformation into the syn geometry, is 
necessary. The anti cFaPydG·dA base pair is established without any 
involvement of the formamidopyrimidine substructure. Whereas 
for 8-oxodG, the C8-oxo group and the hydrogen-donating N7H 
functionality are essential to form the mutagenic 8-oxodG·dA base 
pair, the same atoms have no role in the case of the cFaPydG lesion. 
The observed anti cFaPydG·dA base pair consequently establishes 
a new mechanism for how the observed dG·dC→dT·dA transver-
sion mutation, associated with oxidative damage, is formed. For 
8-oxodG, rotation of the lesion into the syn conformation is essen-
tial to minimize steric problems associated with the close distance 
between the C8=O and the C5H2-methylene groups of the deoxyri-
bose in the canonical anti orientation6. The cFaPydG lesion solves 
this structural problem differently. The lesion turns the formamide 
group into an orthogonal position relative to the heterocycle and, 
in this way, minimizes the steric interaction between the C8=O and 
the C5H2-methylene group. This reduces the need to shift the gly-
cosidic bond from anti into the syn conformation. It is un expected 
that the cFaPydG lesion can base pair with dA despite the anti 
conformation and that the cFaPydG·dA base pair is extended by 
the polymerase. This can be explained by the fact that the struc-
tural perturbations associated with the cFaPydG·dA base pair are 
limited to the template strand. Most important are the perturba-
tions of the position of Tyr714 and Gln797, which give rise to a 
weakened hydrogen-bonding interaction between Gln797 and the 
cFaPydG·dA base pair; also, the stacking interaction of this muta-
genic base pair with Tyr714 are compromised. The wider effects 
of these perturbations are, however, limited to the base pair in 
the n−2 position and not transmitted to the primer strand, which 
occupies the same position observed in structures with lesion-free 
template–primer complexes. The inability of the cFaPydG lesion 
to flip into the syn conformation clearly causes stronger structural 
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superimposed with the polymerase in complex with the cognate dG·dC 
base pair (gray, PDB code 1l5u34) (b). (c,d) Schematic view (c) and 
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 perturbations in comparison to 8-oxodG, which explains why muta-
genic formation of the cFaPydG·dA base pair is reduced to 11% in 
comparison to 8-oxodG·dA, where it is 66%.
The lack of rotation influences, in particular, the planarity of 
the base pair. Such a deviation does not influence the strength of 
the hydrogen bonds but reduces the strength of stacking interac-
tions with the other base pairs and with Tyr714. It seems that the 
ring-opened structure of the cFaPydG lesion, with its considerably 
smaller π-surface, decreases the energetic penalty for reduced stack-
ing. A reduced aromatic character, in turn, may also allow the com-
plex cFaPy lesion to shift more easily into other tautomeric states 
in comparison to the canonical bases. This is crystallographically 
observed for cFaPydA, but it is likely that similar tautomeric shifts 
are possible for cFaPydG as well.
The main difference between 8-oxo–type lesions and cFaPy-
type lesions are therefore that the 8-oxo group can rotate as part of 
the formamide unit away from the C5H2 group into an orthogonal 
position relative to the heterocycle. This gives the cFaPydG lesion 
more structural flexibility, which reduces the need for the lesion to 
rotate into the syn conformation. In addition, the lacking imidazole 
substructure reduces the energetic penalty associated with reduced 
stacking interactions, which makes it easier for cFaPy-containing 
base pairs to deviate from planarity. Although shown here only for 
cFaPydA, we think that cFaPy lesions can, in general, change more 
easily into different tautomeric states in comparison to natural 
purines, broadening their base-pairing properties without the need 
to use the formamide or the Hoogsteen base pairs. What is also 
interesting is the observation that cFaPydG·dG mispairs stall a repli-
cative polymerase, whereas the cFaPydG·dA and 8-oxodG·dA mis-
pairs, which are primarily formed, are extended to form full-length 
primers (Fig. 2a,c). This seems to be the reason why cFaPydG·dA 
and 8-oxodG·dA mismatches escape recognition by the repair sys-
tem, which is triggered by a stalled replicative polymerase during 
replication. We would like to emphasize that our mechanistic studies 
show how a high-fidelity polymerase replicates cFaPydG5 and that 
mutations arise. The in vivo mutagenicity of the bases depends of 
course also on other factors, such as repair or the action of other 
polymerases such as low-fidelity polymerases, which can explain 
different cell type–specific in vivo mutagenicities9. 
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mETHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. PDB: Atomic coordinates and structure factors 
of the protein in complex with DNA have been deposited with the 
following accession codes: cFaPydA, pre-IS (4B9L); cFaPydA·dT, 
n−1 (4B9M); cFaPydA·dT, n−3 (4B9N); cFaPydG, outside the 
pre-IS (4B9S); cFaPydG·dC, n−1 (4B9T); cFaPydG·dA, n−1 (4B9U); 
cFaPydG·dA, n−2 (4B9V). Cambridge Structural Database: Small-
molecular crystallographic data have been submitted under the fol-
lowing accession codes: 9a (CCDC-796512); 11 (CCDC-796513).
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ONLiNE mETHODS
General experimental procedures. All reagents and solvents were purchased 
from Acros, Fischer Scientific (KMF Laborchemie Handels GmbH), Fluka 
(Sigma-Aldrich-Chemie GmbH) and were used as delivered. All of the experi-
ments involving water-sensitive compounds were performed in oven-dried 
glassware under a nitrogen atmosphere. Reactions were monitored by ana-
lytical thin-layer chromatography (TLC) on VWR precoated aluminum plates 
60 F254, visualized by UV light, anisaldehyde or ninhydrin staining. Melting 
points were obtained in open-glass capillaries with a Büchi Smp 20 melting 
point apparatus and are not corrected. IR spectra of the compounds were 
recorded on a Perkin-Elmer FT-IR Spektrum 100 on an ATR unit. 1H NMR 
spectra were obtained on the following spectrometers: Bruker AMX-200, 
ARX-300, DRX-500 and ARX-600 or Varian Mercury 200VX and VXR400S. 
The chemical shifts were referenced to CHCl3 (δ 7.26) in CDCl3, DMSO 
(δ 2.50) in DMSO–d6, MeOH (δ 3.31) in CD3OD–d4, H2O (δ 4.80) in D2O and 
CH3CN (δ 1.94) in CD3CN–d3. If necessary, peak assignment was carried out 
with the help of COSY, HMBC, HMQC or NOESY experiments. 13C spectra 
were obtained on a Bruker DRX-200 (50 MHz), ARX-300 (75 MHz), DRX-500 
(125 MHz) or Varian VXR400S (100 MHz) spectrometer and referenced to the 
solvent signal. 31P spectra were obtained on the spectrometer Varian Mercury 
200VX (81 MHz). 31P chemical shifts are quoted in p.p.m. using 85% H3PO4 as 
an external standard. EI mass spectra were recorded on a Varian MAT CH7A 
or MAT90 (Varian) mass spectrometer. FAB spectra in low and high resolu-
tion were recorded on a Finnigan MAT95 mass spectrometer. ESI spectra and 
high-resolution ESI spectra were obtained on the mass spectrometers Finnigan 
MAT95S, JEOL JMS-700 or PE ScieX API QStar Pulsar i. FT-ICR-ESI mass 
spectra were measured on a Thermo Finnigan LTQ Orbitrap XL FTMS. Final 
concentrations of the purified oligonucleotides and enzyme concentrations 
were determined with a NanoDrop ND-1000 spectrophotometer (Peqlab). 
MALDI-TOF mass spectra of the oligonucleotides were confirmed using a 
Bruker Autoflex II spectrometer. DNA-melting experiments to determine 
curves were performed using a Carey 100 Bio-spectrophotometer equipped 
with Carey temperature controller, sample transport accessory and multi cell 
block (Varian). Commercial oligonucleotides were purchased from Metabion 
or Ella Biotech (Martinsried, Germany).
Oligonucleotide synthesis. Oligonucleotide synthesis was performed on an 
Expedite 8909 Nucleic Acid Synthesis System (PerSeptive Biosystems) using 
standard DNA synthesis conditions. Phosphoramidites for dA, dC, dG, dT and 
CPG carriers were obtained from Amersham, Glen Research or PE Biosystems. 
Oligonucleotides containing the cFaPydA building block were not compatible 
with the regular capping procedure. For these strands, the synthesis protocol 
was modified. The coupling time for 1 was extended to 2 × 7 min. The standard 
capping solution was replaced by a mixture of pivaloyl anhydride or butyric 
anhydride (0.54 M) and 2,6-lutidine (10.5%) in acetonitrile. The mild cap-
ping period was 25 s after incorporation of cFaPydA and each of the following 
bases. In addition, deblocking cycles were shortened using dichloroacetic acid 
to avoid detritylation of the N6 position of the lesion. Also, the coupling time 
for the first following phosphoramidite after the lesion was extended to 144 s. 
The terminal DMT-protecting group was removed from the oligonucleotides 
(see deprotection and purification).
Deprotection and purification. Deprotection and cleavage of the oligodeoxy-
nucleotides from the CPG carrier containing cFaPydA were carried out in a 
mixture of saturated ammonia solution in water (7 M) and ethanol (3:1) at 
17 °C overnight. DNA purification was conducted on analytical and preparative 
HPLC (Waters) using Nucleodur or Nucleosil columns (250 × 4 mm, C18ec, 
particle size 3 μm or 250 × 10 mm, C18ec, particle size 5 μm) from Machery-
Nagel. The applied buffer was 0.1 M triethylammonium acetate in water and 
0.1 M triethylammonium acetate in an 80% aqueous MeCN buffer system. The 
fractions were checked for purity by analytical HPLC. The purified oligonucle-
otides were concentrated in vacuo using a Savant Speed Vac and were desalted 
with Sep-Pak cartridges (Waters) before use. The oligodeoxynucleotides still 
containing the trityl group were deprotected by addition of 100 μL of an 80% 
acetic acid solution. After incubation for 20 min at room temperature, 100 μL 
of water together with 60 μL of a 3-M solution of sodium acetate were added. 
To this solution, 1.6 mL of ethanol were added, and the DNA was precipitated 
at least for 60 min at −20 °C. The DNA was isolated, decanting off the solution, 
and lyophilized, and samples were purified via HPLC as mentioned above.
Alternatively, the DNA was detritylated via SepPac cartridges. The car-
tridges were activated with acetonitrile (10 mL) and equilibrated with distilled 
water (10 mL). The lyophilized oligonucleotides were loaded onto the cartridge 
(0.2 mL/min). The column was washed with distilled water (6 mL), and then 
5 mL trifluoroacetic acid (0.4%) in water was passed through it (during 90 s), 
followed immediately by 6 mL of 0.1 M triethylammonium acetate in water 
(pH 7) and then with 6 mL of water. Finally, the DNA was eluted two times 
each with 4 mL acetonitrile (80%) in water.
Enzymatic digestion. The DNA (2 nmol in 100 μL H2O) was incubated with 
10 μL buffer A (300 mM ammonium acetate, 100 mM CaCl2, 1 mM ZnSO4, 
pH 5.7) and 20 U nuclease S1 (Aspergillus oryzae from Roche) for 3 h at 37 °C. 
After adding 12 μL buffer B (500 mM Tris-HCl, 1 mM EDTA, pH 8.0), 5 U 
antarctic phosphatase (New England Biolabs) and 0.1 unit snake venom 
phosphodiesterase I (Crotalus adamanteus venom from USB corporation), 
the solution was incubated for a further 3 h at 37 °C until the digestion was 
completed. The sample was centrifuged (6,000 r.p.m., 10 min) and analyzed 
by HPLC and FT-ICR-HPLC/MS. For the analysis of the enzymatic digestion, 
a 3 HDO column (150 × 2.0 mm) from Interchim Interchrom Uptisphere was 
used. Eluting buffers were buffer A (2 mM NH4HCOO in H2O, pH 5.5) and 
buffer B (2 mM NH4HCOO in H2O/MeCN (20/80)). Gradients were as fol-
lows: 0−12 min; 0%−3% B; 12−60 min; 3%−60% B; 60−62 min; 60%−100% B; 
62−90 min; 100% B; 90−95 min; 100% B−0% B; 95−130 min; 0% B, with a flow 
of 0.15 mL/min. The elution was monitored at 260 nm and 325 nm.
Single-nucleotide insertion. For the single-nucleotide insertion a 16-mer 
5′-fluorescein–labeled primer was hybridized to either the lesion-containing 
template strand or the lesion-free control. The experiment was conducted by 
using 0.5 μM primer (ODN2-Primer) and 1 μM template (ODN2) to ensure all 
of the primer was fully hybridized. Together with Bst Pol I (1 U, NEB), 5 mM 
Mg2+ and 50 μM each of the individual dNTPs, each duplex was incubated for 
6 min at 55 °C. The reactions were terminated by adding 20 μL TBE-urea 
sample buffer and analyzed by denaturating PAGE.
Steady-state kinetics. The primer extension was performed following the 
same protocol as for single-nucleotide insertion studies, except that the dNTP 
concentration was varied from 0.5 nM to 1 mM. Kinetic constants were derived 
as described in ref. 38.
Primer extension–based pyrosequencing. In a ratio of 2:1, a 34-mer tem-
plate DNA strand (ODN1) was annealed to a 5′-biotinylated 19-mer primer 
strand (ODN1–Primer1, Metabion), ending one base 3′ to the lesion. Hence, 
the primer extension experiments were performed under standing start condi-
tions with Bst Pol I. Bst Pol I (1 U; NEB), 5 mM MgSO4, 50 μM dNTPs and 
0.5 μM dsDNA were incubated in a total volume of 20 μl 1× ThermoPol 
Reaction Buffer (NEB) for 30 min at 55 °C. Subsequently, 2 μl of streptavi-
din Sepharose beads (GE Healthcare, Uppsala, Sweden), 40 μl Binding Buffer 
(PyroMark, Qiagen) and 18 μl ddH2O were added to each sample. After agita-
tion for 15 min at 1,400 r.p.m., the beads were captured with a Vacuum Prep 
Tool (Qiagen) and washed with 70% ethanol, 0.2 M NaOH and washing buffer 
(Qiagen). The elongated biotinylated primers (immobilized on the bead sur-
faces) were annealed to 10 pmol of the sequencing primer (ODN1–Primer2, 
Metabion) in 30 μL annealing buffer (Qiagen). Pyrosequencing was performed 
on a PyroMark Q24 Pyrosequencer using standard conditions (Qiagen). For 
each dNTP, blanks were measured. The data were analyzed using the provided 
software, PyroMark Q24. The average values of the peak heights were calcu-
lated using Microsoft Excel, and the average blank values were subtracted. 
Hence, relative incorporation at every variable position was calculated and 
averaged from three independent experiments.
Protein crystallization. Bst Pol I was expressed and purified as previously 
described39. For co-crystallization, the lesion-containing template (ODN3–
ODN6) was annealed to the primer ending one base 3′ to the lesion in 10 mM 
Na-cacodylate, pH 6.5, 50 mM NaCl, 0.5 mM EDTA and 10 mM MgSO4. Prior 
to crystallization, protein and DNA were mixed in a 1:3 molar ratio, resulting in 
final concentrations of 5 mg/ml and 0.5 mM for Bst Pol I and dsDNA, respec-
tively. Crystals were grown by mixing an equal volume of protein–DNA complex 
with 47–51% ammonium sulfate, 3.0–4.1% MPD and 100 mM MES, pH 5.8, 
using the hanging-drop vapor diffusion method. The crystallization plates were 
incubated at 18 °C, and crystals appeared after 2 to 6 d. For primer extensions, 
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the crystals were soaked overnight (single extension) or for 2–3 d (double and 
triple extension) in an artificial mother liquor supplement with 30 mM of the 
respective triphosphate. Crystals were frozen in 24% sucrose, 55% ammonium 
sulfate, 3.5% MPD, 100 mM MES, pH 5.8, and stored in liquid nitrogen until data 
collection. Data were collected at the beamlines ID14-1 (European Synchrotron 
Radiation Facility (ESRF), Grenoble, France) and PX I and PXIII (Swiss Light 
Source (SLS), Villigen, Switzerland) and processed with the programs XDS40 and 
SCALA41,42. Structure solution was carried out by molecular replacement with 
PHASER43 using the coordinates of PDB code 1U45 (ref. 6). To reduce model 
bias, before model building in COOT44, the temperature factors were reset to the 
Wilson B factor, and simulated annealing omit maps, removing the area around 
the lesion, were calculated with PHENIX45. TLS and restrained refinement 
were carried out in REFMAC546,47 and PHENIX. All of the structural superpo-
sitions were done with LSQKAB41, and structural figures were prepared with 
Pymol (Delano Scientific). Data processing and refinement statistics are sum-
marized in Supplementary Tables 3 and 4. The DNA geometry was analyzed 
with CURVES+48,49.
39. Münzel, M., Lercher, L., Müller, M. & Carell, T. Chemical discrimination 
between dC and 5MedC via their hydroxylamine adducts. Nucleic Acids Res. 
38, e192 (2010).
40. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
41. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 
D Biol. Crystallogr. 50, 760–763 (1994).
42. Evans, P. Joint CCP4 and ESF-EACMB. Newsletter Prot. Crystallogr. 33, 22–24 
(1997).
43. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 
658–674 (2007).
44. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development 
of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
45. Adams, P.D. et al. PHENIX: building new software for automated 
crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 
58, 1948–1954 (2002).
46. Winn, M.D., Murshudov, G.N. & Papiz, M.Z. Macromolecular TLS 
refinement in REFMAC at moderate resolutions. Methods Enzymol. 374, 
300–321 (2003).
47. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular 
crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).
48. Olson, W.K. et al. A standard reference frame for the description of nucleic 
acid base-pair geometry. J. Mol. Biol. 313, 229–237 (2001).
49. Lavery, R., Moakher, M., Maddocks, J.H., Petkeviciute, D. & Zakrzewska, K. 
Conformational analysis of nucleic acids revisited: Curves+. Nucleic Acids Res. 
37, 5917–5929 (2009).
38. Creighton, S., Bloom, L.B. & Goodman, M.F. Gel fidelity assay measuring 
nucleotide misinsertion, exonucleolytic proofreading, and lesion bypass 
efficiencies. Methods Enzymol. 262, 232–256 (1995).
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Supplementary Results 
 
 
 
Supplementary Figure 1: The two main oxidation products of 2´-deoxyguanosine (dG), 8-oxodG and FaPydG 
and their counterparts from 2´-deoxyadenosine (dA), 8-oxodA and FaPydA, respectively (dR = 2´deoxribose). 
 
 
 
 
Supplementary Figure 2: Depiction of the carbocyclic analogs of FaPydA and FaPydG used for this study. 
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a 
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Supplementary Figure 3: Noesy (600 MHz, DMSO–d6) of carbocyclic dG 16. The interactions between the 
C8H and the C3´H, C2´Ha and C5´Ha of the anti-cdG are shown in red and the interactions between the C8H and 
the C1´H of the syn-cdG are shown in blue. The reference interactions of C2´Ha and C2´Hb are shown in green. 
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Supplementary Figure 4: Noesy (600 MHz, DMSO–d6) of dG. The interactions between the C8H and the C3´H 
and C2´Ha of the anti-dG are shown in red and the interactions between the C8H and the C1´H of the syn-dG are 
shown in blue. The reference interactions of C2´Ha and C2´Hb are shown in green. 
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Supplementary Figure 5: Nucleotide insertion and bypass of oxidative lesions. Single nucleotide insertion 
reactions opposite cFaPydA and cFaPydG in comparison to 8-oxodA and 8-oxodG. f = fluorescein, M=Marker. 
The primer was hybridized to a lesion-free control DNA or lesion (= X) containing template strand. 
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Supplementary Figure 6: Incorporation of dNTP by G. stearothermophilus Polymerase I opposite cFaPydA 
and cFaPydG. The concentration of Bst Pol I and dsDNA was constant throughout the experiment. Experiments 
were carried out at 55°C. 
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Supplementary Figure 7: Stereo view of the electron density for the cFaPydA lesion complexes. (a) 
cFaPydA in the pre-IS of the polymerase. (b) cFaPydA•dT at the post insertion site (n-1) after a single insertion 
event. (c) cFaPydA•dT base pair after 3 extension reactions in the crystal at n-3. Composite-omit 2Fo-DFc elec-
tron density map is contoured at 1σ level. The lesion is highlighted in red. 
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Supplementary Figure 8: Stereo view of the electron density for the cFaPydG lesion complexes.  
a) cFaPydG at the pre-IS. Due to the flexibility only the sugar is defined in the electron density. b) cFaPydG•dC 
at the post-IS (n-1). Despite the dynamic character of the lesion, which is emphasized by the higher B-factors 
and weaker electron density, the lesion can be clearly placed. c) cFaPydG•dA mismatch at n-1 and d) n-2. Com-
posite-omit 2Fo-DFc electron density map is contoured at 1σ level. The lesion is highlighted in orange. 
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Supplementary Figure 9: Bst Pol I reading through cFaPydA- and cFaPydG-containing template DNA.  
(a) Comparison of cFaPydA•dT (red) with the correct dA•dT base pair (grey; PDB code 1L3T1) at the 
post-IS (n-1). Superposition was carried out with the coordinates of the polymerase used as refer-
ence frame. (b) Alternative conformation (red) of cFaPydA at the post-IS as indicated by the positive 
2Fo-DFc difference electron density (green). The 2Fo-DFc (blue) and Fo-DFc (green) electron density 
are contoured at 1 σ and 2.5 σ., respectively. (c) Depiction of the alternative cFaPydA•dT base pair. 
(d) Structure of the cFaPydG•dC base pair. (e) and (f) Structure of Bst Pol I in complex with cFaPydG 
after incorporation of a dATP at n-1 (PDB Code 4B9U) and n-2 (PDB code 4B9V). (e) Side view of su-
perimposition with the cognate dG•dC base pair (grey, PDB code 1L5U1) (f) Side view of superimposi-
tion with undamaged DNA (grey; PDB Code 1L5U). 
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Supplementary Figure 10: Rotamer change of Q797. Superposition of the Bst Pol I-DNA complexes of 
cFaPydG•dC (n-1) and dG•dC (PDB code 1L5U). In the complex with the lesion-free DNA Q797 forms a hy-
drogen bond with the sugar O5 of the base at the post-IS n-2. For clarity the primer strand was removed. 
 
Supplementary Table 1:  Quantitative integrals of the interactions between the C8H and the C3´H and C2´Ha of 
the anti-conformers and the C8H and the C1´H of the syn-dG. As reference the integral of the C2´Ha and C2´Hb 
interactions were chosen. In brackets are the integrals divided by the reference integrals. 
Interactions   Peak integral (relative integral) 
 Carbocyclic dG dG 
C2Ha-Hb (reference) 464 559 
C8H-C1´H 62 (0.13) 74 (0.13) 
C8H-C2´Ha 23 (0.06) 33 (0.06) 
C8H-C3´H 107 (0.23) 156 (0.28) 
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Supplementary Table 2: Synthesized oligonucleotides containing the carbocyclic analogues of FaPydA and 
FaPydG and the 8-oxo-type lesions. 
Name Sequence 
M(calc) 
(amu) 
M(found)
a 
(amu)
 
Strands for Primer Extension coupled Pyrosequencing 
ODN1-cFaPydA 5'-GTAGCTAGGTCGATcFaPydAGAGAGACATGCGAGACTGC-3' 10596.8 10598.7 
ODN1-cFaPydG 5'-GTAGCTAGGTCGATcFaPydGGAGAGACATGCGAGACTGC-3' 10612.9 10612.7 
ODN1-8-oxodA 5'-GTAGCTAGGTCGAT8-oxodAGAGAGACATGCGAGACTGC-3' 10597.9 10597.2 
ODN1-8-oxodG 5'-GTAGCTAGGTCGAT8-oxodGGAGAGACATGCGAGACTGC-3' 10612.8 10612.4 
ODN1-Primer 1 5'-Biotin-GCAGTCTCGCATGTCTCTC-3'   
ODN1-Primer 2 5'-GTAGCTAGGTCGA-3'   
Strands for Single Nucleotide Insertions and Primer Extensions 
ODN2-cFaPydA 5'-ACTcFaPydAGAGAGACATGCGAGACTGC-3' 7122.6 7124.4 
ODN2-cFaPydG 5'-ACTcFaPydGGAGAGACATGCGAGACTGC-3' 7138.9 7139.7 
ODN2-8-oxodA 5'-ACT8-oxodAGAGAGACATGCGAGACTGC-3' 7122.6 7122.0 
ODN2-8-oxodG 5'-ACT8-oxodGGAGAGACATGCGAGACTGC-3' 7138.6 7137.2 
ODN2-Primer 3'-CTCTCTGTACGCTCTGACG-fluo-5'   
Strands for Crystallization 
ODN3-cFaPydA 5'-CAGcFaPydAAGAGTCAGGCT-3' 4643.0 4640.4 
ODN4-cFaPydA 5'-CAAcFaPydAAGAGTCAGGCT-3' 4626.2 4625.3 
ODN5-cFaPydG 5'-CATcFaPydGAGAGTCAGGCT-3' 4634.0 4632.0 
ODN6-cFaPydG 5'-CAAcFaPydGCGAGTCAGGCT-3' 4618.0 4618.8 
ODN7-cFaPydA 5'-CATcFaPydACGAGTCAGGCT-3' 4593.9 4593.6 
a
MALDI-TOF; matrix: hydroxypicolinic acid 
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Supplementary Table 3: Data collection, processing and structure refinement statistics of the carbocyclic 
FaPydA-structures. 
 
PDB code 
cFaPydA (pre-IS) 
4B9L 
dT-cFaPydA (n-1)  
4B9M 
dT-cFaPydA (n-3) 
4B9N 
Data collection    
Space group P212121 P212121 P212121 
Cell dimensions     
    a, b, c (Å) 88.4, 93.7, 105.1 88.4, 93.7, 105.1 88.4, 93.7, 105.1 
 ( )  90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 45.4-2.05 (2.16-2.05) 50.0-2.05 (2.2-2.05) 45.9- 2.2 (2.32-2.2) 
Rmerge 0.152 (0.604) 0.061 (0.458) 0.091 (0.586) 
I / I 6.6 (2.4) 17.5 (3.9) 16.0 (3.2) 
Completeness (%) 99.8 (100) 99.7 (100.0) 99.8 /99.1 
Redundancy 4.2 (4.2) 4.1 (4.1) 4.9 (4.9) 
    
Refinement    
Resolution (Å) 45.4-2.05 50.0-2.05 45.9-2.2 
No. reflections 54,997  52,362  44,989  
Rwork / Rfree 0.187 / 0.226 0.18 /0.223 0.183 / 0.2173 
No. atoms 5,385 5,384 5,395 
    Protein 4,683 4,680 4,673 
    DNA 432 472 433 
    Water 270 232 289 
B-factors    
    Protein 45.2 32.0 57.1 
    DNA 76.9 55.2 110.4 
    Water 35.4 46.0 42.0 
R.m.s. deviations    
    Bond lengths (Å) 0.009 0.014 0.006 
    Bond angles ( ) 1.21 1.39 1.0 
*Values in parentheses are for the highest-resolution shell. 
 
13 
 
Supplementary Table 4: Data collection, processing and structure refinement statistics of the carbocyclic 
FaPydG-structures. 
 
PDB code 
cFaPydG (pre-IS) 
4B9S 
dC-cFaPydG (n-1)  
4B9T 
dA-cFaPydG (n-1)  
4B9U 
dA-cFaPydG (n-2)  
4B9V 
Data collection     
Space group P212121 P212121 P212121 P212121 
Cell dimensions      
    a, b, c (Å) 88.1, 93.7, 105.6 88.3, 93.8, 105.6 88.7, 93.9, 105.6 87.9, 94.0, 105.3 
 ( )  90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 46.8-1.75 (1.84-1.75) 45.0-2.65 (2.8-2.65) 46.3–2.1 (2.21-2.1) 47.0-2.0 (2.11-2.0) 
Rmerge 0.043 (0.507) 0.102 (0.474) 0.103 (0.666) 0.060 (0.441) 
I / I 24.3 (3.9) 17.6 (4.0) 11.6 (3.3) 18.9 (4.6) 
Completeness (%) 99.7 (99.4) 95.3 (97.1) 99.3 (99.0) 99.8 (99.8) 
Redundancy 5.9 (6.1) 5.9 (5.8) 4.5 (4.6) 5.9 (6.1) 
     
Refinement     
Resolution (Å) 46.8-1.75 45.0-2.65 46.3-2.1 47.0-2.0 
No. reflections 86,204 34,272 49,156   56,504 
Rwork / Rfree 0.181 / 0.206 0.221 / 0.273 19.1 / 22.4 0.187 / 0.215 
No. atoms 5,484 5,201 5,368 5,362 
    Protein 4,677 4,658 4,658 4,675 
    DNA 439 473 495 473 
    Water 358 70 217 206 
B-factors     
    Protein 26.0 60.7 30.3 30.0 
    Ligand/ion 39.4 121.0 52.4 55.5 
    Water 32.0 92.9 34.4 31.4 
R.m.s. deviations     
    Bond lengths (Å) 0.017 0.011 0.014 0.0139 
    Bond angles ( ) 1.8 1.56 1.6 1.6 
*Values in parentheses are for the highest-resolution shell. 
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Supplementary Note 1 
 
Overview of the synthesis of carbocyclic FaPydA 
Here we report the synthesis of a new phosphoramidite building block for the preparation of 
carbocyclic FaPydA containing DNA (cFaPydA) 1 (Supplementary Fig. 1). Together with 
the corresponding building block for FaPydG (cFaPydG) 2 lesion containing DNA duplexes 
were prepared and crystallized in complex with the large fragment of the high fidelity poly-
merase I from Geobacillus stearothermophilus. 
 
For the synthesis of cFaPydA we prepared the enantiomerically pure amino cyclopentane unit 
(3) starting from Vince lactam via the Boc-protected aminocyclopentane (4) (Supplementary 
Fig. 1). The pyrimidine moiety (5), which serves as a precursor for the pyrimidine 
heterocycle, was obtained from 4,6-dihydroxy-pyrimidine (6) via compound (7) and (8) in 
three steps.  Coupling of (3) and (5) was gave compound (9) in yields of above 80%. Subse-
quent protection of the two OH-groups with TBSCl, followed by reduction of the nitro group 
with Pd/C under hydrogen atmosphere, provided the unstable amine, which was not isolated 
but in situ converted into the formamide (10) with formyl acetic anhydride.  Due to the direct-
ing effect of the two pyrimidine ring nitrogens the formylation occurred exclusively at posi-
tion N5.  Compound (11) was obtained after protection of the N4 nitrogen with 
triphenylmethyl-chloride (TrCl) in pyridine, which is an unusual protecting group for this 
position. Deprotection of the 3´ and 5´ OH groups under mild conditions was conducted using 
HF∙pyridine in pyridine. The pseudo-β-furanosidic configuration of the precursor (11) was 
proven by X-ray crystallography. The structural data show the cis rotamer of the formamide 
group to be the main isomer in the crystal (-N5H-CHO) (Supplementary Figure 1b).  The 
formamide group adopts a position orthogonal to the pyrimidine ring in order to avoid unfa-
vorable steric interactions. NMR spectroscopic analysis of the compound (10) in different 
solvents confirms a strong solvent-dependency of the cis/trans equilibrium with the com-
pound preferring the cis conformation as observed in the crystal structure. The rotation barrier 
calculated from temperature dependent NMR experiments to 71.7 ± 2.9 kJmol
-1
 (DMSO-d6) is 
in good agreement with literature values for unsubstituted formamide (75.5 ± 1.1 kJmol
-1
, 
DMSO-d6) (Supplementary Fig. 2). 
The final functionalization of the 5´ hydroxyl group with 4,4'-dimethoxytrityl chloride 
(DMTCl) for DNA synthesis was carried out under standard conditions followed by conver-
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sion of the 3´ OH group into the phosphoramidite (1) using 3-(bis(diisopropylamino)phos-
phanooxy)-propanenitrile (for detailed procedures see below). 
 
Supplementary Figure 1: (a) Synthesis of the protected carbocyclic lesion analog cFaPydA (1). The carbocy-
clic FaPydG (2) was synthesized as previously reported. (b) Crystal structure of compound 11 with resolved cis 
and trans rotamers of the formamide units. 
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Supplementary Figure 2: 
1
H-NMR (400 MHz, DMSO–d6) of compound 1 at different temperatures. The 
formamide protons are marked in red and blue. The cis protons are shifted upfield due to the anisotropic effect. 
Protons of the C1`NH are highlighted in green. 
 
Both phosphoramidites (1 and 2) were subsequently incorporated into different oligo-
nucleotides (Supplementary Information - Table 2).  
To this end the standard DNA synthesis protocol was adjusted. The coupling time of the car-
bocyclic FaPy-phosphoramidites was extended from 96 sec to 10 min for the cFaPydG com-
pound (2) and even to 14 min for the cFaPydA (1) lesion due to the steric problems associated 
with the bulky triphenylmethyl (trityl) group of 1. The acidic deprotection steps during DNA 
synthesis were shortened in order to avoid cleavage of the acid sensitive trityl group. The 
DNA was subsequently cleaved from the solid support and deprotected using saturated am-
monia solution in ethanol. Final deprotection of the trityl group of 1 was achieved with 80% 
acetic acid in aqueous solution for 20 min at rt. After precipitation of the DNA purification 
was performed by HPL-chromatography. Correct incorporation of the cFaPydA building 
block was proven by enzymatic digestion, followed by high resolution LC-MS characteriza-
tion of the digest (Supplementary Fig. 3). In these experiments we detected next to the four 
canonical nucleotides dA, dC, dG and dT, a fifth broad peak with a retention time of 13.5 min 
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and a moleculer weight of m/z = 268.1408, is excellent agreement with the expected molecu-
lar weight (m/z = 268.1404) for the fully deprotected cFaPydA compound (12) (Supplemen-
tary Fig. 3b). The broad appearance of the peak is attributed to the cis/trans interconversion 
of the formamide group on the column. 
 
Supplementary Figure 3: (a) HPLC/MS (ESI
+
) of the digested oligonucleotide ODN7 with cFaPydA (top, 
blue), (b) monomeric carbocyclic nucleoside cFaPydA 12 (bottom, green). The numbers in the HPL-
chromatograms are retention times in min. The numbers in the mass spectra are the found molecular weights. 
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Detailed synthesis of carbocyclic FaPydA nucleoside phosphoramidite 1 
4,6-dihydroxy-5-nitropyrimidine 7 
 
To a cooled solution consisting of conc. acetic acid (60 mL) and nitric acid (20 mL) 4,6-
dihydroxypyrimidine 6 (20.0 g, 178 mmol) was added slowly over 30 min. The solution was 
kept between 10 and 20 °C. After stirring for another 30 min between 10 and 20 °C, the solu-
tion was additionally stirred for 10 min at rt. The reaction was then poured onto ice (150 mL) 
and the resulting precipitate was filtered off and dried under high vacuum. 4,6-dihydroxy-5-
nitropyrimidine 7 (25 g, 160 mmol) was isolated as a yellow solid. mp: 320 °C(lit °C); 
1
H 
NMR (400 MHz, DMSO-d6): δ 8.72 (s, 1H, HAr), 13.21 (br s, 2H, 2 x OH); 
13
C NMR (100 
MHz, DMSO-d6): δ 119.9 (C-NO2), 150.9 (CH), 155.5 (2 x C-OH); IR (ATR): 3027, 2937, 
1726, 1664 1555, 1468, 1350, 1310, 1280, 1196, 884, 788, 631 cm
-1
; EI-HRMS (m/z): [M]
∙+
 
calcd. for C4H3N3O4, 157.0118; found, 157.0118. 
 
4,6-dichloro-5-nitropyrimidine 8 
 
To a suspension consisting of 4,6-dihydroxy-5-nitropyrimidine 7 (500 mg, 3.18 mmol) and 
oxalyl chloride (2.0 mL, 22.4 mmol, 7 eq), 1 mL of DMF (12.8 mmol, 4 eq) was added care-
fully. The reaction mixture was heated under reflux for 4 h while the reaction mixture 
changed from red to yellow. The mixture was dried under high vacuum and to the resulting 
solid was added ice (5 mL). The solution was extracted with toluene (3 x 20 mL) and the or-
ganic phase was washed another time with water. The organic layer was dried over MgSO4 
and the organic solvent was removed under reduced pressure. 4,6-dichloro-5-nitropyrimidine 
8 was recrystallized from n-hexane to give colorless plates. 
mp: 101 °C; TLC (toluene:EtOAc, 10:1 v/v): Rf = 0.60; 
1
H NMR (400 MHz, DMSO-d6): δ 
8.75 (s, 1H, CHAr); 
13
C NMR (100 MHz, DMSO-d6): δ 119.9 (C-NO2), 150.9 (C-H), 155.5 
(C-Cl); IR (ATR) 3055, 1682, 1588 , 1534, 1428, 1357, 1313, 1127, 1050, 976, 855, 834, 
785, 718 cm
-1
; EI-HRMS (m/z): [M]
∙+
 calcd. for C4H
35
Cl2N3, 192.9440; found, 192.9433. 
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4-amino-6-chloro-5-nitropyrimidine 5 
 
To a suspension of 4,6-dichloro-5-nitropyrimidine 8 (800 mg, 4.12 mmol) in dioxane, kept at 
8 °C in an ice bath, a freshly prepared solution of conc. acetic acid (1.6 mL) in ammonium 
hydroxide (28 %, 3.2 mL) was slowly added via syringe pump to the suspension. The solution 
did not warm up over 15 °C and was stirred for another 90 min under ice cooling. The product 
was then precipitated by adding ice cold distilled water (18 mL). The resulting yellow solid 
was filtrated and recrystallized from benzene to separate it from the diaminated product. The 
recrystallized product 5 could be obtained as small yellow needles (425 mg, 2.43 mmol, 60 
%). mp: 155 °C; TLC (CHCl3:MeOH, 10:1 v/v): Rf = 0.36; FTIR (ATR): 3307, 3144, 1647, 
1575, 1519, 1396, 1340, 1233, 1042, 964, 861, 777 cm
-1
; 
1
H NMR (300 MHz, DMSO–d6):  
7.95 (s, 1H, HAr), 8.67 – 8.80 (br s, 2H, NH2); 
13
C NMR (100 MHz, DMSO–d6):  115.3 
(CAr), 152.0 (CAr), 155.4 (CAr), 160.31 (CAr); EI-HRMS (m/z): [M]
∙+
 calcd. for C4H3
35
ClN4O2, 
173.9945; found, 173.9948. 
 
(1S,2R,4R)-4-ammonium-2-(hydroxymethyl)cyclopentanol-trifluoroacetate 3 
 
The carbamate tert-Butyl N-[(1R,3S,4R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl]carbamate 
4 was synthesized according to literature from Vince lactam and added to 10 ml of 
trifluoroacetic acid in water (95:5). The reaction was stirred for 30 min at rt. This was fol-
lowed by removal of acid and water under reduced pressure. The resulting colorless oil of 3 
(420 mg, 1.71 mmol, 99%) was dried under high vacuum overnight und used without any 
further purification. mp: 3 – 4 °C; FTIR (ATR): 3295, 3045, 2938, 1785, 1668, 1532, 1432, 
1392, 1369, 1350, 1178, 1130, 1077, 1017, 920, 880, 839, 798, 777, 722 cm
-1
; 
1
H NMR (400 
MHz, D2O–d2):  1.07 (dt, 
2
JH-H (C5´Hb,C5´Ha) = 13.3 Hz, 
3
JH-H (C5´Hb,C1´H,C4´H) = 9.1 
Hz, 1 H, C5´Hb), 1.63–1.70 (m, 1 H, C2´Hb), 1.72–1.81 (m, 2 H, C2´Ha, C4´H), 2.03–2.11 (m, 
C5´Ha), 3.27 (dd, 
2
JH-H (C1´´Hb,C1´´Ha) = 11.1 Hz, 
3
JH-H (C1´´Hb,C4´H) = 6.27 Hz, 1 H, 
C1´´Hb), 3.33 (dd, 
2
JH-H (C1´´Ha,C1´´Hb) = 11.2 Hz, 
3
JH-H (C1´´Ha,C4´H) = 5.8 Hz, 1 H, 
C1´´Ha), 3.44–3.52 (m, 1 H, C1´H), 3.83 (m, 1H, C3´H); 
13
C NMR (100 MHz, D2O–d2): δ 
30.24 (C´5), 38.95 (C´2), 48.90 (C´4), 49.65 (C´1), 63.18 (C´´1), 73.08 (C´3), 116.60 (q, 
TFA), 164.20 (q, TFA); 
19
F NMR (200 MHz, D2O–d2): δ –76.30 (s, 3 F, CF3CO2
–
); EI-HRMS 
(m/z): [M + H
+
]: calcd. for [C6H13NO2+H]
+
, 132.1019; found, 132.1020. 
 
 
20 
 
N-4-{[(1´R,3´S,4´R)-3´-Hydroxy-4´-(hydroxymethyl)-cyclopentyl]amino}-5-nitro-6-
amino-pyrimidine 9.  
 
The crude oil of 3 (420 mg, 1.71 mmol), was dissolved in 2.1 mL of dry ethanol, and 4-
amino-6-chloro-5-nitropyrimidine 5 (302 mg, 1.73 mmol, 1 eq) together with triethylamine 
(1.68 mL, 12.1 mmol, 7 eq) was added. The mixture was refluxed for 1 h. After cooling to 
room temperature, the resulting yellow precipitate 9 (377 mg, 1.40 mmol, 81 %) was filtered, 
washed with ethanol, dried under high vacuum and used in the following reaction without any 
further purification. mp: decomp. > 169 °C; TLC (CHCl3:MeOH, 4:1 v/v): Rf = 0.40; FTIR 
(ATR): 3447, 2928, 1651, 1605, 1515, 1398, 1369, 1257, 1137, 1043, 1004, 794, 586, 557, 
425 cm
-1
; 
1
H NMR (400 MHz, DMSO–d6): δ 1.24–1.34 (m, 1 H, C5´Ha), 1.76 (ddd, 
2
JH-H 
(C2´Hb,C2´Ha) = 13.2 Hz, 
3
JH-H (C2´Hb, C1´H) = 7.72 Hz, 
3
JH-H (C2´Hb, C3´H) = 6.53 Hz, 1 
H, C2´Hb), 1.85–1.93 (m, 2 H, C2´Ha, C4´H), 2.25 (dt, 
2
JH-H (C2´Ha,C2´Hb) = 13.0 Hz, 
3
JH-H 
(C2´Ha,C1´H,C3´H) = 8.1 Hz), 1.31 (dt, 
2
JH-H (C5´Ha,C5´Hb) = 13.1 Hz, 
3
JH-H 
(C5´Ha,C1´H,C4´H) = 7.88 Hz, 1 H, C5´Ha), 3.38 (dd, 
2
JH-H (C1´´Hb,C1´´Ha) = 10.5 Hz, 
3
JH-H 
(C1´´Hb,C4´H) = 5.72 Hz, 1 H, C1´´Hb), 3.44 (dd, 
2
JH-H (C1´´Ha,C1´´Hb) = 10.5 Hz, 
3
JH-H 
(C1´´Ha,C4´H) = 5.50 Hz, 1 H, C1´´Ha), 3.96 (dt, 
3
JH-H (C3´H,C2´Hb) = 6.25 Hz, 
3
JH-H 
(C3´H,C2´Ha,C4´H) = 4.41 Hz, 1 H, C3´H), 4.60 (br, 2 H, 2 x OH), 4.71 (m, 1 H, C1´H), 7.97 
(s, 1 H, C1H), 8.51 (br, 1 H, NH), 8.58 (br, 1 H, NH), 9.15 (d, 
3
JH-H (C1´NH, C1´H) = 7.52 
Hz, 1 H, C1´NH);
13
C NMR (100 MHz, DMSO–d6): δ 34.11 (C´5), 41.50 (C´2), 48.90 (C´4), 
50.12 (C´1), 62.52 (C´´1), 72.08 (C´3), 111.68 (C5), 155.99 (C6), 158.77 (C4), 159.42 (C2); 
ESI-HRMS (m/z): [M + H
+
] calcd. for [C10H15N5O4+H]
+
, 270.1197; found, 270.1199. 
 
N-4-{[(1´R,3´S,4´R)-3´-[(tert-Butyldimethylsilyl)oxy]-4´-{[(tert-butyldimethylsilyl)oxy]-
methyl}-cyclopentyl]amino}-5-nitro-6-amino-pyrimidine 9a.  
 
Compound 9 (450 mg, 0.90 mmol) was dissolved in dry DMF (15 mL). To the solution was 
given imidazole (184 mg, 2.71 mmol, 3 eq) and tert-butyldimethylsilylchloride (408 mg, 2.71 
mmol, 3 eq) and the reaction was stirred at rt for 3 h. After complete conversion of the start-
ing material, the reaction mixture was diluted with ethylacetate (125 mL) and washed with 
saturated NaHCO3 (125 mL) and brine (4 x 125 mL.). The combined aqueous phases were 
extracted once again with 100 mL of ethylacetate. The collected organic phases were dried 
over anhydrous Na2SO4, filtrated and the solvent was removed under reduced pressure. The 
crude product was purified via column chromatography (CHCl3 : MeOH 20:1 → 10:1). The 
product was obtained as a yellow solid (336 mg, 0.68 mmol, 75 %). Crystals for X-ray analy-
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sis were received by dissolving 9a in n-heptane at 40 °C. After slowly cooling the solution to 
rt, 9a crystallized in colorless plates over a period of 14 days at rt (Supplementary Figure 4). 
mp: 50 °C; TLC (CHCl3:MeOH, 10:1 v/v): Rf = 0.59; FTIR (ATR): 3397, 3344, 3274, 3122, 
2953, 2927, 2855, 1583, 1546, 1522, 1471, 1390, 1358, 1247, 1116, 1094, 1038, 1006, 960, 
936, 870, 832, 796, 775 cm
-1
; 
1
H NMR (600 MHz, CDCl3): δ 0.03 (s, 3 H, Si-CH3), 0.04 (s, 3 
H, Si-CH3), 0.04 (s, 3 H, Si-CH3), 0.04 (s, 3 H, Si-CH3), 0.87 (s, 9 H, Si-C(CH3)3), 0.88 (s, 9 
H, Si-C(CH3)3), 1.31 (dt, 
2
JH-H (C5´Hb,C5´Ha) = 13.1 Hz, 
3
JH-H (C5´Hb,C1´H,C4´H) = 8.8 Hz, 
1 H, C5´Hb), 1.75 (ddd, 
2
JH-H (C2´Hb,C2´Ha) = 13.1 Hz, 
3
JH-H (C2´Hb,C1´H) = 7.7 Hz, 
3
JH-H 
(C2´Hb,C3´H) = 6.7 Hz, 1 H, C2´Hb), 2.04 (m, 1 H, C4´H), 2.09 (ddd, 
2
JH-H (C2´Ha,C2´Hb) = 
12.6 Hz, 
3
JH-H (C2´Ha,C1´H) = 7.8 Hz, 
3
JH-H (C2´Ha,C3´H) = 4.4 Hz, 1 H, C2´Ha), 1.31 (dt, 
2
JH-H (C5´Ha,C5´Hb) = 13.1 Hz, 
3
JH-H (C5´Ha,C1´H,C4´H) = 7.88 Hz, 1 H, C5´Ha), 3.56 (dd, 
2
JH-H (C1´´Hb,C1´´Ha) = 10.1 Hz, 
3
JH-H (C1´´Hb,C4´H) = 5.0 Hz, 1 H, C1´´Hb), 3.61 (dd, 
2
JH-H 
(C1´´Ha,C1´´Hb) = 10.1 Hz, 
3
JH-H (C1´´Ha,C4´H) = 5.0 Hz, 1 H, C1´´Ha), 4.17 (m, 1 H, 
C3´H), 4.77 (m, 1 H, C1´H), 7.20 (br, 1 H, NH), 8.01 (s, 1 H, C1H), 8.57 (br, 1 H, NH), 9.02 
(d, 
3
JH-H (C1´NH, C1´H) = 7.2 Hz, 1 H, C1´NH); 
13
C NMR (150 MHz, CDCl3): δ –5.49 (Si-
CH3), –5.41 (Si-CH3), –4.78 (Si-CH3), –4.61 (Si-CH3), 17.98 (Si-C(CH3), 18.31 (Si-C(CH3), 
25.80 (Si-C(CH3)3, 25.91 (Si-C(CH3)3, 33.97 (C´5), 42.20 (C´2), 49.75 (C´4), 50.27 (C´1), 
63.27 (C´´1), 73.10 (C´3), 112.69 (C5), 156.57 (C6), 159.33 (C4), 159.48 (C2); ESI-HRMS 
(m/z): [M + H
+
] calcd. for [C22H43N5O4Si2+H]
+
, 498.2926; found, 498.2926. 
 
Supplementary Figure 4: Crystal structure of compound 9a recrystallized from n-heptane. 
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N-4-{[(1´R,3´S,4´R)-3´-[(tert-Butyldimethylsilyl)oxy]-4´-{[(tert-butyldimethylsilyl)oxy]-
methyl}-cyclopentyl]amino}-5-formylamino-6-amino-pyrimidine 10.  
 
The silylether 9a (200 mg, 0.40 mmol) was dissolved in dry ethanol (5 mL) and the reaction 
mixture was degassed carefully. The solution was given to a degassed suspension of Pd/C 
(100 mg) in dry ethanol (5 mL). The mixture was flushed with hydrogen and stirred for 3 h 
under the hydrogen atmosphere (1.2 bar) at rt. Under exclusion of oxygen, the charcoal and 
palladium were filtered off, using a 0.2 μm nylon syringe filter (Millipore
TM
). The solvent was 
evaporated under reduced pressure at rt and the air sensitive amine was carefully co-
evaporated three times using dry pyridine (3 x 1 mL) under high vacuum. The amine was then 
dissolved in 10 mL of degassed THF (abs.), 815 μL of dry pyridine were added and the solu-
tion was cooled to 0 °C. Meanwhile a solution consisting of formic acid (501 μL) and acetic 
acid anhydride (1.28 mL) was heated to 60 °C for 15 min and the mixed anhydride was after-
wards cooled to 0 °C and carefully degassed. From this solution 617 μL of the mixed anhy-
dride were promptly added to the amine and the reaction was stirred at 0 °C overnight reach-
ing rt. After evaporation of the solvents the resulting crude reaction mixture was purified by 
column chromatography (CHCl3:MeOH 20:1 → 10:1). The resulting formamide 10 could be 
obtained as white foam (147 mg, 0.30 mmol, 75 % over two steps). The cis- and trans- 
formamide ratio in DMSO was 3:1 and in CDCl3 1:1. mp: 141 – 143 °C; TLC (CHCl3:MeOH 
10:1 v/v): Rf= 0.19; FTIR (ATR): 3338, 2929, 2856, 1685, 1589, 1501, 1470, 1360, 1327, 
1250, 1077, 1005, 938, 832, 772, 667 cm
-1
;
 1
H NMR (400 MHz, DMSO–d6): δ 0.03 (s, 12 H, 
4 x Si-CH3), 0.87 (s, 9 H, Si-C(CH3)3, 0.87 (s, 9 H, Si-C(CH3)3, 1.10 (ddd, 
2
JH-H 
(C5´Hb,C5´Ha) = 12.6 Hz, 
3
JH-H (C5´Hb,C1´H,C4´H) = 9.3 Hz, 1 H, C5´Hb), 1.68–1.82 (m, 2 
H,C2´Hb,C2´Ha), 1.84–1.92 (m, 1 H,C4´H), 2.11 (ddd, 
2
JH-H (C5´Ha,C5´Hb) = 12.8 Hz, 
3
JH-H 
(C5´Ha,C1´H,C4´H) = 9.3 Hz, 1 H, C5´Ha), 3.51 (dd, 
2
JH-H (C1´´Hb,C1´´Ha) = 9.5 Hz, 
3
JH-H 
(C1´´Hb,C4´H) = 5.0 Hz, 1 H, C1´´Hb), 3.55 (dd, 
2
JH-H (C1´´Ha,C1´´Hb) = 9.5 Hz, 
3
JH-H 
(C1´´Ha,C4´H) = 5.3 Hz, 1 H, C1´´Ha), 4.08 (ddd, 
3
JH-H (C3´H,C2´Ha) = 7.2 Hz, 
3
JH-H 
(C3´H,C2´Hb,C4´H) = 4.30 Hz, 1 H, C3´H), 4.50 (m, 1 H, C1´H), 5.86 (d, 
3
JH-H (C1´NH, 
C1´H) = 7.80 Hz, 0.75 H, [cis-formamide]C1´NH), 5.89 (br, 1 H, NH), 6.07 (br, 1 H, NH), 
6.20 (d, 
3
JH-H (C1´NH,C1´H) = 7.80 Hz, 0.25 H, [trans-formamide]C1´NH), 7.72 (d, 
3
JH-H 
(NHCHO,NHCHO) = 11.6 Hz, 0.25 H [trans-Formamide]NHCHO, 7.84 (s, 0.75 H, [cis-
formamide]C2H), 7.84 (s, 0.25 H, [trans-formamide]C2H), 8.10 (d, 
3
JH-H (NHCHO,NHCHO) 
= 1.40 Hz, 0.75 H [cis-formamide]NHCHO, 8.20 (d, 
3
JH-H (NHCHO,NHCHO) = 11.8 Hz, 
0.25 H [trans-formamide]NHCHO, 8.70 (d, 
3
JH-H (NHCHO,NHCHO) = 1.0 Hz , 0.75 H [cis-
formamide]NHCHO); 
13
C NMR (100 MHz, DMSO–d6): δ –5.44 (Si-CH3), –5.42 (Si-CH3), –
4.82 (Si-CH3), –4.62 (Si-CH3), 17.71 (Si-C(CH3), 18.00 (Si-C(CH3), 25.72 (Si-C(CH3)3, 
25.80 (Si-C(CH3)3, 33.67([trans-formamide]C´5), 33.82 ([cis-formamide]C´5), 40.73 ([trans-
formamide]C´2), 41.40 ([cis-formamide]C´2), 48.69 (C´1), 49.49 ([trans-formamide]C´4), 
49.53 ([cis-formamide]C´4), 63.74 ([cis-formamide]C´´1), 63.85 ([trans-formamide]C´´1), 
72.84 ([cis-formamide]C´3), 72.94 ([trans-formamide]C´3), 93.99 ([cis-formamide]C5), 
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94.18 ([trans-formamide]C5), 155.46 ([cis-formamide]C2), 155.89 ([trans-formamide]C2), 
157.72 ([cis-formamide]C4), 158.69 ([cis-formamide]C6), 159.08 ([trans-formamide]C4), 
160.25 ([trans-formamide]C6), 160.92 ([cis-formamide]CHO), 165.58 ([trans-
formamide]CHO); ESI-HRMS (m/z): [M + H
+
] calcd. for [C23H45N5O3Si2+H]
+
; 496.3134; 
found, 496.3131. 
 
N-4-{[(1´R,3´S,4´R)-3´-[(tert-Butyldimethylsilyl)oxy]-4´-{[(tert-butyldimethylsilyl)oxy]-
methyl}-cyclopentyl]amino}-5-formylamino-6-tritylamino-pyrimidine 10a 
 
The protected silylether 10 (555 mg, 1.12 mmol) was dissolved in dry CH2Cl2 and stirred in a 
Schlenk-flask over molecular sieve (4 Å) for 30 min. The solution was cooled in an ice bath 
and triphenylmethyl chloride (376 mg, 1.35 mmol, 1.2 eq) was added to the solution. The 
mixture was stirred overnight reaching rt. The solvent was removed under vacuum and the 
crude product was purified via column chromatography (CHCl3:MeOH: 200:1→ 20:1). The 
resulting product 10a could be isolated as white foam (462 mg, 0.63 mmol, 57 %). The cis- 
and trans- formamide ratio in AcCN was 2:1 in CDCl3 both conformers were observed in a 
ratio of 1:1. mp: 133 – 134 °C; TLC (CHCl3:MeOH, 20:1 v/v): Rf = 0.48; FTIR (ATR): 3335, 
2914, 2360, 2336, 2060, 2009, 1678, 1588, 1478, 1442, 1326, 1266, 1184, 1155, 1032, 899, 
748, 728, 698, 655, 636, 626, 614 cm
-1
; 
1
H NMR (400 MHz, MeCN–d3): δ 0.05 (s, 4 H, [cis-
Formamide]Si-CH3), 0.06 (s, 8 H, [trans-Formamide]Si-CH3), 0.88 (s, 9 H, Si-C(CH3)3, 0.90 
(s, 9 H, Si-C(CH3)3), 1.09–1.17 (m, 1 H, C5´Hb), 1.65 (ddd, 
2
JH-H(C2´Hb,C2´Ha) = 13.0 Hz, 
3
JH-H(C2´Hb,C1´H) = 8.6 Hz, 
3
JH-H (C2´Hb,C3´H) = 6.6 Hz, 1 H, C2´Hb), 1.84–1.96 (m, 2 H, 
C2´Ha,C4´H), 2.14–2.22 (m, 1 H, C5´Ha), 3.50 (d, 
2
JH-H(C1´´Hb,C1´´Ha) = 5.6 Hz, 0.5 H, 
[trans-formamide]C1´´Hb,C1´´Ha), 3.58 (d, 
2
JH-H(C1´´Hb,C1´´Ha) = 5.7 Hz, 1.5 H, [cis-
formamide]C1´´Hb,C1´´Ha), 4.12–4.16 (dt, 
3
JH-H (C3´H,C2´Hb) = 6.6 Hz, 
3
JH-H 
(C3´H,C2´Ha,C4´H) = 4.3 Hz, 1 H, C3´H), 4.43–4.54 (m, 1 H, C1´H), 5.14 (d, 
3
JH-H (C1´NH, 
C1´H) = 7.6 Hz, 0.75 H, [cis-formamide]C1´NH), 5.40 (d, 
3
JH-H (C1´NH, C1´H) = 7.7 Hz, 
0.25 H, [trans-formamide]C1´NH), 6.93 (d, 
3
JH-H(NHCHO,NHCHO) = 11.7 Hz, 0.25 H, 
[trans-formamide]NHCHO), 7.18–7.28 (m, 10 H, -Trityl), 7.31–7.34 (m, 5 H, -Trityl), 7.42 
(s, 0.75 H, [cis-formamide]NHCHO), 7.51 (s, 0.25 H, [trans-formamide]C2H), 7.59 (s, 0.75 
H, [cis-formamide]C2H), 7.92 (d, 
3
JH-H(NHCHO,NHCHO) = 11.7 Hz, 0.25 H, [trans-
formamide]NHCHO), 8.32 (d, 
3
JH-H(NHCHO,NHCHO) = 1.2 Hz, 0.75 H, [cis-
formamide]NHCHO), 9.02 (br, 0.25 H, [trans-formamide]NH), 9.04 (br, 0.75 H, [cis-
formamide]NH); 
13
C NMR (100 MHz, MeCN–d3): δ –4.73 (Si-CH3), –4.71 (Si-CH3), –4.02 
(Si-CH3), –3.83 (Si-CH3), 19.08 (Si-C(CH3), 19.41 (Si-C(CH3), 26.69 (Si-C(CH3)3, 26.79 (2 x 
Si-C(CH3)3, 26.85 (Si-C(CH3)3, 35.50 (C5´), 43.10 (C2´), 50.83 (C1´), 51.34 (C4´), 65.29 
(C1´´), 71.77 (Cq from -trityl), 74.75 (C3´), 97.66 (C5), 127.91 (CH-Trityl), 128.98 (CH-
Trityl), 130.2 (CH-Trityl), 147,35 (C- from Trityl), 155,93 (C2), 158,28 (C4), 158.99 (C6), 
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162.58 (CHO); ESI-HRMS (m/z): [M + H
+
] calcd. for [C42H59N5O3Si2+H]
+
, 738.4229; found, 
738.4238. 
 
N-4-{[(1´R,3´S,4´R)-3´-hydroxy-4´-(hydroxymethyl)cyclopentyl]amino}-5-formylamino-
6-tritylamino-pyrimidine 11 
 
The silylether 10a (3 x 125 mg, 3 x 169 μmol) and dry tetrahydrofurane (3 x 3.5 mL) were 
given into three sealable polypropylene tubes. Dry pyridine (3 x 131 μL) and HF∙pyridine 
complex (~ 65% HF content, 3 x 131 μL) were added, and the sealed tubes were stirred over-
night at room temperature. To the reaction was given methoxytrimethylsilane (3 x 405 μL) 
and the reaction mixtures were stirred again for 2 h. Afterwards the solvent was evaporated 
under reduced pressure and the resulting white solid was dried in vacuo. The diol was purified 
via column chromatography (chloroform: methanol: 20:1→ 10:1) (243 mg, 477 μmol, 94%). 
Crystals suitable for X-ray analysis were obtained by dissolving 11 in acetonitrile and ap-
peared after 7 days at rt as colorless crystals (Supplementary Fig. 1b). 
TLC (CHCl3:MeOH, 10:1 v/v): Rf = 0.12; FTIR (ATR): 3423, 2956, 2928, 3856, 2360, 1725, 
1700, 1580, 1492, 1470, 1443, 1255, 1117, 1073, 1038, 1004, 938, 874, 834, 773, 745 cm
-1
; 
1
H NMR (400 MHz, MeCN–d3): δ 1.17 (dt, 
2
JH-H(C5´Hb,C5´Ha) = 13.0 Hz, 
3
JH-
H(C5´Hb,C1´H,C4´H) = 8.3, 1 H, C5´Hb, 1.69 (m, 1 H, C2´Hb), 1.82–1.96 (m, 2 H, 
C2´Ha,C4´H), 2.20 (dt, 
2
JH-H(C5´Ha,C5´Hb) = 12.9 Hz, 
3
JH-H(C5´Hb,C1´H,C4´H) = 8.3, 1 H, 
C5´Ha, 3.47–3.55 (m, 2 H, C1´´Hb,C1´´Ha), 4.00–4.04 (m, 1 H, C3´H), 4.41–4.50 (m, 1 H, 
C1´H), 5.35 (d, 
3
JH-H (C1´NH,C1´H) = 7.67 Hz, 0.75 H, [cis-formamide]C1´NH), 5.95 (d, 
3
JH-
H (C1´NH,C1´H) = 7.7 Hz, 0.25 H, [trans-formamide]C1´NH), 6.99 (d, 
3
JH-H 
(NHCHO,NHCHO) = 11.4 Hz, 0.25 H [trans-formamide]NHCHO), 7.18–7.22 (m, 3 H, 3 x 
para-H of trityl), 7.24–7.29 (m, 6 H, 6 x CH-Trityl), 7.31–7.35 (m, 6 H, 6 x CH-Trityl), 7.50 
(s, (NHCHO,NHCHO), 0.75 H [cis-formamide]NHCHO), 7.51 (s, 0,75 H, [cis-
formamide]C2H), 7.59 (s, 0.25 H, [trans-formamide]C2H), 7.92 (d, 
3
JH-H(NHCHO,NHCHO) 
= 11.75 Hz, 0.25 H, [trans-formamide]NHCHO), 8.31 (d, 
3
JH-H(NHCHO,NHCHO) = 1.16 
Hz, 0.75 H, [cis-formamide]NHCHO), 8.57 (br, 1 H, NH), 2 x OH not observed; 
13
C NMR 
(100 MHz, MeCN–d3): δ 35.76 (C5´), 43.09 (C2´), 50.44 (C4´), 50.94 (C1´), 65.04 (C1´´), 
71.73 (C- from Trityl), 74.77 (C3´), 97.61 (C5), 127.89 (CH-Trityl), 128.96 (CH-Trityl), 
130.18 (CH-Trityl), 147.35 (CH- from Trityl), 155.11 (C2), 155,90 (C4), 158.27 (C6), 162.65 
(CHO); ESI-HRMS (m/z): [M + H
+
] calcd. for [C30H31N5O3+H]
+
, 510.2500; found, 510.2503. 
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N-4-{[(1´R,3´S,4´R)-4´-{[(Dimethoxytrityl)oxy]methyl}-3´-hydroxycyclopentyl]amino}-5-
(formylamino)-6-tritylamino-pyrimidine 11a  
 
Compound 11 (214 mg, 0.42 mmol) was dissolved two times in dry pyridine (2 x 1 mL) and 
concentrated in vacuo two times. The residue was dissolved again in dry pyridine (8.5 mL) 
and stirred for 12 h over 4 Å molecular sieves. The solution was then cooled in an ice bath 
and dimethoxytritylchloride (DMTCl) (86 mg, 0.25 mmol, 0.6 eq) was given to the solution. 
After another hour additional DMTCl (86 mg, 0.25 mmol, 0.6 eq) was added. The mixture 
was stirred for another hour at 0 °C and finally for 18 h at rt. The reaction was terminated 
adding 5 mL of MeOH. The molecular sieves were filtered off and the solvent was removed 
under reduced pressure. The resulting crude yellow product was purified via column chroma-
tography using a CHCl3:MeOH gradient: 200:1 → 100:1 →50:1 → 10:1 with 0.5% pyridine. 
Compound 11a was isolated as a white foam (249 mg, 0.31 mmol, 73 %) ); mp: 60–61 °C; 
(CHCl3:MeOH, 20:1 v/v): Rf= 0.29; FTIR (ATR): 3444, 2968, 2915, 2836, 2360, 2338, 1724, 
1607, 1508, 1456, 1446, 1285, 1244, 1175, 1152, 1136, 1068, 1030, 982, 903, 861, 822, 791, 
726, 704, 651 cm
-1
; 
1
H NMR (400 MHz, MeCN–d3): δ 1.17 (dt, 
2
JH-H(C5`Hb,C5`Ha) = 12.6 
Hz, 
3
JH-H(C5`Hb,C1´H,C4´H) = 9.6 Hz, 1 H, C5´Hb), 1.69 (ddd, 
2
JH-H(C2`Hb,C2`Ha) = 13.4 
Hz, 
3
JH-H(C2`Hb,C1`H,C5´Hb) = 8.1 Hz, 
3
JH-H(C2`Hb,C1`H,C5´Ha) = 7.2 Hz, 1 H, C2´Hb), 
1.86–1.92 (m, 1 H, C2´Ha), 1.99–2.10 (m, 1 H, C4´H), 2.23–2.33 (m, 1 H, C5`Ha), 3.01–3.05 
(m, 1 H, C1``Hb), 3.07–3.10 (m, 1 H, C1``Ha), 3.77 (s, 6 H, 2 x OCH3), 3.94–4.03 (m, 1 H, 
C3´H), 4.43–4.53 (m, 1 H, C1`H), 5.20 (d, 
3
JH-H (C1´NH,C1´H) = 7.6 Hz, 0.75 H, [cis-
Formamide]C1´NH), 5.43 (d, 
3
JH-H (C1´NH,C1´H) = 7.7 Hz, 0.25 H, [trans-
Formamide]C1´NH), 6.09 (s, 1 H, OH), 6.85–6.89 (m, 4 H, 4 x meta-H of para-CH3OPh), 
6.99 (d, 
3
JH-H (NHCHO,NHCHO) = 12.0 Hz, 0.25 H [trans-formamide]NHCHO), 7.18–7.23 
(m, 5 H, CH- of DMT and Trityl), 7.24–7.35 (m, 20 H, CH- of DMT and Trityl), 7.49 (s, 0.75 
H, [cis-formamide]NHCHO), 7.53 (s, 1 H, C2H), 7.92 (d, 
3
JH-H(NHCHO,NHCHO) = 11.7 
Hz, 0.25 H, [trans-formamide]NHCHO), 8.34 (d, 
3
JH-H(NHCHO,NHCHO) = 1.1 Hz, 0.75 H, 
[cis-Formamide]NHCHO), 8.58 (br, 1 H, NH); 
13
C NMR (100 MHz, MeCN-d3): δ 36.38 
(C5´), 42.52 (C2´), 48.55 (C4´), 50.41 (C1´), 55.97 (2 x OCH3) 66.28 (C1´´), 71.42 (C- from 
Trityl), 74.31 (C3´), 68.69 (C- from DMT), 97.32 (C5), 114.06 (4 x meta-C of p-CH3OPh), 
127.55 (CH- from Trityl), 128.63 (CH- fromTrityl), 128.84 (CH- from DMT), 129.13 (C from 
DMT), 129.85 (CH- from Trityl), 131.05 (CH- from DMT ), 131.06 (CH- from DMT), 132.29 
(CH- from DMT), 137.43 (CH- from DMT), 137.48 (CH- from DMT), 146.54 (CH- from 
DMT), 147.00 (C- from Trityl), 155.58 (C2), 157.91 (C4), 158.59 (C6), 159.64 (C- from 
DMT), 162.29 (CHO); ESI-HRMS (m/z): [M + H
+
] calcd. for [C51H49N5O5+H]
+
, 812.3806; 
found, 812.3813. 
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(1´S,2´R,4´R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((5-formamido-6-
(tritylamino)-pyrimidin-4-yl)amino)cyclopentyl-(2-cyanoethyl)-diisopropyl-
phosphoramidite 1  
 
Under Argon, compound 11a (228 mg, 0.28 mmol) was dissolved in degassed dry dichloro-
methane (3 mL) together with diisopropylaminotetrazolate (24.3 mg, 0.14 mmol, 0.5 eq). The 
reaction mixture was degassed again before cooling in an ice bath and 3-
(bis(diisopropylamino)phophanooxy)propanenitrile (100 μL, 0.32 mmol, 1.1 eq) was added 
and stirred overnight at room temperature. The resulting mixture was dried under reduced 
pressure. Pure phosphoramidite could be obtained by column chromatography (CHCl3: 
MeOH 20:1; 0.5 % pyridine) on desactivated silicagel (2 % pyridine). The dried white prod-
uct was dissolved in a small amount of dry degassed dichloromethane and slowly added de-
gassed n-pentane (100 volume equivalents). The resulting white precipitate was isolated de-
canting off the solvent under argon and dried under high vacuum. The phosphoramidite 1 
could be obtained as a white crystalline solid (215 mg, 0.21 mmol, 76%). The dried product 
could be stored under an argon atmosphere at -20 °C for at least one year without any oxida-
tion. mp: decomp. > 113 °C (decomp.); TLC (CHCl3:MeOH. 10:1 v/v): Rf = 0.68 mixture of 
stereoisomers); FTIR (ATR): 3130, 2943, 2360, 1711, 1630, 1542, 1483, 1455, 1417, 1368, 
1353, 1314, 1266, 1221, 1368, 1174, 1153, 1098, 1050, 1018, 979, 913, 893, 862, 862, 817, 
794, 758, 716, 676, 643 cm
-1
; 
1
H NMR (600 MHz, CDCl3): δ 1.00–1.02 (m, 3 H , [isomer 
1]PN[CH(CH3)2]2), 1.08–1.13 (m, 3 H , [isomer 2]PN[CH(CH3)2]2), 1.17–1.22 (m, 6 H , 
[isomer 1 + 2]PN[CH(CH3)2]2), 1.24–1.28 (m, 1 H, C5`Hb), 1.54–1.67 (m, 1 H, C2`Hb), 2.13–
2.17 (m, 1 H, C2`Ha), 2.23–2.30 (m, 1 H, C4`H), 2.38–2.44 (m, 1 H, C5`Ha), 2.53–2.58 (m, 2 
H, CH2CN), 2.97–3.08 (m, 1 H, C1``Ha), 3.16–3.21 (m, 1 H, C1``Hb), 3.47–3.61 (m, 2 H, 
[(CH3)2CHN]2PR2), 3.67–3.76 (m, 2 H, CH2CH2CN), 3.77–3.79 (m, 6 H, CH3OPh), 4.08–
4.13 (m, 1 H, C3`H), 4.44–4.50 (m, 1 H, C1`H), 6.62 (br s, 1 H, NHCHO), 6.85–6.89 (m, 4 H, 
4 x meta-H of para-CH3OPh), 7.17–7.21 (m, 5 H, CH- of DMT and Trityl), 7.23–7.30 (m, 15 
H, CH of DMT and Trityl), 7.37–7.42 (m, 4 H, CH- from of DMT and Trityl), 7.76 (s, 1 H, 
C2H), 8.09 (br s, 1 H, NHCHO), 8.68 (br, 1 H, NH); 
13
C NMR (150 MHz, CDCl3):  20.16, 
20.39 (CH2CN), 24.34, 24.44, 24.53, 24.56 (4 x PN[CH(CH3)2]2), 36.09, 36.33 (C5´), 41.12, 
41.31 (C2´), 43.04, 43.09 (2 x PN[CH(CH3)2]2), 46.96, 47.01 (C4´), 49.87 (C1´), 55.17, 55.20 
(2 x OCH3), 58.12, 58.25 (OCH2CH2CN), 64.14, 64.59 (C1´´), 74.81, 74.92 (C- from Trityl), 
75.51, 75.62 (C3´), 85.71, 85.74 (OC(p-CH3OPh)2Ph), 85.77, 85.80 (C5), 112.95, 112.97 (4 x 
meta-C from p-CH3OPh), 117.65, 117.66 (CN), 123.68 (C- from DMT), 123.68–130.11 
127.55 (CH- from Trityl), 128.63 (CH- from Trityl), 128.84 (CH- from DMT), 129.13 (CH- 
from DMT), 129.85 (CH- from Trityl), 131.05 (CH- from DMT), 131.06 (CH- from DMT), 
132.29 (CH- from DMT), 137.43 (CH- from DMT), 137.48 (CH- from DMT), 146.54 (CH- 
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from DMT), 147.00 (C- from Trityl), 155.58 (C2), 156.59 (C4), 158.34, 158.35 (C6), 160.25 
(CHO). 
31
P NMR (200 MHz, CDCl3): δ 148.65, 149.04 (ROP(N(iPr)2)CH2CH2CN); ESI-
HRMS (m/z): [MH]
-
 calcd. for [C51H49N5O5H]
-
, 1010.4739; found, 1010.4767. 
 
 
N-(5-(Formylamino)-4-{[(1’R,3’S,4’R)-3’-hydroxy-4’-(hydroxymethyl)cyclopentyl]-
amino}-6-aminopyrimidine 12 
 
Compound 10 (78 mg, 0.16 mmol) was dissolved in dry THF (3 mL) with dry pyridine (122 
µL) and afterwards pyridine∙HF complex (122 µL, 70 %) was added and the mixture was 
stirred overnight at rt in a sealable polypropylene tube. The diol precipitated as a white fine 
solid, which was centrifuged afterwards. The isolated product was resuspended in dry ethyl 
acetate (1 mL) and afterwards stirred for another two hours together with 370 µL MeOTMS. 
The product was again centrifuged, and to the decanted supernatant were given another was 
370 µL of MeOTMS and the solution was stirred for another hour. Both fractions were com-
bined and the solvent was removed under reduced pressure. The resulting white solid was 
dried under high vaccum yielding 40.0 mg (0.15 mmol)of 12 (94 %). mp: decomp.> 147 °C; 
TLC (Reversed Phase; MeOH:H2O, 2:1 v/v): Rf = 0.88; FTIR (ATR): 3157, 2957, 2879, 
2680, 2499, 1669, 1646, 1635, 1595, 1503, 1467, 1449, 1441, 1416, 1374, 1331, 1285, 1270, 
1249, 1197, 1159, 1151, 1136, 1077, 1035, 1004, 859, 825, 802, 765, 752, 731, 707, 682 cm
-
1
; 
1
H-NMR (400 MHz, MeOH-d4): δ 1.30–1.37 (m, 1 H C5´Hb), 1.82–2.02 (m, 3 H, 
C4´H,C2´Hb,C2´Ha), 2.11 (dt, 
2
JH-H (C5´Ha,C5´Hb) = 13.3 Hz, 
3
JH-H (C5´Ha,C1´H,C4´H) = 
7.7 Hz, 1 H, C5´Ha), 3.53–3.58 (m, 2 H, C1´´Hb,C1´´Ha), 4.05–4.09 (m, 1 H, C3´H), 4.56 – 
4.63 (m, 1 H, C1´H), 8.02 (br s, 1 H, NHCHO), 8.24 (br s, 1 H, CHO), 8.50 (s, 1 H, C2H), 2 x 
OH, C1´NH, 2 x NH not detected; 
13
C NMR (100 MHz, MeOH-d4): δ 35.48(C5´), 42.61 
(C2´), 50.21 (C4´), 51.67 (C1´), 64.59 (C1´´), 74.34 (C3´), 93.88 (C5), 149.62 (C2), 155.96 
(C4), 159.32 (C6), 164.56 (CHO); ESI-HRMS (m/z): [MH]
+
 calcd. for [C11H17N5O3H]
+
, 
268.1404; found, 268.1404. 
 
X-Ray crystallographic structures of compound 9a and 11 
Single crystals of 9a and 11 suitable for X-ray diffraction were carefully mounted on the top 
of a thin glass wire. Data collection was performed with an Oxford Xcalibur3 diffractometer 
equipped with a Spellman generator (50 kV, 40 mA) and a Kappa CCD detector, operating 
with Mo Kα radiation (λ = 0.71071 Ǻ). Data collection was performed with the Crysalis CCD 
software, for the data reduction the Crysalis RED software
1
 was used. Absorption correction 
using the SCALE3 ABSPACK multiscan method
2
 was applied. Structures were solved an 
refined with SHELX-97
3
 and finally checked using PLATON
4
. Details for data collection and 
structure refinement are summarized in the corresponding cif files. CCDC-796512 (9a) and 
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CCDC-796513 (11 2 MeCN) contain the supplementary crystallographic data. The data can 
be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
 
Overview over the synthesis of carbocyclic 2´-deoxyguanosine 
The synthesis of the carbocyclic 2´-deoxyguanosine (Supplementary Fig. 5) starts from 13 
with reduction of the nitro group with Pd/C under hydrogen and reaction of the resulting 
amine with diethoxymethyl acetate to give the protected purine 14 in a 26 % yield. For the 
acetyl deprotection 14 was stirred in 0.4 M NaOH to give 15 in a 84 % yield, followed by TBS 
deprotection in HF/pyridine with 94 % yield of 16.   
 
Supplementary Figure 5: Synthesis of carbocyclic dG (16). 
 
Detailed synthesis of carbocyclic 2´-deoxyguanosine 
N-[9-[(1´R,3´S,4´R)-3´-[(tert-Butyldimethylsilyl)oxy]-4´-[[(tert-butyldimethylsilyl)oxy]-
methyl]cyclopentyl]-6-oxo-6,9-dihydro-1H-purin-2-yl]-acetamide 14 
 
13 (1.60 g, 2.88 mmol) was dissolved in dry methanol (30 mL). 700 mg 10 % Pd/C were add-
ed and the reaction mixture was degassed carefully. The argon atmosphere was changed into a 
hydrogen atmosphere and the mixture was stirred over night under hydrogen (1.2 bar) at rt. 
The charcoal and palladium were filtered off under exclusion of oxygen, using a a 0.2 μm 
nylon syringe filter (Millipore
TM
). The solvent was evaporated under reduced pressure at rt 
and the air sensitive amine was diluted in diethoxymethyl acetate (16 mL). The mixture was 
stirred at rt for 18 h and then heated up to 100 °C for 1 h. The cooled solution was diluted 
with ethyl acetate (200 mL) and washed with brine (3 x 250 mL). The organic layer was dried 
with MgSO4 and evaporated under reduced pressure. The crude reaction mixture was purified 
by column chromatography (CHCl3:MeOH 80:1 → 40:1). The resulting purine 14 could be 
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obtained as an orange foam (400 mg, 0.75 mmol, 26 % over two steps). TLC (CHCl3:MeOH, 
10:1 v/v): Rf = 0.30; FTIR (ATR): 3155, 2952, 2927, 2855, 2739, 17112, 1680, 1611, 1553, 
1471, 1463, 1397, 1375, 1361, 1321, 1251, 1116, 10889, 1051, 1004, 938, 834, 813, 775, 742, 
724, 668 cm
-1
; 
1
H NMR (400 MHz, CDCl3): δ 0.04 (s, 3H, Si-CH3), 0.05 (s, 3H, Si-CH3), 
0.06 (s, 6H, Si-CH3), 0.87 (s, 9H, Si-C(CH3)3), 0.89 (s, 9H, Si-C(CH3)3), 1.71 – 1.81 (dt, 
2
JH-H 
(C5´Ha, C5´Hb) = 13.0 Hz, 
3
JH-H (C5´Ha, C1´H, C4´H) = 9.3 Hz, 1H, C5´Ha), 2.07 – 2.16  (m, 
3H, C2´Ha, C2´Hb, C4´H), 2.30 (s, 3H, acetyl-CH3), 2.36 – 2.45 (dt, 
2
JH-H (C5´Hb, C5´Ha) = 
13.0 Hz, 
3
JH-H (C5´Hb, C1´H, C4´H) =  8.1 Hz, 1H, C6´Hb), 3.57 – 3.62 (dd, 
2
JH-H (C1´´Ha, 
C1´´Hb) = 10.1 Hz,
 3
JH-H (C1´´Ha, C1´´OH) = 4.7 Hz, 1H, C1´´Ha), 3.66 – 3.72 (dd, 
2
JH-H 
(C1´´Hb, C1´´Ha) = 10.1 Hz,
 3
JH-H (C1´´Hb, C1´´OH) = 4.5 Hz, 1H, C1´´Hb), 4.28 – 4.33 (m, 
1H, C3´H), 4.85 – 4.94 (p, 
2
JH-H (C1´H, C2´Ha, C2´Hb, C5´Ha, C5´Hb) = 8.6 Hz, 1H, C1´H), 
7.75 (s, 1H, C8H), 8.96 (s, 1H, NH), 11.95 (s, 1H, NH). 
13
C NMR (101 MHz, CDCl3): δ -5.46 
(Si-CH3), -5.42 (Si-CH3), -4.75 (Si-CH3), -4.62 (Si-CH3), 17.98 (Si-C(CH3)3), 18.34 (Si-
C(CH3)3), 24.43 (acetyl-CH3), 25.79 (Si-C(CH3)3), 25.93 (Si-C(CH3)3), 33.36 (C5´), 41.58 
(C2´), 49.73 (C4´), 53.18 (C1´), 62.93 (C1´´), 72.84 (C3´), 121.55 (C5), 137.16 (C8), 146.74 
(C2), 148.16 (C4), 155.68 (C6), 171.52 (acetyl-C). ESI-HRMS (m/z): [MH]
-
, calcd. for 
[C25H46N5O4Si2H]
-
: 536.3083; found, 536.3075. 
2-Amino-9-[(1´R,3´S,4´R)-3´-[(tert-butyldimethylsilyl)oxy]-4´-[[(tert-butyldimethylsilyl) 
oxy]-methyl]cyclopentyl]-1,9-dihydro-purine-6-one 15 
 
14 (250 mg, 0.47 mmol) was dissolved in 0.4 M NaOH in MeOH:H2O 4:1 and stirred for 2 h 
at 50 °C until the reaction was complete. The mixture was neutralized with acetic acid and 
evaporated under reduced pressure. The crude residue was purified by column chromatog-
raphy (CH2Cl2:MeOH 10:1). The resulting purine 15 could be obtained as a yellow foam 
(195 mg, 0.39 mmol, 84 %). TLC (CH2Cl2:MeOH 10:1 v/v): Rf = 0.31; FTIR (ATR): 3317, 
3156, 2952, 2928, 2855, 1695, 1627, 1597, 1569, 1536, 1471, 1361, 1253, 1164, 1111, 1005, 
938, 834, 813, 775, 669 cm
-1
; 
1
H NMR (400 MHz, CDCl3): δ 0.06 (s, 3H, Si-CH3), 0.06 (s, 
3H, Si-CH3), 0.06 (s, 3H, Si-CH3), 0.07 (s, 3H, Si-CH3), 0.89 (s, 9H, Si-C(CH3)3), 0.90 (s, 
9H, Si-C(CH3)3), 1.69 – 1.79 (dt, 
2
JH-H (C5´Ha, C5´Hb) = 13.0 Hz, 
3
JH-H (C5´Ha, C1´H, C4´H) 
= 9.4 Hz, 1H, C5´Ha),  1.94 – 2.29 (m, 3H, C2´Ha, C2´Hb, C4´H), 2.37 – 2.47 (dt, 
2
JH-H 
(C5´Hb, C5´Ha) = 12.9 Hz, 
3
JH-H (C5´Hb, C1´H, C4´H) = 7.9 Hz, 1H, C5´Hb), 3.60 – 3.65 (m, 
1H, C1´´Ha), 3.66 – 3.72 (m, 1H, C1´´Hb), 4.29 – 4.34 (dt, 
3
JH-H (C3´H, C2´H) = 6.1 Hz, 
3
JH-H 
(C3´H, C4´H) = 4.5 Hz, 1H, C3´H), 4.83 – 4.96 (p, 
2
JH-H (C1´H, C2´Ha, C2´Hb, C5´Ha, 
C5´Hb) = 8.5 Hz, 1H, C1´H), 6.23 (s, 2H, NH2), 7.64 (s, 1H, C8H), 11.92 (s, 1H, NH). 
13
C 
NMR (101 MHz, CDCl3):  δ -5.43 (Si-CH3), -5.40 (Si-CH3), -4.74 (Si-CH3), -4.59 (Si-CH3), 
18.00 (Si-C(CH3)3), 18.35 (Si-C(CH3)3), 20.95, 25.82 (Si-C(CH3)3), 25.95 (Si-C(CH3)3), 
33.30 (C5´), 41.29 (C2´), 49.80  (C4´), 52.92 (C1´), 63.13 (C1´´), 72.85 (C3´), 76.68, 117.17 
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(C5), 136.13 (C8), 151.72 (C2), 153.21 (C4), 159.11 (C6). ESI-HRMS (m/z): [MH]
-
 calcd. 
for [C23H44N5O3Si2H]
-
, 494.2977; found, 494.2974. 
 
2-Amino-9-((1´R,3´S,4´R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl)-1,9-dihydro-6H-
purin-6-one 16 
 
15 (180 mg, 0.36 mmol) was dissolved in ethyl acetate (9.6 mL) and HF (70 % in pyridine; 
0.36 mL) was added and stirred over night. The reaction was quenched with 
methoxytrimethylsilane (2 mL). After evaporation under reduced pressure, the crude reaction 
mixture was purified by column chromatography (CH2Cl2:MeOH 20:1 → 5:1). The carbocy-
clic deoxyguanosine 16 could be obtained as a white powder (90 mg, 0.34 mmol, 94 %). TLC 
(CH2Cl2:MeOH, 2:1 v/v): Rf = 0.29; FTIR (ATR): 3497, 3320, 3214, 2730, 2362, 2335, 1727, 
1629, 1569, 1538, 1488, 1411, 1380, 1380, 1322, 1252, 1177, 1158, 1068, 1047, 1033, 1006, 
916, 849, 776, 673 cm
-1
; 
1
H NMR (599 MHz, DMSO-d6): δ 1.55 – 1.61 (dt, 
2
JH-H (C5´Hb, 
C5´Ha)= 12.8 Hz, 
3
JH-H (C5´Hb, C1´H, C4´H) = 9.4 Hz, 1H, C5´Hb), 1.92 – 1.99 (m, 2H, 
C2´Hb, C4´H), 2.05 – 2.12  (ddd, 
2
JH-H (C2´Ha, C2´Hb)= 12.8 Hz, 
3
JH-H (C2´Ha, C3´H) = 10.0 
Hz, (C2´Ha, C1´H) = 6.3 Hz, 1H, C2´Ha), 2.25 – 2.30 (m, 1H C5´Ha), 3.38 – 3.45  (m, 1H, 
C1´´Ha), 3.47 – 3.54 (m, 1H, C1´´Hb), 4.02 – 4.08 (m, 1H, C3´H), 4.60 – 4.65 (t, 
2
JH-H 
(C1´´OH, C1´´Ha, C1´´Hb) = 5.2 Hz, 1H, C1´´OH), 4.73 – 4.77 (d, 
2
JH-H (C3´OH, C3´H) = 4.0 
Hz, 1H, C3´OH), 4.76 – 4.85  (tt, 
3
JH-H (C1´H, C2´Hb, C5´Hb) = 9.9 Hz, 
3
JH-H (C1´H, C5´Ha) = 
7.6 Hz, 1H, C1´H), 6.42 (s, 2H, NH2), 7.79 (s, 1H, C8H), 10.57 (s, 1H, NH). 
13
C NMR (101 
MHz, DMSO- d6): δ 34.06 (C5´), 40.66 (C2´), 49.23 (C4´), 52.06 (C1´), 62.77 (C1´´), 71.50 
(C3´), 116.74 (C5), 135.35 (C8), 151.07 (C2), 153.21 (C4), 156.80 (C6). ESI-HRMS (m/z): 
[MH]
-
 calcd. for [C11H16N5O3H]
-
, 266.1248; found, 266.1247. 
 
 
1. CrysAlis RED, O.D.L., Version 1.171.27p5 beta (release 01-04-2005 CrysAlis171.NET) (compiled Apr 1 2005, 17:53:34). 
2. ABSPACK, S. An Oxford Diffraction program (1.0.4, gui:1.0.3) (C) Oxford Diffraction Ltd. (2005). 
3. Sheldrick, G.M. A short history of SHELX. Acta Crystallogr A 64, 112-22 (2008). 
4. Spek, A.L. PLATON, A Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The Netherlands,. (1999). 
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Supplementary Note 2 
Theoretical studies 
In order to identify possible differences in conformational preferences between 2,6-diamino-
4-hydroxy-5-formamidopyrimidine of 2'-desoxyguanosine (18) and its cyclopentane analogue 
19, a conformational search for both systems has been conducted at the B3LYP/6-31+G(d) 
level of theory. This method has recently been used by Schlegel et al. in a series of theoretical 
studies on the formation of damaged nucleobases.
1
 Thermal corrections to enthalpies at 
298.15 K have been calculated at the same level using the rigid rotor/harmonic oscillator 
model. Single point energies have subsequently been calculated at the MP2(FC)/G3MP2large 
level of theory and combined with thermal corrections obtained at B3LYP/6-31+G(d) level in 
order to calculate enthalpies at 298.15 K. The MP2(FC)/G3MP2large calculations form an 
integral part of the G3(MP2)B3 scheme developed for the calculation of accurate thermo-
chemical data and the G3MP2large basis set corresponds effectively to a 6-311++G(2df,2p) 
basis for the systems studied here.
2
 All calculations have been performed with Gaussian 09.
3
 
In order to avoid hydrogen bonding interactions between the C3' and C5' hydroxy groups with 
the nucleobase, the orientation of these former groups was chosen such that the O-H bonds 
point away from the central furan/pentane ring system. The most favorable conformations 
found in the gas phase are shown in Supplementary Figure 8 for both systems.  
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Supplementary Figure 1. 2D and 3D structures of formamidopyrimidine desoxynucleoside 18 and its carbo-
cyclic analogue 19.  
 
It is noteworthy that, in the absence of the interaction partners present in a polar solvent or a 
protein surrounding, the formamido groups form intramoleculare hydrogen bonds to the 
anomeric amino N-H bond. The rotation angle chi
4,5
 around the C-N bond defined by the cen-
ters O/C1'/N/C6 in 18 amounts to chi(18) = -82.7
o
. In carbocyclic analog 19 an almost identi-
cal rotational angle of chi(19) = -84.9
o
 is found.  
The rotational profile in 18 was explored starting from the most favorable conformation 
shown in Supplementary Figure 1 driving the chi angle with a step size of 20
o
 in positive 
and negative directions. In selected regions additional points were added with a step size of 
10
o
. The resulting rotational profile around the C1'-N bond is surprisingly similar at 
B3LYP/6-31+G(d) and MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of theory (Sup-
plementary Fig. 2). Minor differences concern the flat region between 180 and 210
o
, where 
MP2 theory hints at formation of a shallow minimum, while B3LYP theory does not. 
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Supplementary Figure 2: Rotational profile for dihedral angle chi (O/C1'/N/C6) in formamidopyrimidine 18 at 
the B3LYP/6-31+G(d) and MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of theory. 
 
In analogy to the procedure chosen for 18 the rotational profile in carbocyclic analogue 19 
was explored starting from the most favorable conformation shown in Supplementary Fig-
ure 1 and a step size of 20
o
. Additional data points were again added in seletced regions. It is 
again found that the rotational potential is largely similar at B3LYP/6-31+G(d) and 
MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of theory (Supplementary Fig. 3). Minor 
differences again concern the region with chi angles from 180 - 210
o
, where MP2 theory pre-
dicts a more shallow potential energy surface. In contrast to heterocyclic reference system 18, 
however, both methods agree in that a true minimum exists at a rotational angle of 203
o
, 
whose energy is almost identical to the global rotational minimum at chi = +275
o
. 
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Supplementary Figure 3: Rotational profile around angle chi (CH2/C1'/N/C6) in carbocyclic 
formamidopyrimidine 19 at the B3LYP/6-31+G(d) and MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of 
theory. 
 
A direct comparison of the rotational potentials for heterocyclic formamidopyrimidine 18 and 
its carbocyclic analogue 19 as calculated at the MP2(FC)/G3MP2large//B3LYP/6-31+G(d) 
level is shown in Supplementary Figure 4. Both rotational potentials are largely similar in 
that a global minimum exists at chi angles around 275
o
 and a second, less stable minimum at 
chi values around 60
o
. The rotational potentials differ in the magnitude of the rotational barri-
er through the fully eclipsed conformation at chi = 0
o
, and also in the flat region with chi = 
180 - 210
o
, where a true minimum exists for 19, but (apparently) not for 18.  
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Supplementary Figure 4: Rotational profile around angle chi (X/C1'/N/C6) in formamidopyrimidine 18 (red 
dots) and its carbocyclic analogue 19 (blue diamonds) at the MP2(FC)/G3MP2large//B3LYP/6-31+G(d) level of 
theory. 
The surprisingly similar rotational potentials for 18 and 19 identified here are closely similar 
to those obtained at the B3LYP/6-31G(d) level for model systems carrying methyl protecting 
groups on the C3' and C5' hydroxy groups.
6
 This implies that the conformational similarity 
between the hetero- and carbocyclic systems 18 and 19 is neither dependend on the exact de-
tails of the model systems chosen for study nor on the particular level of theory.  
 
How much of the similarity between hetero- and carbocyclic formamidopyrimidine deriva-
tives is retained in the undamaged nucleosides was subsequently explored for 2'-
deoxyguanosine 17 and its carbocyclic analogue 16 using the same theoretical approach as 
before. In order to avoid hydrogen bonding interactions between the C3' and C5' hydroxy 
groups with the nucleobase, the orientation of these former groups was again chosen such that 
the O-H bonds point away from the central furan/pentane ring system. The most favorable 
conformations found for these systems in the gas phase at MP2(FC)/G3MP2large//B3LYP/6-
31+G(d) level are shown in Supplementary Figure 5.  
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Supplementary Figure 5: 2D and 3D structures of 2'-deoxyguanosine 17 and its carbocyclic analog 16.  
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In contrast to the formamidopyrimidine derivatives studied before, two conformations 17a 
and 17b of similar stability can be identified for 2'-deoxyguanosine. The more stable confor-
mation 17a with chi = +70.2
o
 orients the guanine base such that the N1 nitrogen atom points 
towards the ribose ring, while the less stable conformation 17b with chi = -119.0
o
 orients the 
guanine base in the opposite direction. This latter conformer is less stable than 17a by 3.70 
kJ/mol (MP2(FC)/G3MP2large//B3LYP/6-31+G(d) level). The relative stability of these con-
formers was reconfirmed at full G3(MP2)B3 level, at which the energy difference amounts to 
2.9 kJ/mol. A rather similar situation is found for the carbocyclic analogue 16 with the more 
favourable conformer 16a (chi = +61.5
o
) and the slightly less stable conformer 16b (chi = 
-118.1
o
). The energy difference is again rather small with +3.9 kJ/mol at 
MP2(FC)/G3MP2large//B3LYP/6-31+G(d) and +3.0 kJ/mol at full G3(MP2)B3 level. 
 
 
Supplementary Figure 6: Rotational profile for dihedral angle chi (O/C1'/N9/C6) in 2'-deoxyguanosine 17 at 
the B3LYP/6-31+G(d) and MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of theory. 
 
The rotational profile in 17 was explored starting from the local minimum shown in Supple-
mentary Figure 5 driving the chi angle with a step size of 20
o
 in positive and negative direc-
tions. In selected regions additional points were added with a step size of 10
o
. The resulting 
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rotational profile around the C1'-N9 bond is again quite similar at B3LYP/6-31+G(d) and 
MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of theory (Supplementary Figure 6). Mi-
nor differences again concern the flat region between 180 and 260
o
, where MP2 theory places 
the minimum at somewhat smaller angles (at around 210
o
) as compared to the B3LYP minim 
at 240
o
. The rotational barriers are also quite similar at both levels of theory, the larger barrier 
of just over 30 kJ/mol leading through the structure with fully eclipsed O/C/N/C dihedral an-
gle. This is significantly lower as compared to the FaPydG derivative, where the correspond-
ing rotational barrier is more than 20 kJ/mol higher (Supplementary Figure 2). A second 
major difference between FaPydG derivative 18 and 2'-deoxyguanosine 17 concerns the rela-
tive energies of the gauche conformations at rotational angles around -80 and +60 degrees. 
While the gauche conformation at -80
o
 is the only low-.energy conformation in FaPydG de-
rivative 18, both structures are practically isoenergetic in 2'-deoxyguanosine 17 (Supplemen-
tary Figure 2 vs. Figure 6).  
Repeating the above approach for carbocyclic analogue 16 and starting again from the struc-
ture shown in Supplementary Figure 4 yields the rotational profile shown in Supplemen-
tary Figure 7. The latter is quite similar to that of the parent heterocyclic system 17 and dis-
plays a larger shallow region between dihedral angles of 190 to 270
o
 and a more clearly de-
fined gauche conformation with dihedral angle of chi(16) = +61.5
o
. Relative energies for the-
se two minima are rather small at the B3LYP/6-31+G(d) level used for geometry optimiza-
tions, but differ slightly at MP2(FC)/G3MP2large//B3LYP/6-31+G(d) level at which the 
gauche conformation at around 60
o
 is energetically preferred by 4.3 kJ/mol.  
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Supplementary Figure 7: Rotational profile around angle chi (CH2/C1'/N/C6) in carbocyclic 2'-deoxyguanosine 
16 at the B3LYP/6-31+G(d) and MP2(FC)/G3MP2large//B3LYP/6-31+G(d) levels of theory. 
A direct comparison of the rotational potentials for 2'-deoxyguanosine 17 and its carbocyclic 
analogue 16 as calculated at the MP2(FC)/G3MP2large//B3LYP/6-31+G(d) level is shown in 
Supplementary Figure 8. Both rotational potentials are largely similar in that a global mini-
mum exists at chi angles around 60
o
 and a second, less stable minimum at chi values around 
180 - 260
o
. The rotational potentials differ mainly in the magnitude of the rotational barrier 
through the fully eclipsed conformation at chi = 0
o
, which is higher in the heterocyclic parent 
system 17 by approx. 14.3 kJ/mol as compared to carbocyclic analogue 16. This barrier dif-
ference is most likely due to unfavorable electrostatic interactions between the N1 nitrogen 
atom of the guanine ring system and the ring oxygen atom of the ribose ring, both of which 
carry a partial negative charge. Replacement of the oxygen by CH2 in analogue 16 replaces 
this repulsive interaction by a weakly attractive component. In the more favorable low-energy 
region of the rotational potential between chi = +50 - +280
o
 there is, however, hardly any dif-
ference between parent system 17 and its carbocyclic analogue 16. 
 
40 
 
 
 
Supplementary Figure 8: Rotational profile around angle chi (X/C1'/N/C6) in 2'-deoxyguanosine 17 (red dots) 
and its carbocyclic analogue 16 (blue diamonds) at the MP2(FC)/G3MP2large//B3LYP/6-31+G(d) level of theo-
ry. 
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ABSTRACT: Oxidative degradation of DNA is a major mutagenic
process. Reactive oxygen species (ROS) produced in the course of
oxidative phosphorylation or by exogenous factors are known to attack
preferentially deoxyguanosine. The latter decomposes to give
mutagenic lesions, which under physiological conditions are efficiently
repaired by specialized maintenance systems in the cell. Although
many intermediates of the degradation pathway are today well-known,
we report in this study the discovery of a new intermediate with an
interesting guanidinoformimine structure. The structure elucidation of
the new lesion was possible by using HPLC−MS techniques and
organic synthesis. Finally we report the mutagenic potential of the new lesion in comparison to the known lesions imidazolone
and oxazolone using primer extension and pyrosequencing experiments.
■ INTRODUCTION
Guanine is the nucleobase with the lowest oxidation potential
of the four canonical nucleobases.1 Therefore, reactive oxygen
species (ROS) degrade preferentially dG bases to give dG-
derived lesions.2−6 These lesions are mutagenic and typically
repaired by dedicated DNA repair enzymes.7−12 Scheme 1
summarizes the main degradation pathway of 2′-deoxyguano-
sine. Most of the oxidation products are today known.13 The
structures of certain putative intermediates along the dG
degradation pathway and their mutagenic properties remain,
however, to be uncovered. Particularly the reaction of the
oxazolone lesion (dZ) to the aminoriboside, which hydrolyzes
to give an AP site as the final product of the oxidative dG
degradation, is an enigmatic transformation. One-electron
oxidation of dG followed by reaction of the dG-radical cation
(dG•+) with water and finally either oxidation or reduction of
the 8-OH-dG radical give rise to 8-oxo-guanosine (8-oxo-dG)14
or formamidopyrimidine (FaPy-dG) lesions,15−17 respectively
(Scheme 1). Both are well studied oxidative lesions, which
strongly contribute to the mutagenic effect of ROS. A second
more complex degradation pathway involves deprotonation of
dG•+ and trapping of the radical by O2
•−. The corresponding 5-
OOH-dG intermediate predominantly leads to the imidazolone
(dIz) lesion,5,18 known to rearrange to oxazolone (dZ).19,20
The formation of spiroiminohydantoin (dSp), guanidinohy-
dantoin (dGh), and iminoalantoin (dIa), reported before,21 is
assumed to take place via an intramolecular redox reaction in
which the C5-peroxyl group participates in the oxidation of C8
to generate 8-hydroxy-dG as the precursor of these compounds.
Oxazolone (dZ) is the last characterized intermediate before
the occurrence of 1′-aminoriboside, which hydrolyzes to give an
abasic site. The mutagenic effect of ROS is caused by all of
these degradation intermediates, which exist in damaged DNA
in unknown relative amounts. They all have been implicated in
human pathogenesis and disease.22−24 For example, 8-oxo-dG25
and FaPy-dG lesions26,27 are known to produce G to T
transversion mutations, while imidazolone lesions are assumed
to induce G to C transversion mutations.28
■ RESULTS AND DISCUSSION
In order to get more insight into the imidazolone/oxazolone
based degradation pathway we performed HPLC−MS experi-
ments with purified dIz lesion-containing DNA strands. For the
study we prepared the oligonucleotide ODN1 (Figure 1A) and
irradiated the DNA strand, containing a single dG base in the
middle of the sequence, in the presence of riboflavin. The latter
is a well-known dG photooxidant, which leads to the formation
of imidazolone lesions.20,29 Indeed, irradiation of ODN1 gave a
mixture of products with one major component. This
oligonucleotide (dIz-ODN1) was isolated and the presence of
the imidazolone lesion was confirmed by high resolution ESI
mass spectrometry. Figure 1A shows the HPL-chromatogram of
the purified dIz-containing ODN1 strand, together with the
high resolution mass spectrum. The molecular peak for dIz-
ODN1 appears at m/z = 1367 ([M − 3H]3−), while the second
major peak at m/z = 1374 is caused by the corresponding
monosodium adduct. To further confirm the presence of the
dIz lesion in the purified oligonucleotide, we digested the DNA
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with P1 nuclease and subsequently incubated the reaction
mixture with alkaline phosphatase and snake venom
phosphodiesterase. The obtained nucleoside mixture was
again analyzed by HPLC−MS. Figure 1B shows the HPLC
signals of the natural nucleosides present in the digest, as well
as a new signal which appears with a retention time of 9.6 min.
This signal gives an m/z value of 229.0930, which is in perfect
agreement with the calculated molecular weight of the dIz
nucleoside. These results confirm that the first, major reaction
product, formed during riboflavin induced dG oxidation, is
indeed the imidazolone lesion.
While handling the dIz-containing ODN1 strand, we noticed
that the imidazolone lesion is rather unstable. The lesion
degraded quickly to give further reaction products. Figure 2
shows the HPL-chromatogram of the formerly pure dIz-
containing DNA strand after standing of the solution for 24 h at
room temperature. It is clearly visible that at least two
additional compounds were formed within the DNA. To
investigate the stability in more detail, we dissolved the dIz-
containing DNA in different buffers at various pH values and
monitored the decomposition reaction by LC−MS.
Indeed, the imidazolone lesion is unstable and rapidly
degrades (t1/2 = 18 h at pH = 7.0) to give two further products
with a rate that depends on the salt concentration, the
temperature, and more importantly, the pH of the buffer. It is
most stable when the DNA solution is kept cold (<10 °C) at
pH = 7.0. Changing the pH value (Supplementary Figure S2)
or increasing the temperature of the solution, e.g., to 37 °C,
caused rapid decomposition.
As previously reported,30 analysis of the dIz decomposition
reaction by HPLC−MS showed that the dIz-ODN1 initially
forms the oxazolone product dZ, which is detectable at m/z =
686.27 (z = 6). If a solution of the dIz-ODN1, for example, was
allowed to stand for 24 h at room temperature at pH 7.0, the
solution contained finally only residual amounts of dIz-ODN1.
Instead, the dZ-ODN1 dominated (>90%) and another, so far
Scheme 1. Oxidative Degradation of 2′-Deoxyguanosine by
Direct Electron Abstraction and the Corresponding Base
Modifications
Figure 1. (A) HPLC of the purified dIz-ODN1 and the corresponding
high resolution mass spectrum ([M − 3H]3−calcd = 1367.5547, [M −
4H + Na]3−calcd = 1374.8820). (B) HPLC−MS spectra obtained from
the total enzymatic digestion of the dIz-ODN1. dIz [M + H]+calcd =
229.0931, dC [M + H]+calcd = 228.0979, and dT [M + H]
+
calcd =
243.0975.
Figure 2. HPLC of dIz-ODN1 after standing for 24 h at room
temperature and the corresponding high resolution mass spectrum.
dIz-ODN [M − 6H]6−calcd = 683.2737, dZ-ODN [M − 6H]6−calcd =
686.2755, and dGf-ODN [M − 6H]6−calcd = 678.9438.
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unknown reaction product, appeared. Analysis of the DNA by
mass spectrometry after 48 h led to the surprising discovery of a
new compound that accumulates with time to significant
amounts (>25%). Certainly the new compound is more stable
than the original imidazolone lesion.
For this so far unknown compound (dGf) formed in ODN1,
we determined a molecular weight only 26 mass units lighter
than the original dIz-ODN1 (Supplementary Figure S3).
Because the dGf-ODN1 accumulated only after formation of
the oxazolone lesion dZ, we reasoned that the new compound,
dGf, must be a further dZ-derived degradation product that
builds up in solution and that could be the unknown link
between the dZ lesion and the amino-riboside. Based on the
molecular weight and the fact that dGf is formed likely from dZ,
we speculated that the compound forms by decarboxylation
and therefore proposed the guanidinoformimine structure
shown in Scheme 2.
The high resolution mass spectrum shown in Figure 2
provides in total three sets of signals caused by dIz-, dZ-, and
dGf-ODN1. The calculated value of the dGf-containing DNA
strand (m/z = 678.9438, z = 6) is in excellent agreement with
the experimentally determined value of m/z = 678.9436 (z =
6), strongly supporting the decarboxylation idea.
In order to gain further support for the structure, we next
performed a total enzymatic digest of dIz-ODN1, which was
allowed to stand in solution for 2 days, and analyzed the digest
by HPLC−MS (Figure 3). The experiment proved the
simultaneous presence of DNA containing dIz, dZ, and dGf
lesions. Again, the molecular weight of dGf, now as the
nucleoside, with m/z = 203.1140, was in excellent agreement
with the proposed structure. Furthermore, we were able to
observe a signal corresponding to the putative dGf-aglycon
(Gf) in an MS/MS experiment. The fragment has the
molecular weight of m/z = 87.0668.
In order to investigate if the lesion composition changes in
double-stranded DNA, we repeated the study with a dIz-
containing DNA double strand. The same decomposition
products dIz, dZ, and dGf were observed at a similar ratio as in
single-stranded DNA. However, the decomposition process was
slightly slower in the duplex, probably due to partial shielding
of the lesions from the aqueous environment.
To finally prove that the dGf product possesses the proposed
guanidinoformimine structure, we next wanted to show that the
key fragmentation product with m/z = 87.0668 is indeed the
deribosylated fragment. To this end we synthesized the 3′,5′-
bisacetyl-dG derivative (ac2dG).
31,32 After 8 min of irradiation
of the compound in the presence of riboflavin, we isolated the
bisacetyl-protected ac2dIz nucleoside in 90% yield. An aqueous
solution of the ac2dIz derivative was allowed to stand at room
temperature for several days. Analysis of the solution during
this time showed that within 12 h the ac2dIz nucleoside fully
converted to the corresponding ac2dZ nucleoside. After about 3
days, a new compound with a molecular weight (m/z =
287.1349) calculated for ac2dGf was formed in about 20% yield.
In the bisacetylated form, the reaction to the dGf compound is
hence significantly slower than in DNA. The ac2dGf compound
was next used for MS/MS experiments, which allowed us to
detect again the fragment at m/z = 87.0668. This proves that
the new intermediate is the deribosylated species with the
proposed guanidinoformimine structure (Supplementary Fig-
ure S6). In order to collect additional data which support the
structure, we also performed NMR studies, although this was
possible only for the obtained compound mixture. In support of
the structure, we detected a signal at 7.78 ppm that corresponds
to the amidinium-CH (Supplementary Figure S7). The signal
grew with time in line with increasing amounts of dGf in
solution.
From our study we conclude that the first dG degradation
product is the dIz lesion, which rearranged within a few hours
to give the dZ lesion as the dominating species. Subsequently
decarboxylation occurs giving the new dGf intermediate. This
compound is already detectable after 1 day and accumulates
while the amount of the dZ lesion decreases (20 mM in water,
rt). Finally 1′-amino-ribose is detected as the hydrolysis product
of the dGf compound. The aminoriboside hydrolyses thereafter
to form the abasic site. In this scenario, the dIz lesion is only
able to contribute to the mutagenic effect of ROS in the first
hours after lesion formation. Thereafter the dZ lesion will
contribute dominantly followed by the newly discovered dGf
lesion.
In order to determine the mutagenic effect of the lesions
(dIz, dZ, and dGf), we performed primer extension experi-
ments using one high (Klenow exo−) and two low fidelity
polymerases (hPolκ and scPolη, respectively) and lesion-
containing oligonucleotides X-ODN2 (X = dG, dIz, dZ, or
Scheme 2. Decomposition of the Oxazolone Containing
Oligonucleotide via the New Lesion As an Intermediate to
1′-Aminoriboside
Figure 3. Enzymatic digest and HPLC−MS/MS of the dIz-ODN1
after 2 days. The experimental exact masses are in agreement with the
calculated values. dT [M + H]+calcd = 243.0975, dC [M + H]
+
calcd =
228.0979, dIz [M + H]+calcd = 229.0931, dZ [M + H]
+
calcd = 247.1037,
dGf [M + H]+calcd = 203.1139, and Gf [M + H]
+
calcd = 87.0665.
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dGf). The polymerases were allowed to extend a comple-
mentary primer strand along the lesion containing template in
the presence of all four canonical triphosphates. In order to
estimate the bypass efficiencies exhibited by the polymerases
mentioned above we performed primer extension studies and
followed the reaction using polyacrylamide gel electrophoresis.
The experiment revealed that all lesions can be bypassed
although the bypass efficiency was found to be limited (Figure
4A). We discovered that the efficiencies vary significantly
depending on the polymerase and the lesion. Polκ is almost
completely stalled and is hardly able to incorporate even a
single nucleotide opposite the lesions. The Klenow fragment in
contrast incorporates one nucleotide relatively efficiently, after
which it stalls to a large extent. Polη has the highest bypassing
capabilities. For all three polymerases the dGf lesion constitutes
the most severely blocking lesion. Despite the low bypass
efficiency, still significant amounts of the primers were fully
extended. To characterize and quantify the mutations
associated with the bypass, we sequenced the fully extended
strands by pyrosequencing.33,34 The results of the primer
extensions and of the pyrosequencing experiments are
summarized in Figure 4.
As a control, all studies were also performed with a dG-
ODN2 template strand, always resulting in quantitative
incorporation of dC opposite the dG residue, independently
of the polymerase used. The Klenow fragment, as a model for a
high fidelity polymerase, inserts only dC opposite dG into the
primer strand. The dIz lesion is preferentially base paired with
dC (46%), but also dA (21%) and dG (33%) are inserted. The
dZ lesion, in contrast, instructs the polymerase to insert a dA
(59%) with remarkable efficiency. The dGf compound induces
the incorporation of dC, dA, and dG with very similar
efficiencies of about 30%. The low fidelity polymerase Polκ
pairs the lesions dIz and dZ preferentially with dC (58%, 41%).
However, incorporation of dG is the second best option
opposite dIz and the counterbase of preference for the dGf
lesion. Polη, in contrast, base pairs all lesions preferentially with
dG (≈ 60%) followed by dC (≈ 40%). Finally, we observed
that none of the polymerases performs any base pairing with
dT, which is very surprising.
The results show that all investigated polymerases are able to
bypass the three lesions to a certain extent. Polη is the
polymerase that will generate dG to dC transversion mutations
with the highest rate in vitro. In vivo studies have, however,
shown that in cells small oxidative lesions are likely bypassed
with a high fidelity polymerase35 and by the low fidelity
polymerase Polκ.36 Bypass by Polη in vivo is consequently
unlikely.37 We observe that in the cases of dZ and dGf the high
fidelity Klenow fragment incorporates the correct base dC in
roughly only 30% of all bypass reactions. Polκ shows a
comparable selectivity. Overall, Polκ reduces the error-rate
during bypass only marginally. The unusually high incorpo-
ration of dA, by both Klenow fragment and Polκ, can be
partially explained by the A-rule of polymerases.38−41 We
explain the small differences between our data and data in the
literature also with the different method that we utilized here to
investigate the error-rate during bypass.42−44 In our case only
fully elongated primers are sequenced to provide data. Primers,
in which the polymerase inserted a base opposite the lesion
which are not fully extended, are consequently not analyzed.
Quite interesting is the observation that the new dGf
intermediate is bypassed by all polymerases despite its open
structure. dG incorporation opposite this lesion is slightly
favored in the low fidelity systems, while the high fidelity
Klenow fragment incorporates dG, dC, and dA with similar
probability. We believe that the non-instructive character of the
new lesion is explainable by its small size, its flexibility, and
possibly the existence of different tautomers. The molecules
themselves should exist in cyclic fully conjugated quasi
“homoaromatic” structure45−47 due to the presence of an
Figure 4. (A) Polyacrylamide gel electrophoresis of the primer
extension experiments and (B) graphical representation of the
mutagenesis assay results. X-ODN2 (where X = dG, dIz, dZ, or
dGf) is annealed to a biotinylated primer, which is extended in vitro by
the polymerase of interest. The corresponding biotinylated strands,
containing the lesion’s counter-base Y, are annealed to a reverse primer
and analyzed by pyrosequencing. The mutagenic “fingerprint” of each
dG degradation product is directly visualized. A dG-containing control
strand was used for each polymerase. Here incorporation of dC was
always 100%. Incorporation of dT was not observed during the
analysis.
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internal H-bond, known to be quite strong in similar systems. It
seems that this H-bond allows the dGf lesion to adopt a quasi-
heterocyclic structure, with the result that the dGf structure can
function as a standard nucleobase (Figure 5), which explains
the efficient bypass. In this cyclic structure, the dGf compound
can, however, exist in different tautomeric forms, which could
be responsible for the flexible coding properties as depicted in
Figure 5.
■ CONCLUSION
In summary we report the discovery of a new intermediate
along the oxidative dG degradation pathway. The new dGf-
lesion constitutes a significant barrier to replication in vitro, but
depending on the polymerase, substantial bypass is observed as
well. The flexible base pairing properties of the compound
direct polymerases to pair it in a severely error-prone manner,
thus rendering it a highly mutagenic lesion. This property is
explained by us with a rigid, cyclic structure of the lesion held
together by an intramolecular hydrogen bond and by the
existence of different tautomeric states.
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Discovery and Mutagenicity of a Guanidinoformimine Lesion as a new 
Intermediate of the Oxidative Deoxyguanosine Degradation Pathway 
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Department of Chemistry, Ludwig-Maximilians-Universität, Munich, Butenandtstraße 5-13, 81377, Munich, 
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Materials and Methods: All solvents and reagents were obtained in commercially available 
qualities puriss., p. a., or purum. Dry solvents were purchased from Fluka or Acros and were used 
as received. Acetonitrile for HPLC and MS was purchased from VWR in HPLC grade. Unmodified 
oligonucleotides were purchased from Metabion international AG. The exonuclease deficient DNA 
polymerase I from E. coli (Klenow exo− fragment) was purchased by New England BioLabs GmbH. 
1H NMR spectra were obtained on Varian Mercury-200 MHz, Varian INOVA-400 MHz or Varian 
600 MHz spectrometers. 13C NMR spectra were obtained on a Varian INOVA-400 MHz or Varian 
600 MHz spectrometer. ESI spectra were obtained on a Thermo Finnigan LTQ-FT ICR 
spectrometer. Analytical HPLC analysis was performed on a Waters 2695 apparatus equipped with 
thermostatic sample chamber, Waters 2996 Photo Diode Array detector and a Macherey - Nagel 
cc250/4 Nucleosil 120-3 C18 column.  Preparative HPLC separations were achieved on a Waters 
1525 system equipped with a Waters 2487 UV detector and a vp 250/10 Nucleodur 100-5 C18ec 
column from Macherey - Nagel. The elution system used both for analytical and preparative HPLC 
consisted of buffer A (100 mM NHEt3OAc in water, pH=7.0) and buffer B (100 mM NHEt3OAc in 
80% acetonitrile, pH=7.0) using gradients and flow rates depending on the experiment. The 
S2 
 
digestion experiments were analyzed by LC-ESI-MS on a Thermo Finnigan LTQ Orbitrap XL 
coupled with a Dionex Ultimate 3000 HPLC system, having a flow of 0.15 mL/min over an 
Uptisphere120-3HDO column from Interchim. Elution buffers were buffer C (2 mM NH4CHOO in 
H2O (pH 5.5)) and buffer D (2 mM NH4CHOO in 80% MeCN (pH 5.5)). The gradient applied was 
0 → 12 min: 0 % → 3 % buffer D; 12 → 60 min: 3 % → 60 % buffer D; 60 → 62 min: 60 % → 
100 % buffer D; 62 → 70 min: 100 % buffer D; 70 → 85 min: 100 → 0 % buffer D; 85 → 95 min: 
0 % buffer D. The elution was monitored at 260 nm (Dionex Ultimate 3000 Diode Array Detector).  
Photooxidation of dG-ODN1: 200 nmol lyophilised, HPLC purified dG-ODN1 (5 -́
CTCTTTGTTTCTCC-3′) was dissolved in sodium cacodylate buffer (0.2 mL, 1 M) and a saturated 
solution of riboflavin in water (1.8 mL). The mixture was placed in a 10 mm quartz cuvette, 
subjected to oxygen bubbling for 15 min and irradiated under bubbling for 5 min at 5°C, at a 
distance of 7 cm from the source. For the irradiation, a 500 W high pressure Mercury UV lamp 
equipped with a 350 nm cut-off filter was used. The crude photolysis mixture was subjected to 
centrifugal filtration at 4°C using a Millipore Amicon 3000 MWCO centrifugal filter, in order to 
remove excess of riboflavin. HPLC purification was accomplished using an elution system of 5-
20% buffer B in 60 min. The pure dIz containing oligonucleotide (5′-CTCTTT(dIz)TTTCTCC-3′, 
dIz-ODN1) was kept cold in order to avoid further decomposition of the lesion. 
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Figure S1: High resolution mass spectrum of dIz-ODN1 (5′-CTCTTT(dIz)TTTCTCC-3′). 
pH dependency of dIz-ODN1 decomposition: 5 nmol of lyophilized, HPLC purified dIz-ODN1 
were dissolved in 200 µL of triethylammonium acetate buffer of pH=5.4 (Fig. S2 A), pH=7.0 (Fig. 
S2 B) or pH=8.4 (Fig. S2 C). The decomposition of the dIz lesion (T=25°C) was followed by 
analytical HPLC using a gradient of 0-25 % buffer B in 45 min. The half life times of dIz at the 
oligonucleotide level, were found to be 3, 18 and 15 h at pH values of 5.4, 7.0 and 8.5 respectively. 
 
Figure S2: Stability of dIz-ODN1 (5′-CTCTTT(dIz)TTTCTCC-3′) at different pH conditions. 
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Figure S3: High resolution mass spectrum of the dIz-ODN1 and its observed decomposition products dZ-
ODN1 and dGf-ODN1. 
Synthesis of the 3′,5′-bisacetyl-dG (ac2dG)1,2: 
 
Deoxyguanosine (3.00 g, 11.22 mmol, 1 eq) and 4-dimethylaminopyridine (102.8 mg, 0.84 mmol, 
0.075 eq) were dissolved in a mixture of acetonitrile (130 mL) and triethylamine (3.75 mL, 
26.9 mmol, 2.4 eq). Acetic anhydride was added (2.54 mL, 26.9 mmol, 2.4 eq - 1.2 molar 
equivalents for each hydroxyl group) and the solution was stirred for 3 h at room temperature. 5 mL 
methanol were added and stirring continued for 5 min. The suspended material was directly 
collected by filtration and washed with cold ethanol and ether. After drying under high vacuum, 
ac2dG was obtained pure (Figure S4) as a white powder (3.8 g, 96%). Rf = 0.25 (CH2Cl2/EtOH 
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90:10); m.p.: 224°C; ESI-MS: [M−H]+calc.= 350.1106, [M−H]+exp. = 350.1106; 1H-NMR and 13C-
NMR were in absolute accordance with those previously reported. 
 
Figure S4: HPLCs of the starting material (dG), eluting at 18.5 min, and the pure product (ac2dG), eluting at 
38 min. Elution system: 0 to 30 % buffer B in 45 min. 
Photooxidation of the 3′,5′-bisacetyl-dG (ac2dG): 2 mL saturated solution of riboflavin in water 
was saturated with 3′,5′-bisacetyl-dG (ac2dG) and subjected to O2 bubbling for 15 min. The mixture 
was irradiated as described above for the dG-ODN1. The crude photolysis mixture was purified by 
HPLC using a gradient from 0 to 30 % buffer B in 45 min. 
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Figure S5: 3D-HPLC and corresponding UV spectra of ac2dIz (Rt = 29.4 min), starting to decompose to 
ac2dZ (Rt = 26.0 min). Elution system 0 to 30 % buffer B in 45 min. 
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Figure S6: High resolution mass spectra of ac2dG (A), ac2dIz (B), ac2dZ (C), ac2dGf (D) and the low 
resolution MS/MS spectrum of the Gf-aglycone fragment (E), as measured by an ion trap experiment. 
1H-NMR data: 
 
Figure S7: 1H-NMR of a mixture of ac2dIz, ac2dZ and ac2dGf compounds as obtained after 
incubation of an HPLC purified ac2dIz water solution at 37°C for 24 h. The characteristic signal for 
the formimine proton appears at 7.78 ppm. 
Enzymatic digestion of dIz-ODN1 (5′-CTCTTT(dIz)TTTCTCC-3′): 11 units P1 nuclease were 
added to a solution containing 1.5 nmol dIz-ODN1 (60 µL, 24.4 µM solution) and the mixture was 
incubated at 0°C for 6 h. 10 units alkaline phosphatase and 0.2 units snake venom 
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phosphodiesterase were added and incubation at 0°C was continued for another 12 h. The mixture 
was centrifuged (13400 rpm) for 15 min and the supernatant injected to the HPLC-MS. 
Enzymatic digestion of dZ-ODN1 (5′-CTCTTT(dZ)TTTCTCC-3′): 1.5 nmol dIz-ODN1  
(60 µL, 24.4 µM solution) were left to stand at room temperature over night in order to form the 
corresponding hydrolysis product 5′-CTCTTT(dZ)TTTCTCC-3′ (dZ-ODN1). 11 units P1 nuclease 
were added and the mixture was incubated at 37°C for 3 h. 10 units alkaline phosphatase and 0.2 
units snake venom phosphodiesterase were added and incubation at 37°C was continued for another 
3 h. The mixture was centrifuged (13400 rpm) for 15 min and the supernatant injected to the HPLC-
MS. 
Purification of human polymerase κ (hPolκ19-526): Human polymerase kappa was cloned from 
human cDNA. The Stargate® system was used as a cloning strategy and the first codons were 
optimized for E.coli usage by using the primers below: 
5′ P-AAT GGG CCT GAA CGA TAA TAA AGC AGG AAT GGA AGG AT-3′ 
5′ P-TCC CTT GTT GGT GTT TCC TGT CCT CTT C-3′ 
The PCR-product was applied in a Stargate® reaction to form an entry clone (pPSG-IBA10) 
containing a short version of human polymerase kappa (hPolκ19-526). The pPSG-IBA33 was used as 
expression plasmid, which was transformed in E. coli Rosetta 2 (DE3) cells. hPolκ19-526 was 
expressed using an autoinduction medium (ZYP-5052) adopted from Studier.3 The cells were 
grown at 37°C for 4 h and then for 16 h at 25°C and harvested by centrifugation. Subsequently, the 
pellet was lysed in His-Buffer A (50 mM Tris pH=7.4, 500 mM NaCl, 20 mM Imidazol, 0.2 % 
Tween 20) using a french press and applied to a Ni-NTA superflow column. Polκs was eluted in 
buffer B (50 mM Tris pH=7.4, 500 mM NaCl, 250 mM Imidazol). The protein was then transferred 
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to Heparin buffer A (50 mM Tris 7.4, 100 mM NaCl 5 mM DTT, 5 % glycerol) and injected into a 
heparin column. A high salt buffer (Heparin buffer B: 50 mM Tris 7.4, 800 mM NaCl, 5mM DTT,  
5 % glycerol) was used for elution. The central peak fractions were collected and concentrated 
using a Millipore Amicon 30K 15 ml filter. As a polishing step the protein was applied to Superdex 
G75 with gel filtration buffer (25 mM HEPES pH=7.0, 200 mM NaCl, 10 mM MgCl2, 1 mM 
TCEP) as mobile phase. The protein was again concentrated and stored at -20°C by supplementing 
the buffer with 50% glycerol. 
Purification of yeast polymerase η (scPolη): scPolη was purified as described before.4-6 
Primer extension and denaturing polyacrylamide gel electrophoresis: 5 pmol of X-ODN2 (5′-
CTA CCT ACC TCC ATX ACA CAT CCC ACA CTC C-3′) containing either dG, dIz, dZ or dGf 
at position X, were hybridized (2 min 50°C, then cooling -1°C/30sec) with 5 pmol of a fluorescein 
labeled primer (5′-Fluo-GGA GTG TGG GAT GTG T-3′). Subsequently, primer extension 
experiments were performed with the exonuclease deficient DNA polymerase I from E. coli 
(Klenow exo−), hPolκ19-526 and scPolη. The polymerases (1 U Klenow exo−, 1 µM scPolη, or 0.5 
µM hPolκ19-526), 50 µM dNTPs and 0.5 µM dsDNA were incubated in a total volume of 10 µL 
1×NEBuffer 2 (New England Biolabs; 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM 
Dithiothreitol, pH 7.9) for 30 min, at optimized temperatures (30°C for scPolη, 37°C for Klenow 
exo− and hPolκ19-526). The reactions were terminated by adding 10 µL TBE-Urea sample buffer and 
analyzed by denaturating polyacrylamide gel electrophoresis. 
Pyrosequencing analysis:7 10 pmol of X-ODN2 (5′-CTA CCT ACC TCC ATX ACA CAT CCC 
ACA CTC C-3′) containing either dG, dIz, dZ or dGf at position X, were hybridized with a biotin 
labeled primer (5′-Biotin-GGAGTGTGGGATGTGT-3′). Subsequently, primer extension 
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experiments were performed with the Klenow exo−, hPolκ19-526 and scPolη. The polymerases (1 U 
Klenow exo−, 1 µM scPolη, or 0.5 µM hPolκ19-526), 50 µM dNTPs and 0.5 µM dsDNA were 
incubated in a total volume of 20 µL 1×NEBuffer 2 (New England Biolabs; 50 mM NaCl, 10 mM 
Tris-HCl, 10 mM MgCl2, 1 mM Dithiothreitol, pH 7.9) for 30 min, at optimized temperatures (30°C 
for scPolη, 37°C for Klenow exo− and hPolκ19-526). 2 µL Streptavidin Sepharose beads (GE 
Healthcare, Uppsala, Sweden), 40 µL Binding Buffer (Qiagen, Hilden, Germany) and 18 µL 
ddH2O were added. After agitation at 1400 rpm for 15 min the beads were captured with a Vacuum 
Prep Tool (Qiagen, Hilden, Germany), washed with 70% EtOH, 0.1 M NaOH and Washing Buffer 
(Qiagen, Hilden, Germany). The beads were dissolved in 25 µL Annealing Buffer (Qiagen, Hilden, 
Germany) containing 5 pmol sequencing primer (5′-CTACCTACCTCCAT-3′), Metabion, 
Martinsried, Germany). Pyrosequencing was performed on a PyroMark Q24 Pyrosequencer using 
standard conditions (Qiagen, Hilden, Germany). The data was analyzed by the software provided by 
the manufacturer. Peak heights were exported to Microsoft Excel and the average value for each 
signal was calculated. The average blank values obtained for each of the four dNTPs were 
subtracted from the values obtained for the incorporation of the individual triphosphates. The 
corresponding values were used for the calculation of the relative incorporation at every variable 
position. The obtained data set was the average of three measurements. 
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Figure S8: Graphical representation of the pyrosequencing assay. 
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Improved Synthesis and Mutagenicity of Oligonucleotides Containing
5-Hydroxymethylcytosine, 5-Formylcytosine and 5-Carboxylcytosine
Martin Mnzel, Ulrike Lischke, Dimitrios Stathis, Toni Pfaffeneder, Felix A. Gnerlich,
Christian A. Deiml, Sandra C. Koch, Konstantin Karaghiosoff, and Thomas Carell*[a]
Introduction
Hydroxymethylcytosine (hmC) is a new DNA base that was
detected in various tissues and in embryonic stem cells.[1] It
is currently believed that this so-called sixth base of the
genome is involved in epigenetic programming processes.[2]
Hydroxymethylcytosine is generated from the epigenetic
marker base 5-methylcytosine (mC) by hydroxylation of the
C5-methyl group performed by ketoglutarate-dependent
TET enzymes (TET1-3).[3] The presence of mC in promoter
regions is considered to be a main signal that finally leads to
the silencing of the corresponding gene.[4] Others and us
speculated that the new base hmC is an intermediate in
active demethylation pathways (Scheme 1) that allow cells
to actively remove the C5-methyl groups of mC in the ab-
sence of replication.[1e, 3,5] This removal would in principle
enable cells to unblock silenced genes and therewith to
dynamically modulate their genetic program.
Unblocking of genes via hmC can in principle occur in
multiple ways (Scheme 1). First, hmC could be an early in-
termediate of an oxidative demethylation pathway in which
hmC is further oxidized to 5-formylcytosine (fC) and 5-car-
boxylcytosine (caC). Demethylation is thereafter possible
via either elimination of formic acid from fC or decarboxy-
lation of caC. Formic acid elimination is a known process
that occurs during steroid biosynthesis,[6a] while decarboxyla-
tion at pyrimidine bases occurs during uridine biosynthesis
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Scheme 1. Postreplicative modification of cytosine to hmC and putative
active demethylation pathways. DNMT: DNA methyltransferase, TET:
ten-eleven-translocation (methylcytosine dioxygenase), AID: activity in-
duced cytosine deaminase, TDG: thymine DNA glycosylase, SMUG1:
single-strand selective monofunctional uracil DNA glycosylase, BER:
base excision repair.
 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Chem. Eur. J. 2011, 17, 13782 – 1378813782
and in the pyrimidine salvage pathways of certain eukaryo-
tes.[6a–d] Alternatively, it is possible that hmC or the further
oxidized bases fC and caC are substrates of special DNA-
repair glycosylases. These would generate abasic sites that
are repaired by gap-filling with 2’-deoxycytidine (dC) using
well established DNA repair pathways.[8a,9b]
Recently, others and us indeed discovered the oxidized
nucleobases fC and caC in embryonic stem cells and in se-
lected other tissues.[7–8] We could show that the fC levels de-
crease during stem cell development suggesting that fC is
indeed involved in stem cell differentiation.[7] For fC, caC
and hmC it was shown that these bases are substrates for
repair enzymes. fC and caC are processed by the thymine-
DNA glycosylase (TDG),[8a,9] while hmC was found to be
converted to hydroxymethyluridine (hmU) by the enzyme
cytosine deaminase (AID). hmU is removed from DNA by
the glycosylase SMUG1 (single-strand selective monofunc-
tional uracil DNA glycosylase).[10]
Currently the function of the new bases fC and caC is un-
known and their role in a putative epigenetic active deme-
thylation process is still unclear. Regarding their potential
role as key epigenetic control intermediates during cell dif-
ferentiation, the previously observed mutagenic potential of
fC is problematic (Figure 1).[11] It was speculated that a pu-
tative strong intramolecular H-bond between the exocyclic
N4 amino group and the carbonyl oxygen at C5 shifts the
amino–imino equilibrium towards the mutagenic imino
form, which would enable fC to form a wrong base pair with
dA (Figure 1).[11–12] For caC mutagenicity data are so far not
reported. The existence of a strong H-bond in caC is sup-
ported by the unusual low pKa value of the C5-carboxylic
acid of pKa <1.5.
[13] In line with the electron-deficient char-
acter of the new bases fC and caC, the acidity of the corre-
sponding protonated bases [HfC]+ and [HcaC]+ (protona-
tion occurs at N3) is unusually high with pKaACHTUNGTRENNUNG[HfC]+ = 2.4
and pKaACHTUNGTRENNUNG[HcaC]+ =4.0 (for comparison: pKa[HC]+ = 4.4,
pKa ACHTUNGTRENNUNG[HhmC]+ = 4.4, and pKaACHTUNGTRENNUNG[HmC]+ = 4.5).[11b, 13]
Results and Discussion
In order to investigate the mutagenic properties of caC and
to re-examine the mutagenic potential of hmC and fC we
prepared hmC, fC and caC oligonucleotides (Scheme 1).[14]
Strands containing hmC were prepared as described by us
before.[15] To access oligonucleotides containing fC in the re-
quired quantity and quality as needed for the current study
we developed an improved fC phosphoramidite reagent
using a carbonylative coupling strategy[1e, 15a] with 5-iodo-2’-
deoxycytidine (1) that was recently also employed by the
He group to synthesize similar fC and caC phosphorami-
dites.[16] The improved fC phosphoramidite features a benzo-
yl protecting group at the N4-position (Scheme 2), which we
found to be more stable than the acetyl protecting group.
The protected fC building blocks give in our hands higher
overall yields than the corresponding fC phosphoramidite
without any protecting group at N4.[16] The direct incorpora-
tion of fC also avoids the oxidative diol cleavage that was
developed by Karino et al. to generate fC in oligonucleo-
tides from a diol-precursor phosphoramidite.[11b] The direct
incorporation of an fC building block via phosphoramidite
chemistry is also possible for RNA. Here, however, a DMF
protecting group was chosen for N4.[17]
The caC phosphoramidite reagent was developed based
on results of Sekine and co-workers.[13] We chose to protect
the N4 amine groups with an acetyl group and we used a
methyl ester to protect the C5 carboxylic acid (Scheme 2).
Both protecting groups are cleaved under the standard basic
conditions typically needed to cleave the oligonucleotide
from the solid support.
Starting point for the synthesis of the fC phosphoramidite
building block is TBS-protected 5-iodo-2’-deoxycytidine (1)
which was synthesized as described previously.[15a] The
formyl group was introduced by a carbonylative coupling,
which we already employed for the synthesis of the free fC
nucleoside and an hmC phosphoramidite.[1e, 15a] The resulting
TBS-protected 5-formyl-2’-de-
oxycytosine was benzoylated to
give 2. Cleavage of the TBS
groups was achieved with HF in
pyridine.[18] When the latter re-
action is carried out in EtOAc,
the free nucleoside 3 precipi-
tates and no further purification
is needed. Finally, the 5’-hy-
droxyl group of compound 3
was protected with a DMT
group and the 3’-hydroxyl
group phosphitylated to give
the final compound 4.
In the first step towards the
caC phosphoramidite building
block, 1 was converted to the
methyl ester in a Pd0-catalyzed
reaction.[19] During the reaction
the CO pressure has to be ad-
Figure 1. fC and caC exhibit an intramolecular hydrogen bond that was proposed to shift the amino/imino
equilibrium towards the imino tautomeric form which would then form a mutagenic base pair with dA.
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justed carefully because otherwise a carbonylative Buchwald
coupling occurs as a side reaction. Compound 5 was subse-
quently obtained after acetylation. In line with the reduced
electron deficiency of the caC compound, the N4 acetyl pro-
tecting group is considerably more stable in compound 5
than in the fC derivative. For the cleavage of the silyl esters,
we treated 5 with HF in pyridine/ethyl acetate which caused
precipitation of pure 6. The free nucleoside was finally
DMT-protected and phosphitylated to give the caC phos-
phoramidite building block 7.
For the incorporation of fC into oligonucleotides a stan-
dard solid-phase DNA synthesis was performed with phos-
phoramidite 4. Coupling times for 4 were doubled to ensure
good yields. As shown in Figure 2, the incorporation of fC
proceeds without difficulty. After cleavage of the oligonu-
cleotide from the resin and deprotection, the desired ODN1
with X= fC was obtained as the main product (Figure 2 A,
B). The same results were obtained for the 37mer ODN2
(Scheme 2). Deprotection was in both cases possible with
either conc. NH4OH or with 0.4 m NaOH in MeOH.
MALDI-TOF analysis of the oligonucleotides proved the
correct molecular weight of the synthesized strands (Fig-
ure 2 C). After total digestion of the prepared oligonucleo-
tides the four canonical bases were obtained with the fC
base co-eluting with dT. Detection of the fC component was
ensured by mass spectrometry (see Supporting Informa-
tion).[7]
Incorporation of caC was possible with the phosphorami-
dite 7 using again rather standard solid-phase DNA synthe-
sis conditions. The coupling times were extended to ensure
good yields. In this case, however, standard deprotection
conditions could not be employed, because treatment with
ammonia or with K2CO3 in methanol would not yield the
desired acid but either the amide or the methyl ester. De-
protection was therefore performed with NaOH in water/
methanol.[15a] As shown in Figure 3 A, this procedure allows
to obtain the caC containing DNA strands as the only prod-
uct. The caC containing DNA strands were subsequently pu-
rified by reversed phase HPLC (Figure 3 B) and the correct
composition was again proven by MALDI-TOF mass spec-
trometry (Figure 3 C) and HPLC-MS analysis of the nucleo-
tides obtained after total enzymatic digest. Under our condi-
tions, the caC nucleoside eluted with a retention time of
5.3 min. Thus, fC- and caC-containing oligonucleotides can
be efficiently prepared in high yields. With the improved
phosphoramidite reagents the DNA strands are obtained
under the described coupling and deprotection conditions in
excellent purity.
In order to characterize and compare the base-pairing
properties of hmC, fC and caC we measured melting points
of sequence identical oligonucleotides under exactly the
Scheme 2. Synthesis of the fC phosphoramidite 4 and of the caC phos-
phoramidite 7. X = fC or caC.
Figure 2. Analysis of ODN1 containing fC (Sequence of ODN1: 5’-
GTAATGXGCTAG-3’; X = fC): A) Reversed-phase HPLC chromato-
gram of ODN1 (X = fC) directly after cleavage from the resin (0–50 %
buffer B in 45 min). B) Reversed-phase HPL chromatogram of ODN1
(X= fC) after cleavage of the DMT group and purification (0–20 %
buffer B in 45 min). C) MALDI-TOF spectrum of the purified strand
ODN1 (X = fC). D) Digestion of the purified DNA strand ODN1 (X=
fC) yields the canonical nucleosides plus fC, which co-elutes with dT.
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same conditions (Figure 4). To this end, ODN1, with the re-
spective modified dC-bases present at position X, was mixed
with the ODN3 counter strand, which contained individual
canonical nucleosides at position Y. The solutions were re-
peatedly heated and cooled between 80 and 20 8C. In all
cases the cytosine derivatives paired best with dG (R1 = H:
51.4 8C; R1 = CH2OH: 51.0 8C; R
1 = CHO: 52.7 8C; R1 =
COOH: 51.3 8C). Second best base pairing was in most cases
observed with dA. For fC we noted a slightly increased sta-
bility of the fC:dT base pair. As already observed for
hmC[20] the base pairing properties of fC and caC differ only
marginally from dC. In addition, the stability differences be-
tween the nC:dG (n = hm, f, ca) base pairs and all mis-
matches are so high that a severe mutagenic effect of the
modified dC bases can be excluded based on the melting
point data.
To investigate the mutagenic potential further we devel-
oped a novel primer extension assay which we coupled di-
rectly to a pyrosequencing procedure. For the study we hy-
bridized the nC containing oligonucleotides (ODN2) with a
biotinylated primer strand (ODN4) and used various high
and low fidelity polymerases to extend the primer past the
modified cytosines to the full length product as shown in
Figure 5. The resulting transcripts were isolated using strep-
tavidine coated sepharose beads and subsequently used as
new templates for pyrosequencing. As such they were hy-
bridized to the reverse primer (ODN5) and subjected to
standard pyrosequencing conditions using the Klenow poly-
merase.[21] The experiment has the advantage that it pro-
vides incorporation data in a situation in which all triphos-
phates are present simultaneously and compete for incorpo-
ration.
We examined the mutagenic potential of hmC, fC and
caC first with the high fidelity polymerase Klenow exo.
Figure 3. Analysis of ODN1 containing caC (Sequence of ODN1: 5’-
GTAATGXGCTAG-3’; X = caC): A) Reversed-phase HPLC chromato-
gram of ODN1 (X = caC) directly after cleavage from the resin (0–50 %
buffer B in 45 min). B) Reversed-phase HPLC chromatogram of ODN1
(X = caC) after cleavage of the DMT group and purification (0–20 %
buffer B in 45 min). C) MALDI spectrum of the purified strand ODN1
(X = caC). D) HPLC chromatogram of purified ODN1 (X = caC) after
enzymatic digestion.
Figure 4. Melting point analysis of ODNs, which contain different 5-sub-
stituted cytosines. 13 mer duplexes (ODN1: 5’-GTAATGXGCTAG-3’)
containing dC, hmC, fC, and caC as X was hybridized with different
ODN3 s (5’-CCTAGCYCATTAC-3’) containing either dA, dC, dG, or dT
in the Y-position opposite the cytosine bases. The duplexes
(ODN1:ODN3) were repeatedly heated and cooled between 20 and
80 8C. Melting points of all individual base–counterbase combinations are
shown.
Figure 5. Sequencing based mutagenicity assay with different cytosine de-
rivatives. All values are the average of three independent measurements.
A) ODN2, containing the modification, was elongated with different
polymerases, the transcript was isolated, hybridized to a reverse primer
and sequenced in a pyrosequencer. B) Nucleosides that are incorporated
opposite the different cytosine derivatives. In contrast to the known mu-
tagenic 4-NHOHdC none of the other C5-modified cytosines are strongly
mutagenic.
Chem. Eur. J. 2011, 17, 13782 – 13788  2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chemeurj.org 13785
FULL PAPERImproved Synthesis and Mutagenicity of Oligonucleotides
However, due to the fact that modified bases are in vivo po-
tentially replicated with a low fidelity polymerase, we also
studied the common eukaryotic low fidelity polymerase eta
(Saccharomyces cerevisiae) and polymerase kappa (Homo
sapiens). For the study we used as control nucleosides dT as
a non-mutagenic base and the mutagenic base 4-NHOHdC, in
which the exocyclic amino group is replaced by a hydroxyla-
mine group.[22] This base is known to exhibit its mutagenicity
due to the increased presence of the imino tautomeric form,
which is also believed to be the basis for the mutagenicity of
fC.[23] All data obtained are compiled in Figure 5. As expect-
ed, dC directs exclusively the incorporation of dG into the
primer, while dT instructs the incorporation of dA. 4-NHOHdC
directs the incorporation of both dA and dG, which is in ac-
cordance with the proposal that it derives its mutagenic
effect from the fact that it exists partially in the imino tauto-
meric form.[21b, 23] To our surprise, we noted that fC in our
coupled assay is, in contrast to previous reports, but in
agreement with our melting point studies, only marginally
mutagenic. All examined polymerases efficiently base
paired fC with dG. In addition we indeed observed a small
additional incorporation of dA. The incorporation is detect-
ed slightly above the error limit of the experiment, indicat-
ing that the formyl group promotes formation of the imino
tautomeric form only to a very small extent. For caC and
hmC we could not detect any other incorporation but dG.
Our data clearly show that none of the new C5-modified nu-
cleobases hmC, fC and caC are mutagenic. They all retain
the base pairing behaviour of dC.
To investigate if the previously detected mutagenicity of
fC may be caused by degradation products such as abasic
sites, which may be generated by an accelerated proton cata-
lyzed depyrimidination of fC, we performed stability studies.
To this end fC and caC containing oligonucleotides were ex-
posed to different pH conditions for 18 h and the decompo-
sition was studied by HPLC. We noticed that neither the fC
nor the caC containing ODN1 decomposed during this time
in solutions buffered between pH 7 and 5 (37 8C). Under
physiological conditions fC and caC are hence stable DNA
modifications that show no increased lability. Only when we
treated ODN1 (with X= fC and X=caC) under nonphysio-
logical, mildly acidic conditions (0.01% formic acid), we ob-
served rapid decomposition of the strands. Under these con-
ditions we observed an increased lability of fC and caC com-
pared to dC because the dC containing control strands de-
composed significantly slower.
We next recrystallized the fC base in order to obtain
deeper insight into the intramolecular H-bond between the
exocyclic amino group NH2(4) and the carbonyl–oxygen at
C5, which was suggested to be the molecular reason for the
increased mutagenicity. The structure of fC is depicted in
Figure 6. The H-bond is indeed present in line with NMR
studies carried out before.[12b, 24] The low mutagenic potential
of fC, however, suggests that this H-bond does not shift the
amino/imino equilibrium substantially towards the imino-
tautomeric form.
Summary and Conclusion
In the last two years, it was discovered that the epigenetic
base mC is further oxidized to hmC, fC and caC. Although
the function of these new bases is still unclear at this point,
they are present in substantial amounts in stem cells and
neuronal cells. In principle oxidation of mC could occur in
order to stimulate cellular mutagenic events. This is for ex-
ample observed in the case of adenine, which is deaminated
by special enzymes in immune cells to generate inosine,
which base pairs with dC and not dT.[25] This mutagenic pro-
cess is vital for a correct immune response. Alternatively,
hmC, fC and caC could be new bases that have epigenetic
functions. The previously reported mutagenicity of fC,
which was found to be only slightly less mutagenic than
8-oxodG,[11a] argued against a pure epigenetic function. The
strong H-bond between the NH2(4) group and the carbonyl
oxygen at C5 was suggested to promote the imino tautomer-
ic state, which was proposed to stimulate pairing possibilities
with dA.[11a, 12a] In this study we re-examined the mutagenici-
ty of fC and we measured for the first time the mutagenic
effect of caC. Both compounds were measured against
4-NHOHdC, which is a known mutagenic dC modification due
to an increased imine character. We also report a crystal
structure of fC, which indeed shows the expected H-bond.
Our data show that 4-NHOHdC is mutagenic and that it pairs
both with dG and dA in accordance with increased exis-
tence of the imino-tautomeric form. The new bases fC and
caC, however, only pair with dG and do not show such dual
base pairing characteristics. They were also found to be
stable under physiological conditions, which eliminates the
possibility that they exhibit a mutagenic potential due to
rapid depyrimidination. We believe that the previously ob-
served mutagenicity of fC in vivo is therefore not caused by
Figure 6. Molecular structure of fC in the crystal showing the intramolec-
ular hydrogen bond between the aldehyde oxygen atom and the amino
group. ORTEP representation, thermal ellipsoids are drawn at 50 %
probability level.
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a polymerase acting on the fC base but by molecular struc-
tures that are formed due to the in vivo action of either
base- or nucleotide excision repair acting on the modifica-
tions. Indeed, it was recently shown that fC and caC are se-
lectively excised by the enzyme TDG, which would generate
an abasic site.[8a, 9b] In summary, our data show that fC and
caC are non-mutagenic and therefore can be involved in ep-
igenetic programming of cells without disturbing the genetic
sequence information.
Experimental Section
General remarks : Chemicals and solvents were purchased from ABCR,
Alfa Aesar, Acros, Fluka, Sigma–Aldrich or TCI in the qualities puriss.,
p.a. or purum. Dry solvents (<50 ppm H2O) were obtained from Fluka
and Acros. All reactions employing dry solvents were performed under
inert atmosphere (N2). Technical grade solvents were distilled prior to
use for column chromatography and liquid–liquid extractions on a rotary
evaporator (Heidolph Laborota 4000). Reaction products were dried at
high vacuum (0.1 mbar). Aqueous solutions were concentrated on a
SpeedVac plus CS110 A or SPD 111V from Savant or lyophilized (Christ
ALPHA 2-4). Thin layer chromatography (TLC) was performed with
aluminium plates (silica gel 60 F254, 10 5 cm). Substances were visual-
ized by illumination with UV light (l =254 nm). ESI-MS was performed
on a Finnigan LTQ FTICR. MALDI-TOF was performed on a Bruker
Autoflex II. NMR spectra were recorded on the following spectrometers:
Varian Oxford 200, Bruker AC 300, Varian XL 400 and Bruker AMX
600. The chemical shifts (d) are given in ppm, the coupling constants (J)
in Hz. Exonuclease-deficient DNA polymerase I from E. coli (Klenow
exo) was obtained from NEB, Pol h was purified as described before[26]
and Pol k was cloned from human cDNA and expressed in Rosetta 2
(DE3) cells.
Oligonucleotide synthesis and deprotection : DNA synthesis was per-
formed on an Expedite 8909 Nucleic Acid Synthesis System (PerSeptive
Biosystems) or an ABI 394 DNA/RNA synthesizer (Applied Biosystems)
using standard DNA synthesis conditions. Phosphoramidites for dA, dC,
dG, dT and CPG carriers were obtained from Amersham, Glen Research
or PE Biosystems. The hmC and fC phosphoramidites were dissolved in
dry MeCN, the caC phosphoramidite in dry toluene. The oligonucleotides
were removed from the resin under concomitant cleavage of the standard
nucleobase protecting groups by treatment with 750 mL conc. NH3 and
250 mL ethanol at room temperature for 18 h (fC) or treatment with 0.4 m
NaOH in water/methanol 1:4. Subsequently, the solution was decanted
from the resin. When the deprotection was carried out with NaOH, a 1m
TEA/AcOH solution (600 mL) was added and the solution concentrated
to a final volume of 750 mL. After deprotection with NH4OH the solution
was concentrated to dryness and subsequently taken up in water. Please
note that deprotection with NaOH is not compatible with DMF protect-
ing groups.
HPLC and cleavage of DMT groups : Purification and analysis of ODNs
was performed on a Waters system (Alliance 2695 with PDA 2996; prep-
arative HPLC: 1525EF with 2484 UV detector) with VP 250/10 Nucleosil
100-7 C18 and VP 250/4 Nucleosil 20-3 C18 columns from Macherey–
Nagel using a gradient of 0.1 m triethylamine/acetic acid in water and
80% acetonitrile. The oligonucleotides still containing the trityl group
were deprotected by addition of 100 mL of an 80 % acetic acid solution.
After incubation at RT for 20 min, 100 mL of water together with 60 mL
of a 3 m solution of sodium acetate were added. Finally, the ODN was
precipitated by the addition of 1600 mL ethanol at 20 8C (30 min). The
strands were stored in ddH2O.
Enzymatic digestion : For the enzymatic digestion DNA mixtures (4 to
10 mg in a final volume of 100 mL H2O) were heated to 100 8C for 5 min
to denature the DNA and rapidly cooled on ice. Buffer E (10 mL, 300 mm
ammonium acetate, 100 mm CaCl2, 1 mm ZnSO4, pH 5.7) and nuclease S1
(80 units, Aspergillus oryzae) were added to the mixture and incubated
for 3 h at 37 8C. Addition of buffer F (12 mL, 500 mm Tris-HCl, 1 mm
EDTA), antarctic phosphatase (10 units), snake venom phosphodiester-
ase I (0.2 units, Crotalus adamanteus venom) and incubation for further
3 h at 37 8C completed the digestion. The supernatant was removed, the
volume reduced to 100 mL and measured with HPLC-ESI-MS.
HPLC-ESI-MS : The samples (100 mL injection volume) were analyzed
by HPLC-ESI-MS on a Thermo Finnigan LTQ Orbitrap XL and were
chromatographed by a Dionex Ultimate 3000 HPLC system using gradi-
ent of 2 mm ammonium format in water and 80% acetonitrile over an
Uptisphere120–3HDO column from Interchim.
Melting points : Melting profiles were measured on a Jasco V-650 spectro-
photometer using quartz glass cuvettes with 1 cm path length. In these
were in a total volume of 1 mL: 1 mmol ODN, 1 mm counterstrand,
150 mm NaCl and 10 mm Tris pH: 7.4. First, the oligonucleotides were hy-
bridized by slowly cooling the samples down from 80 8C to 20 8C. The
melting profiles started with a denaturing run (20 to 80 8C) with a slope
of 0.5 8C min1. At least two denaturing and two renaturing ramps were
performed and averaged for evaluation of the melting point. (TM =zero-
crossing of second derivative of the 400 nm-background corrected change
in hyperchromicity at 260 nm.) For analysis of the data, the program
Origin (Microcal) was used.
Pyrosequencing analysis : A 37 mer template DNA strand (ODN 2: 5’-
d(GTA GCC AGG TCG CAC GCG TGC TAX GAT GCG AGA
CTG C)-3’ was prepared containing either dC, mC, hmC, fC, caC, or
4-NHOHdC, or dT at position X. 10 pmol of the template were hybridized
with a biotinylated primer (ODN 4: 5’-d(biotin-GCAGTCTCGCATC)-3’,
Metabion). Subsequently, the primer extension experiments were per-
formed with the exonuclease deficient DNA polymerase I from E. coli
(Klenow exo), Pol h and Pol k. The polymerases (1 U Klenow exo,
1 mm Pol h, or 0.5 mm Pol k), 50 mm dNTPs and 0.5 mm dsDNA were incu-
bated in a total volume of 20 mL 1 NEBuffer 2 for 30 min at different
temperatures (30 8C for Pol h, 37 8C for Klenow exo and Pol k). To this
solution 2 mL streptavidin sepharose beads (GE Healthcare, Uppsala,
Sweden), 40 mL binding buffer (Qiagen, Hilden, Germany) and 18 mL
ddH2O were added. After agitation at 1400 rpm for 15 min the beads
were captured with a Vacuum Prep Tool (Qiagen, Hilden, Germany),
washed with 70% EtOH, 0.1m NaOH and Washing Buffer (Qiagen,
Hilden, Germany). The beads were dissolved in 25 mL Annealing Buffer
(Qiagen, Hilden, Germany) containing 5 pmol sequencing primer ODN5
(5’-d(GTAGCCAGGTCGCACGCGTGCTA)-3’, Metabion, Martinsried,
Germany). Pyrosequencing was performed on a PyroMark Q24 Pyrose-
quencer using standard conditions (Qiagen, Hilden, Germany). The data
was analyzed by the software provided by the manufacturer. Peak heights
were exported to Microsoft Excel and the average of all blank sites for
the individual nucleobases calculated. This resulted in one blank for dT,
one blank for dC, one blank for dG and one blank for dA. This value
was subtracted from the values for the incorporation of the individual tri-
phosphates. With these data the relative incorporation at every variable
position was calculated. The data are the average of three measurements.
Recrystallization : Single crystals, suitable for X-ray diffraction, were ob-
tained by very slow evaporation of the solvent of a fC solution in metha-
nol. The crystals were introduced into perfluorinated oil and a suitable
single crystal was carefully mounted on the top of a thin glass wire. Data
collection was performed with an Oxford Xcalibur 3 diffractometer
equipped with a Spellman generator (50 kV, 40 mA) and a Kappa CCD
detector, operating with MoKa radiation (l= 0.71071 ). Data collection
was performed with the CrysAlis CCD software;[27] CrysAlis RED soft-
ware[27] was used for data reduction. Absorption correction using the
SCALE3 ABSPACK multiscan method[28] was applied. The structures
were solved with SHELXS-97,[29] refined with SHELXL-97[30] and finally
checked using PLATON.[31] All hydrogen atoms involved in hydrogen
bonding were found in the differential Fourier map and refined. Details
for data collection and structure refinement are summarized in Table S4.
CCDC 843055 contains the supplementary crystallographic data for this
paper. The data can be obtained free of charge from The Cambridge
Crystallographic Date Centre via www.ccdc.cam.ac.uk/data_request/cif.
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Buffer Systems for HPLC 
buffer system I: analytical and  preparative reversed phase HPLC 
Buffer A: 0.1 M NHEt3OAc 
Buffer B: 0.1 M NHEt3OAc in 80% MeCN 
 
buffer system II: analytical HPLC of enzymatic digestion products; LC-MS 
Buffer C: 2 mM NH4CHOO 
Buffer D: 2 mM NH4CHOO in 80% MeCN 
always used with standard gradient: 0 ?  12 min; 0 % ?  3 % buffer D; 12 ?  60 min; 3 % ?  
60 % buffer D; 60 ?  62 min; 60 % ?  100 % buffer D; 62 ?  70 min; 100 % buffer D; 70 ?  
85 min; 100 ?  0 % buffer D; 85 ?  95 min; 0 % buffer D. 
 
MALDI-MS 
MALDI spectra were recorded on a Bruker autoflex II unit with an MTP AnchorChip var/384 
target. Prior to the measurements the samples were desalted using MF-Millipore membrane 
filters (0.025 µM). Desalting times depended on the molecular weight of the analyte. 
(4000 Da: 30 min, 12000 Da: over night) 
MALDI matrix: 
HPA Crown: 3-hydroxypicolinic acid (50 mg), 15-Crown-5 (10 µl), ammonium 
hydrogencitrate (10 mg) in 500 µL ddH2O and 500 µL MeCN 
 
Sequences of DNA Strands 
ODN1: 5' d(GTA ATG XGC TAG G)3' X = dC, mC, hmC, fC, caC 
ODN2: 5' d(GTA GCC AGG TCG CAC GCG TGC TAX GAT GCG AGA CTG C) 3' X = 
dC, mC, hmC, fC, caC 
ODN3: 5' d(CCT AGC YCA TTA C)3' Y = dA, dG, dC, dT 
ODN4: 5' d(Bio GCA GTC TCG CAT C)3' 
ODN5: 5' d(GTA GCC AGG TCG CAC GCG TGC TA)3' 
 
Stability assay of fC and caC at the oligonucleotide level 
The oligonucleotides used for this assay where HPLC purified and tested for analytical purity 
prior to the stability analysis. A solution of ODN1 (18 pmol/µL, X = dC, fC, caC) was spiked 
with 0.01 % HCOOH and directly incubated at 37°C. Additionally, ODN1 was incubated in 
buffered solution at pH 7.0 and 5.0 at 37°C. Sequential injections (10 µL, 180 pmol DNA) 
every six hours and over a time frame of 18 h reveals the decomposition of the fC and caC 
strands in direct comparison with the control dC containing strand. The analytical HPLC runs 
where performed by application of buffer system I, with pH value strictly regulated to 7.00 
(flow rate: 0.5 mL/min, gradient: 0? 20 % buffer B in 45 min). 
 
LC MS analysis of digested DNA strands 
 
Figure S1: LC/MS analysis of the digested nucleoside mixtures. A) Mass filter for 5-CHOdC. B) Mass 
filter for 5-COOHdC. C) Mass filter for dT. d) Mass filter for dC. 
 
Purification of human polymerase ? 
Human polymerase kappa was cloned from human cDNA. The Stargate® system was used as 
a cloning strategy and the first codons were optimized for E.coli usage by using the primers 
below. 
 
Primer: 
5’P – AATG GGC CTG AAC GAT AAT AAA GCA GGA ATG GAA GGA T 
5’P – TCCC TTG TTG GTG TTT CCT GTC CTC TTC 
 
Furthermore the PCR-product was applied in a Stargate® reaction to form an entry clone 
(pPSG-IBA10) containing a short version of human polymerase kappa (pol?s, 19-526). The 
pPSG-IBA33 was used as expression plasmid, which was transformed in Rosetta 2 (DE3) 
cells. Pol?s was expressed using an autoinduction medium (ZYP-5052) adopted from Studier 
(Protein Expression and Purification 41 (2005) 207–234). The cells were grown at 37°C for 
4 h and then for 16 h at 25°C and harvested by centrifugation. Subsequently the pellet was 
lysed in His-Buffer A (50 mM Tris pH = 7.4, 500 mM NaCl, 20 mM imidazol, 0.2 % Tween 
20) using a french press and applied to a Ni-NTA superflow column. Pol?s was eluted in 
buffer B (50 mM Tris pH=7.4, 500 mM NaCl, 250 mM imidazol). Furthermore the protein 
was transferred to Heparin buffer A (50 mM Tris 7.4, 100 mM NaCl, 5 mM DTT, 5 % 
glycerol) and injected into a heparin column. A high salt buffer (Hep B, 50 mM Tris pH = 7.4, 
800 mM NaCl, 5mM DTT, 5 % glycerol) was used for elution. Afterwards the central peak 
fractions were pooled and concentrated using an Amicon 30K 15 ml. As a polishing step the 
protein was applied to Superdex G75 with gel filtration buffer (25 mM HEPES pH = 7.0, 200 
mM NaCl, 10 mM MgCl2, 1 mM TCEP) as mobile phase. The protein was again concentrated 
and stored at -20°C by supplementing the buffer with 50 % glycerol. 
 
Purification of yeast polymerase ? 
Pol ? was purified as described before.[1] 
 
Crystal Structure of fC 
A characteristic feature of the structure of fC is a strong intramolecular hydrogen bond (Table 
1) between the oxygen atom of the CHO group and the adjacent NH2 group involving the 
hydrogen atom H22. Due to this hydrogen bonding the orientation of the CHO-group is fixed 
and there is no disorder of this group with respect to a rotation around the Cring-CHO bond 
observed. The most fascinating feature is the crystal packing of fC. It is determined by an 
extensive network of intermolecular hydrogen bonds. To this network participates the NH2 
group, both OH groups and the oxygen atoms of both carbonyl groups of each molecule. 
Interestingly, while the primary OH-group acts only as donor, the secondary OH-group acts 
both as donor and as acceptor (Fig. S2). In the crystal every molecule undergoes O–H···O 
hydrogen bonds with four neighboring molecules acting two times as acceptor via the 
carbonyl oxygen atoms and two times as donor via both OH-groups. With two further 
molecules N–H···O hydrogen bonds are formed. This results in the formation of layers (Fig. 
S3), which are strongly puckered due to the fixed angle between the five-membered and the 
six-membered ring of fC. These layers are packed to form the crystal. 
O3
C6
O2
C9
N1
C7
C1
C10
H50
C2
O2
O5
C8
N3
H50
C4
O4
C3
O5
C5
H40
H21
N2
O1
N2
H21H22
O4
O1
H40
O4
a)
b)
b)
c)
d)
e) e)
f)
 
Figure S2: Crystal structure of fC showing the hydrogen bonds in which one molecule of fC 
is involved in the crystal. ORTEP representation, thermal ellipsoids are drawn at 50% 
probability level. Symmetry codes: a) 1-x, -0.5+y, 1-z; b) 2-x, -0.5+y, 2-z; c) -1+x, y, -1+z; d) 
1+x, y, 1+z; e) 1-x, 0.5+y, 1-z; f) 2-x, 0.5+y, 2-z. 
 
Figure S3: Crystal structure of fC, view of a puckered layer of hydrogen bonded molecules 
along the b-axis; thermal ellipsoids are drawn at 50% probability level. 
 
Table S1: Hydrogen bonding parameters for fC in the crystal. 
 D – H  H ··· A D ··· A D – H ··· A 
N2 – H21 ··· 
O4a)  
0.93(3) 1.92(3) 2.848(3) 173(3) 
N2 – H22 ··· O1 0.83(3) 2.09(3) 2.745(3) 136(3) 
O4 – H40 ··· 
O1b) 
0.84(3) 1.86(3) 2.706(3) 176(3) 
O5 – H50 ··· 
O2c) 
0.86(3) 1.86(3) 2.719(3) 176(3) 
Symmetry codes: a) 1-x, -0.5+y, 1-z; b) 2-x, -0.5+y, 2-z; c) -1+x, y, -1+z. 
 
 
Table S2: Selected atom distances (in ? ) in the molecular structure of fC in the crystal. 
O1 – C5  1.242(3) C2 – C4 1.371(4) 
O2 – C1 1.244(3) C3 – C4 1.446(4) 
O3 – C6 1.420(3) C4 – C5 1.435(4) 
O3 – C9 1.450(3) C6 – C7 1.525(4) 
O4 – C8 1.424(3) C7 – C8  1.517(4) 
O6 – C10  1.421(3) C8 – C9  1.531(4) 
C9 – C10   1.513(4) N1 – C2  1.339(3) 
N1 – C6  1.509(3) N1 – C1  1.429(3) 
N2 – C3  1.331(4) N3 – C3  1.335(3) 
N3 – C1 1.344(3)   
 
Table S3: Selected bond angles (in °) in the molecular structure of fC in the crystal. 
C6 – O3 – C9  110.3(2) C6 – C9 – C10 115.2(2) 
O3 – C9 – C8 104.4(2) O3 – C9 – C10 110.3(2) 
C1 – N1 – C2 120.5(2) O5 – C10 – C9 112.0(2) 
C1 – N1 – C6 117.3(2) C2 – N1 – C6 122.2(2) 
C1 – N3 – C3 120.0(2) O2 – C1 – N3 123.4(2) 
N1 – C1 – N3 119.6(2) O2 – C1 – N1 117.0(2) 
N1 – C2 – C4  121.3(2) N2 – C3 – C4 121.3(2) 
N3 – C3 – C4 122.1(2) N2 – C3 – N3 118.5(2) 
C2 – C4 – C3 116.6(2) C2 – C4 – C5 118.4(2) 
C3 – C4 – C5 125.0(2) O1 – C5 – C4 124.0(3) 
N1 – C6 – C7 112.0(2) O3 – C6 – C7 106.5(2) 
O3 – C6 – N1 108.3(2) C6 – C7 – C8 102.1(2) 
O4 – C8 – C9 113.5(2) C7 – C8 – C9 101.7(2) 
O4 – C8 – C7 110.4(2)   
 
Table S4: Details for X-ray data collection and structure refinement for compound fC 
Empirical formula C10H13N3O5 
Formula mass 255.23 
T[K] 173(2) 
Crystal size [mm] 0.2×0.15×0.05 
Crystal description pale yellow block 
Crystal system monoclinic 
Space group P21  
a [? ] 5.0787(4) 
b [? ] 16.7550(12) 
c [? ] 6.5815(5) 
ß [°] 103.791(9) 
V [? 3] 543.90(7) 
Z 2 
?calcd. [g cm-3] 1.559 
µ [mm-1] 0.127 
F(000) 268 
T  range [°] 4.30 – 33.51 
Index ranges -4=h=7 
 -24=k=21 
 -10=l=9 
Reflns. collected 3819 
Reflns. obsd. 2105 
Reflns. unique 2933  
(Rint = 0.0322) 
R1, wR2 (2s  data) 0.0502, 0.0799 
R1, wR2 (all data) 0.0806, 0.0895 
GOOF on F2 0.956 
Peak/hole [e ? -3] 0.28/-0.24 
 
 
Synthesis of compounds 1-11 
 
5-formyl-3', 5'-(O-tert-butyl-dimethylsilyl)-2'deoxycytidine (8) 
 
The reaction was carried out as described previously. The scale could be increased to 16 g. [2] 
1H-NMR (300 MHz, CDCl3): d (ppm) = 9.51 (s, 1H, C-CH=O), 8.57 (s, 1H, N-CH=C-CHO), 
8.37 (s, 1H, 1x NH2), 7.46 (s, 1H, 1x NH2), 6.19 (t, 3J = 6.1, 1H, O-CH-N), 4.40 – 4.32 (m, 
1H, O-CH-CH2-CH-N), 4.08 – 4.02 (m, 1H, O-CH-CH-CH2-O), 3.95 (dd, 3J = 2.7, 2J = 11.7, 
1H, 1x O-CH2-CH-O), 3.78 (dd, 3J = 2.6, 2J = 11.6, 1H, 1x O-CH2-CH-O), 2.59 (ddd, 3J = 
3.6, 3J = 5.8, 2J = 10.3, 1H, 1x O-CH-CH2-CH-N), 2.20 – 2.08 (m, 1H, 1x O-CH-CH2-CH-
N), 0.89 (s, 9H, O-Si-C(CH3)3), 0.88 (s, 9H, O-Si-C(CH3)3), 0.10 (s, 3H, O-Si-CH3), 0.08 (s, 
6H, O-Si-CH3), 0.07 (s, 3H, O-Si-CH3).  
13C-NMR (75 MHz, CDCl3): d (ppm) = 187.1, 162.1, 153.1, 152.6, 104.9, 88.8, 87.9, 71.5, 
62.6, 42.8, 25.9 (3C), 25.7 (3C), 18.4, 17.9, -4.5, -4.9, -5.2, -5.4.  
HRMS (ESI+): calculated for C22H42N3O5Si2+ [M+H+]+: 484.2658, found: 484.2654 
melting range: 150 - 152 °C 
IR (ATR): (cm-1) = 3365 (w), 2952 (w), 2929 (w), 2857 (w), 1651 (s), 1245 (m), 1083 (s), 
829 (s), 776 (s). 
 
3',5'-(tert-butyl-dimethylsilyl)-4-N-benzoyl-5-formyl-2'deoxycytidine (2) 
 
A round bottom flask was charged with 680 mg (1.41 mmol, 1.0 eq) 8 and 20 mL pyridine 
and was subsequently cooled to 0 °C. 875 µL (7.03 mmol, 5.0 eq) Bz-Cl were added slowly, 
the reaction mixture stirred at 0 °C for 30 min and for 2 h at room temperature. The reaction 
was stopped by addition of ice and diluted with 300 mL EtOAc. The solution was washed 
with sat. NaHCO3 (1x 300 mL) and sat. NH4Cl (1x 300 mL). The organic layer was separated, 
dried over MgSO4 and subsequently evaporated to dryness. The crude product was purified by 
column chromatography (iHex/EtOAc 99:1? 29:1? 9:1) to give 435 mg (52 %) of 2 as a 
colorless oil along with 197 mg (20 %) of the double benzoylated derivative. 
1H-NMR (400 MHz, CDCl3): d (ppm) = 9.60 (br s, 1H, NH), 8.75 (s, 1H, CHO), 8.11 (ddd, 
4J = 2.8, 3J = 3.9, 3J = 8.5, 3H, Ph-H, N-CH=C-CHO), 7.63 – 7.44 (m, 3H, Ph-H), 6.22 (t, 3J 
= 6.2, 1H, O-CH-N), 4.40 – 4.34 (m, 1H, O-CH-CH2-CH-N), 4.10 (dd, 3J = 2.6, 3J = 5.7, 1H, 
O-CH-CH-CH2-O), 3.97 (dd, 3J = 2.6, 2J = 11.6, 1H, 1x O-CH2-CH-O), 3.80 (dd, 3J = 2.5, 2J 
= 11.6, 1H, 1x O-CH2-CH-O), 2.71 – 2.61 (m, 1H, 1x O-CH-CH2-CH-N), 2.13 (dt, 3J = 6.1, 
2J = 13.5, 1H, 1x O-CH-CH2-CH-N), 0.90 (2x s, 18H, O-Si-C(CH3)3), 0.11 (s, 3H, O-Si-
CH3), 0.10 (s, 3H, O-Si-CH3), 0.09 (s, 3H, O-Si-CH3), 0.07 (s, 3H, O-Si-CH3). 
13C-NMR (101 MHz, CDCl3): d (ppm) = 187.5, 174.7, 170.5, 159.4, 142.9, 133.6, 133.0, 
130.1 (2C), 128.4 (2C), 91.6, 89.1, 88.4, 71.0, 62.6, 42.7, 25.9 (3C), 25.7 (3C), 18.4, 18.0, -
4.5, -4.9, -5.3, -5.4. 
HRMS (ESI+): calculated for C29H46N3O6Si2+ [M+H+]+: 588.2920, found: 588.2920. 
IR (ATR): (cm-1) = 2954 (w), 2929 (w), 2885 (w), 2856 (w), 1718 (m), 1692 (m), 1658 (s), 
1567 (s), 1471 (s), 1250 (s), 1080 (s), 829 (s), 776 (s). 
 
 
4-N-benzoyl-5-formyl-2'deoxycytidine (3) 
 
In a polypropylene tube 395 mg (0.67 mmol, 1.0 eq) of the TBS-protected nucleoside 2 were 
dissolved in dry EtOAc (final concentration 60 mM). Subsequently 272 µL (3.36 mmol, 
5.0 eq) pyridine and 262 µL (10.1 mmol, 15 eq) HF (70 % in pyridine) were added and the 
reaction mixture stirred 14 h at rt. During this time a white solid precipitated. 1 mL/mmol 
TMSOMe were added and the reaction mixture stirred another 30 min. Subsequently the solid 
was collected by centrifugation (6000 rpm, 15 min). The crude product (purity >90 %) was 
not further purified and directly taken on to the next reaction. Yield: 198 mg (82 %). 
1H-NMR (400 MHz, pyridine-D5/DMSO-D6): d (ppm) = 9.82 (br s, 1H, NH), 9.64 (s, 1H, 
CHO), 8.22 (d, 3J = 7.1, 2H, Ph-H), 7.62 (s, 1H, N-CH=C-CHO), 7.55 (d, 3J = 7.4, 1H, Ph-
H), 7.48 (t, 3J = 7.4, 2H, Ph-H), 6.60 (dd, 3J = 4.9, 3J = 6.3, 1H, O-CH-N), 4.90 (dd, 3J = 5.8, 
3J = 10.5, 1H, O-CH-CH2-CH-N), 4.46 (dt, 3J = 2.9, 3J = 4.7, 1H, O-CH-CH-CH2-O), 4.22 
(dd, 3J = 3.0, 2J = 12.0, 1H, 1x O-CH2-CH-O), 4.12 (dd, 3J = 2.9, 2J = 12.0, 1H, 1x O-CH2-
CH-O), 2.94 (ddd, 3J = 5.8, 3J = 6.3, 2J = 13.5, 1H, 1x O-CH-CH2-CH-N), 2.69 (ddd, 3J = 4.9, 
3J = 6.1, 2J = 13.5, 1H, 1x O-CH-CH2-CH-N). 
13C-NMR (101 MHz, CDCl3): d (ppm) = 188.4, 159.1, 153.8, 152.2, 149.6, 134.1, 132.6, 
128.6 (2C), 127.9 (2C), 106.5, 88.9, 87.9, 69.2, 60.5, 41.8. 
HRMS (ESI+): calculated for C17H18N3O6+ [M+H+]+: 360.1190, found: 360.1191. 
Melting Range: >200 °C decomposition. 
IR (ATR): (cm-1) = 3477 (br, m), 3306 (br, m), 2988 (w), 2931 (w), 2906 (w), 2851 (w), 
1721 (s), 1650 (s), 1570 (s), 1473 (s), 1251 (s), 1238 (s), 1092 (s), 795 (m). 
 
5'-(dimethoxytrityl)-4-N-benzoyl-5-formyl-2'deoxycytidine (9) 
 
 
A round bottom flask was charged with rigorously dried 3 Å molecular sieves. 146 mg 
(0.41 mmol, 1.0 eq) of the nucleoside 3 (final concentration: 100 mM) and 151 mg 
(0.45 mmol, 1.1 eq) DMT-Cl were dissolved in pyridine. The reaction mixture was stirred for 
14 h and the molecular sieves subsequently filtered off. The filtrate was evaporated to dryness 
and the crude product purified by column chromatography. Eluent for column 
chromatography: DCM/MeOH (49:1; 0.1 % NEt3). Yield: 170 mg (63 %) of 9 as a pale 
yellow solid. 
 
1H-NMR (400 MHz, DMSO-D6): d (ppm) = 8.97 (s, 1H, C-CH=O), 8.81 (s, 1H, N-CH=C-
CHO), 8.00 – 7.89 (m, 2H, Ph-H), 7.70 (t, 3J = 7.3, 1H, Ph-H), 7.61 (t, 3J = 7.3, 2H, Ph-H), 
7.33 (m, 4H, DMT-H), 7.27 – 7.18 (m, 5H, DMT-H), 6.88 (dd, 4J = 0.7, 3J = 9.1, 4H, DMT-
H), 6.09 (dd, 3J = 5.1, 3J = 6.4, 1H, O-CH-N), 5.42 (d, 3J = 4.8, 1H, OH), 4.34 – 4.26 (m, 1H, 
O-CH-CH2-CH-N), 4.07 (dd, 3J = 4.3, 3J = 7.9, 1H, O-CH2-CH-CH-O), 3.71 (2x s, 6H, O-
CH3), 3.34 – 3.26 (m, 2H, O-CH2-CH-O), 2.49 – 2.43 (m, 1H, 1x O-CH-CH2-CH-N), 2.34 
(ddd, 3J = 4.5, 3J = 6.3, 2J = 11.3, 1H, 1x O-CH-CH2-CH-N). 
13C-NMR (101 MHz, DMSO-D6): d (ppm) = 189.0, 163.8, 159.3, 158.2 (2C), 154.3, 152.7, 
144.5, 135.4, 135.2, 133.3, 133.2, 129.77 (2C), 129.76 (2C), 129.1 (4C), 128.0 (2C), 127.7 
(2C), 126.9, 114.1 (2C), 113.3 (2C), 105.8, 87.7, 86.4, 86.0, 69.4, 63.0, 55.0 (2C), 40.7. 
HRMS (ESI+): calculated for C38H36N3O8+ [M+H+]+: 662.2497, found: 662.2500. 
Melting Range: 115 – 123 °C 
IR (ATR): (cm-1) = 2934 (w), 1716 (m), 1650 (s), 1601 (m), 1565 (s), 1508 (m), 1470 (s), 
1247 (s), 1174 (m), 1089 (m), 1068 (m), 1031 (m), 827 (m), 790 (m), 701 (s). 
3'-(diisopropylamino-cyanoethoxyphosphino)-5'-(dimethoxytrityl)-4-N-benzoyl-5-
formyl-2'deoxycytidine (4) 
 
In a Schlenck tube 100 mg (0.15 mmol, 1.0 eq) of DMT-protected nucleoside 9, 14 mg 
(0.13 mmol, 0.5 eq) diisopropyltetrazolide, and 55 µL (0.18 mmol, 1.2 eq) 
bis(diisopropylamino)(2-cyanoethoxy)phosphine, were dissolved in 10 mL rigorously 
degassed DCM and the solution degassed three more times (freeze, pump, thaw). The reaction 
mixture was stirred at rt for 15 h and subsequently concentrated in an argon atmosphere. The 
crude product was purified by column chromatography. The test tubes that were used to 
collect the fractions were flushed with argon prior to use. Eluent for column chromatography: 
DCM/MeOH (49:1, 0.1 % NEt3). Yield: 113 mg (95 %, colorless foam) of 4 as a mixture of 
two diastereomers on P.  
 
31P-NMR (81 MHz, Acetone): d (ppm) = 149.64, 149.45. 
HRMS (ESI+): calculated for C47H53N5O9P+ [M+H+]+: 862.3575, found: 862.3580. 
 
3',5'-(tert-butyl-dimethylsilyl)-5-carboxymethyl-2'deoxycytidine (10) 
 
In a glass autoclave 1.00 g (1.72 mmol, 1.0 eq) 1 and 49 mg (0.19 mmol, 0.1 eq) 
Pd(MeCN)2Cl2 were dissolved in 20 mL methanol and subsequently 600 µL (3.44 mmol, 
2.0 eq) DIPEA added. The autoclave was flushed once with CO and the reaction mixture then 
stirred for 18 h at 60 °C with a CO pressure of 3 bar. After completion of the reaction the gas 
was discharged and the solvent evaporated in vacuo. The crude product was purified by 
column chromatography (DCM/MeOH 99:1, dry loaded) to give 696 mg (84 %) of 10 as a 
yellowish solid. 
1H-NMR (300 MHz CDCl3): d (ppm) = 8.59 (s, 1H, N-CH=C-COOMe), 7.93 (s, 1H, 1x 
NH2), 7.31 (s, 1H, 1x NH2), 6.15 (dd, J=5.9, 7.3, 1H, O-CH-N), 4.36 – 4.29 (m, 1H, O-CH-
CH2-CH-N), 4.03 (dd, 3J = 2.9, 3J = 5.6, 1H, O-CH2-CH-CH-O), 3.83 (dd, 3J = 3.2, 2J = 11.3, 
1H, 1x O-CH2-CH-O), 3.79 (s, 3H, C-CO-O-CH3), 3.74 (dd, 3J = 3.1, 2J = 11.3, 1H, 1x O-
CH2-CH-O), 2.58 (ddd, 3J = 2.4, 3J = 5.8, 2J = 13.4, 1H, 1x O-CH-CH2-CH-N), 1.94 (ddd, 3J 
= 6.1, 3J = 7.3, 2J = 13.4, 1H, 1x O-CH-CH2-CH-N), 0.86 (s, 9H, O-Si-C(CH3)3), 0.85 (s, 9H, 
O-Si-C(CH3)3), 0.05 (s, 6H, Si-CH3), 0.04 (s, 6H, Si-CH3). 
13C-NMR (75 MHz, CDCl3): d (ppm) = 165.1, 163.7, 154.0, 147.4, 95.1, 88.7, 87.7, 72.7, 
63.0, 51.8, 42.8, 25.8 (3C), 25.7 (3C), 18.2, 17.9, -4.7, -5.0, -5.6, -5.7. 
HRMS (ESI+): calculated for C23H44N3O6Si2+ [M+H+]+: 514.2763, found: 514.2762 
IR (ATR): (cm-1) = 2930 (m), 2857 (m), 1720 (s), 1674 (s), 1501 (m), 1101 (s), 1075 (s), 
822 (s), 776 (s). 
melting range: 129  - 131 °C 
 
 
3',5'-(tert-butyl-dimethylsilyl)-4-N-acetyl-5-carboxymethyl-2'deoxycytidine (5) 
 
In a round bottom flask 550 mg (1.07 mmol, 1.0 eq) 57 were dissolved in 50 mL THF. 
Subsequently 7 mL (53 mmol, 50 eq) Ac2O, 87 µL (1.07 mmol, 1.0 eq) pyridine and 7 mg 
(0.05 mmol, 0.1 eq) DMAP were added. The mixture was stirred for 15 h at rt. After 
completion of the reaction 5 mL MeOH were added and the solution was concentrated in 
vacuo to give 585 mg (98 %) of 5 as a yellowish solid. 
1H-NMR (599 MHz, CDCl3): d (ppm) = 10.71 (s, 1H, NH), 8.80 (s, 1H, N-CH=C-COOMe), 
6.13 (dd, 3J = 6.1, 3J = 7.1, 1H, O-CH-N), 4.35 (dt, 3J = 2.2, 3J = 5.5, 1H, O-CH-CH2-CH-N), 
4.11 (q, 3J = 2.7, 1H, O-CH2-CH-CH-O), 3.88 – 3.84 (m, 4H, CO-O-CH3, 1x O-CH2-CH-O), 
3.77 (dd, 3J = 2.9, 2J = 11.4, 1H, 1x O-CH2-CH-O), 2.69 (ddd, 3J = 2.3, 3J = 5.9, 2J = 13.5, 
1H, 1x O-CH-CH2-CH-N), 2.64 (s, 3H, N-CO-CH3), 1.99 (ddd, 3J = 6.0, 3J = 7.3, 2J = 13.4, 
1H, 1x O-CH-CH2-CH-N), 0.89 (s, 9H, O-Si-C(CH3)3), 0.84 (s, 9H, O-Si-C(CH3)3), 0.08 (s, 
3H, Si-CH3), 0.07 (s, 3H, Si-CH3), 0.06 (s, 3H, Si-CH3), 0.04 (s, 3H, Si-CH3). 
13C-NMR (151 MHz, CDCl3): d (ppm) = 172.0, 164.9, 159.6, 153.1, 148.7, 95.7, 89.4, 88.7, 
72.9, 63.1, 52.4, 42.9, 27.2, 25.8 (3C), 25.7 (3C), 18.2, 18.0, -4.6, -4.9, -5.6, -5.7. 
HRMS (ESI+): calculated for C25H46N3O7Si2+ [M+H+]+: 556.2869, found: 556.2866 
Melting Range: 132 - 134 °C 
IR (ATR): (cm-1) = 2927 (w), 2857 (w), 1644 (s), 1537 (m), 1284 (s), 1255 (s), 1119 (s), 
1006 (m), 817 (s), 761 (s). 
 
4-N-acetyl-5-carboxymethyl-2'deoxycytidine (6) 
 
In a polypropylene tube 473 mg (0.85 mmol, 1.0 eq) of the TBS-protected nucleoside 5 were 
dissolved in dry EtOAc (final concentration 60 mM). Subsequently 332 µL (12.8 mmol, 
5.0 eq) pyridine and 343 µL (4.26 mmol, 15 eq) HF (70 % in pyridine) were added and the 
reaction mixture stirred 14 h at rt. During this time a white solid precipitated. 1 mL/mmol 
TMSOMe were added and the reaction mixture stirred another 30 min. Subsequently the solid 
was collected by centrifugation (6000 rpm, 15 min). The crude product was further purified 
by column chromatography (DCM/MeOH 19:1) to give 212 mg (76 %) of 6 as a colorless 
solid. 
1H-NMR (400 MHz, CD3OD): d (ppm) = 9.12 (s, 1H, N-CH=C-COOMe), 6.18 (t, 3J = 6.0, 
1H, O-CH-N), 4.38 (dt, 3J = 4.6, 3J = 6.2, 1H, O-CH-CH2-CH-N), 3.99 (dd, 3J = 3.4, 3J = 7.5, 
1H, O-CH2-CH-CH-O), 3.89 – 3.82 (m, 4H, CO-O-CH3, 1x O-CH2-CH-O), 3.76 (dd, 3J = 
3.4, 2J = 12.0, 1H, 1x O-CH2-CH-O), 2.47 (ddd, 3J = 4.8, 3J = 6.4, 3J = 13.7, 1H, O-CH-CH2-
CH-N), 2.26 – 2.16 (m, 1H, O-CH-CH2-CH-N), 2.02 (s, 3H, N-CO-CH3). 
13C-NMR (101 MHz, CD3OD): d (ppm) = 173.6, 166.8, 165.4, 156.7, 150.2, 97.2, 89.4, 88.7, 
71.4, 62.3, 52.6, 42.8, 20.6. 
HRMS (ESI+): calculated for C13H18N3O7+ [M+H+]+: 328.1139, found: 328.1138 
IR (ATR): (cm-1) = 3305 (br, m), 2928 (w), 1634 (s), 1584 (m), 1484 (m), 1437 (s), 
1326 (m), 1296 (s), 1255 (s), 1101 (s), 792 (s). 
melting range: > 200 °C decomposition 
 
5'-(dimethoxytrityl)-4-N-acetyl-5-carboxymethyl-2'deoxycytidine (11) 
 
A round bottom flask was charged with rigorously dried 3 Å molecular sieves. 173 mg 
(0.53 mmol, 1.0 eq) of the nucleoside 6 (final concentration: 66 mM) and 185 mg (0.53 mmol, 
1.0 eq) DMT-Cl were dissolved in pyridine. The reaction mixture was stirred for 14 h and the 
molecular sieves subsequently filtered off. The filtrate was evaporated to dryness and the 
crude product purified by column chromatography. Eluent for column chromatography: 
DCM/MeOH (49:1). Yield: 158 mg (48 %) of 11 as a colorless solid. 
1H-NMR (400 MHz, CD3CN): d (ppm) = 10.69 (s, 1H, NH), 8.89 (s, 1H, N-CH=C-COOMe), 
7.46 – 7.41 (m, 2H, DMT), 7.35 – 7.21 (m, 7H, DMT), 6.88 – 6.82 (m, 4H, DMT), 6.05 (t, 3J 
= 5.9, 1H, O-CH-N), 4.35 (m, 1H, O-CH-CH2-CH-N), 4.05 (dd, 3J = 3.9, 3J = 7.5, 1H, O-
CH2-CH-CH-O), 3.76 (s, 6H, CH=C-O-CH3), 3.44 – 3.38 (m, 1H, 1x O-CH2-CH-O), 3.23 
(dd, 3J = 3.9, 2J = 10.9, 1H, 1x O-CH2-CH-O), 3.18 (s, 3H, CO-O-CH3), 2.56 – 2.47 (m, 4H, 
1x O-CH-CH2-CH-N, N-CO-CH3), 2.34 – 2.26 (m, 1H, 1x O-CH-CH2-CH-N). 
13C-NMR (101 MHz, CD3CN): d (ppm) = 172.0, 166.5, 160.7, 159.82, 159.81, 154.2, 150.1, 
145.9, 136.94, 136.87, 131.08 (2C), 131.04 (2C), 129.1 (2C), 128.9 (2C), 128.0, 114.1 (4C), 
97.1, 88.9, 87.8, 87.4, 71.1, 63.7, 56.0 (2C), 52.8, 42.3, 27.1. 
HRMS (ESI+): calculated for C34H36N3O9+ [M+H+]+: 630.2446, found: 630.2443 
IR (ATR): (cm-1) = 3277 (m), 3223 (m), 2952 (m), 2935 (w), 2837, 1659 (s), 1547 (m), 
1506 (s), 1439 (m), 1329 (m), 1296 (s), 1255 (s), 1174 (s), 1098 (s), 837 (m), 792 (s), 701 (s). 
melting range: 97 - 98 °C 
 
3'-(diisopropylamino-cyanoethoxyphosphino)-5'-(dimethoxytrityl)-5-carboxymethyl-
2'deoxycytidine (7) 
 
In a Schlenck tube 158 mg (0.25 mmol, 1.0 eq) of DMT-protected nucleoside 11 (final 
concentration: 50 mM), 22 mg (0.13 mmol, 0.5 eq) diisopropyltetrazolide, and 98 µL (0.30 
mmol, 1.2 eq) bis(diisopropylamino)(2-cyanoethoxy)phosphine, were dissolved in 10 mL 
rigorously degassed DCM and the solution degassed three more times (freeze, pump, thaw). 
The reaction mixture was stirred at rt for 15 h and subsequently concentrated in an argon 
atmosphere. The crude product was purified by column chromatography. The test tubes that 
were used to collect the fractions were flushed with argon prior to use. Eluent for column 
chromatography: DCM/MeOH (49:1, 0.1 % NEt3). Yield: 196 mg (94 %, colorless foam) of 7 
as a mixture of two diastereomers on P.  
The compound was directly used for solid phase DNA synthesis. Its identity was proven by 
successful incorporation into DNA. 
31P-NMR (81 MHz, Acetone): d (ppm) = 149.46, 149.32. 
HRMS (ESI+): calculated for C43H53N5O10P+ [M+H+]+: 830.3525, found: 830.3530. 
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